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Introduction - Neutrophils are the most abundant innate immune cells, essential for 
clearing pathogens from injured or infected sites and directing the ensuing 
inflammatory response. Sites of inflammation tend to be hypoxic due to rapid tissue 
volume expansion, loss of vascular integrity and oxygen consumption by infiltrating 
immune cells. Neutrophils are well suited to the hypoxic niche and have metabolic 
adaptations that enable them to exist in hypoxia, including a reliance on anaerobic 
respiration, despite possessing a mitochondrial network. The role of neutrophil 
mitochondria is unclear, and relatively few studies have examined what role the 
mitochondria play in regulating neutrophil apoptosis and function, and how hypoxia 
modulates anaerobic and aerobic neutrophil metabolism. 
Methods - Neutrophils isolated from healthy volunteers were cultured in normoxia 
(21% O2) and hypoxia (1% O2) in vitro and neutrophil function and metabolic flux 
interrogated ex vivo. Functional consequences of hypoxic response pathway 
manipulation were investigated in infection models carried out in mice with myeloid 
specific PHD3 knockout. 
Results – Neutrophil mitochondrial membrane potential and reactive oxygen species 
production are enhanced in hypoxia through a mechanism independent of oxidative 
phosphorylation. Neutrophil mitochondrial reactive oxygen species are capable of 
stabilising HIF-1α and enhancing hypoxic survival of neutrophils. Manipulation of 
the hypoxic response pathway and neutrophil metabolism through knockout of 
PHD3 enhances control of bacterial infection through changes in neutrophil 
metabolic flux. 
Conclusion - We describe a signalling role for the neutrophil mitochondria in 
hypoxic conditions that is independent of oxidative phosphorylation activity. 
Neutrophil anaerobic metabolism is also linked closely to antioxidant production 
through the pentose phosphate pathway that compensates for mitochondrial oxidant 
signalling from the mitochondria. Regulation of glycolysis is therefore required for 
both reactive oxygen signalling and for managing oxidative stress in hypoxic 
conditions. These pathways are also regulated by the activity of PHD3, in a manner 





Our bodies need oxygen – we breathe oxygen into our lungs, which then enters into 
our bloodstream and is used by cells to produce energy. In sites of infection and 
inflammation, oxygen levels can be very low because inflamed tissue has huge 
numbers of cells using large amounts of oxygen. In order to adapt to these low 
oxygen sites, specific white blood cells called neutrophils, which can help kill 
bacteria, can not only function without oxygen, but actually live longer in these 
conditions. These cells are very unusual in this regard as oxygen is an absolute 
requirement in other cells. 
Neutrophils have also been linked to a number of inflammatory diseases. The 
activity of neutrophils can cause damage to the body. Understanding the regulation 
of the lifespans of these cells in low oxygen will therefore be very important when 
looking for treatments for these chronic inflammatory conditions. 
My research shows that in low oxygen, neutrophils use the mitochondria, the 
powerhouse of the cell and the source of energy from oxygen, in a slightly different 
way to other cells. The neutrophils use a byproduct of the energy producing process 
called reactive oxygen species to prolong their lifespan in low oxygen. The 
neutrophils do not use a lot of the same energy-producing pathways as other cells. 
This is part of what makes them specialized to low oxygen. Neutrophils also extend 
their lifespan in hypoxia through regulating the way they use glucose. Blocking part 
of the machinery that neutrophils use to adapt to hypoxic conditions can improve the 
way that neutrophils clear bacteria at the site of infection.  
These findings shed some light on the activity of these cells and highlight two 
potential therapeutic targets that could be exploited in treating chronic inflammatory 
diseases. Further work will be needed to explore the consequences of targeting these 
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1.1. The role of the neutrophil in health and disease 
1.1.1. Antimicrobial response 
Neutrophils are the most abundant leukocyte in the mammalian circulation and are 
critical for the elimination of invading pathogens and mediation of the ensuing acute 
inflammatory response through the synthesis and release of inflammatory lipids and 
proteins (Kennedy and Deleo, 2009). Terminally differentiated, short-lived cells that 
are rapidly turned-over in the body, neutrophils have short lifespans, with estimates 
from human studies ranging from 8-12 hours in the circulation, which extends to 1-2 
days after infiltrating tissue, to just over 5 days following release from the bone 
marrow (Dancey et al., 1976)(Pillay et al., 2010). The bone marrow releases 
neutrophils at a rate of 1011 cells per day, and as such they account for 50% to 70% 
of all circulating leukocytes (Luo and Loison, 2008).  
The activity of neutrophils is essential for proper control of infection. Neutropoenia, 
a condition defined by low levels of circulating neutrophils, is associated with 
immunodeficiency and recurrent bacterial infections (Zeidler et al., 2009). 
Neutrophils primarily clear bacteria through phagocytosis and subsequent digestion 
of pathogens in the phagolysosome, utilising toxic chemicals stored in specialized 
lysosomes known as granules. Neutrophils possess three types of granules; primary, 
or azurophilic, granules which contain anti-microbial proteins such as 
myeloperoxidase (MPO), lysozyme, neutrophil elastase (NE), defensins, proteinase-
3 and cathepsin G. Secondary granules contain the antimicrobial peptides lactoferrin, 
lysozyme, hCAP-18, NGAL and Nramp-1. Tertiary granules contain 
metalloproteases including gelatinase (summarised in Pham, 2006). During 
phagocytosis of bacteria, these granules fuse with the phagosome to form the 
phagolysosome, exposing the engulfed pathogen to the toxic granule contents. 
Granule proteins exert antimicrobial effects through proteolysis (NE, cathepsin G, 
proteinase 3), compromise of the microbial cell membrane and cell wall (defensins, 
lysozyme) and sequestration of nutrients (chelators). Neutrophils can also release 




NADPH oxidase. NADPH oxidase produces large amounts of superoxide in the 
phagolysosome, which can oxidise bacterial components directly, or be dismuted 
into H2O2, which can then be converted to hypochlorous acid by MPO and exert 
potent bactericidal effects (Thomas et al., 2014).  
Neutrophils may also release granule contents into the extracellular space through a 
process known as degranulation. Release of granule contents can kill extracellular 
pathogens, but also cause damage to host tissues. Activity of serine proteases on 
chemoattractants can also potentiate their activity and positively regulate the 
inflammatory response. NADPH oxidase present on the membrane can release 
reactive oxygen species (ROS) into the extracellular environment, which aids with 
antimicrobial control but also contributes to tissue damage (Pham, 2006). 
Neutrophils may also release neutrophil extracellular traps (NETs) to clear bacteria. 
NETs are large, extracellular fibres released by neutrophils, and composed of 
cytoplasmic and granule proteins including NE, cathepsin G and MPO bound to 
networks of decondensed nuclear and mitochondrial chromatin (Thomas et al., 
2014). NETs immobilise and kill bacteria, fungi, viruses and parasites through 
providing a highly localised concentration of antimicrobial proteins to act on the 
bacteria (reviewed in Papayannopoulos, 2018). Release of NETs is thought to be 
mediated by ROS-mediated translocation of NE to the nucleus, which can disrupt 
histone proteins and allow unpacking and decondensing of DNA (Papayannopoulos 
et al., 2010). 







Figure 1.1-1: Cytotoxic functions of neutrophils. Neutrophils clear bacteria 
through phagocytosis (A) and then subsequent destruction of intracellular bacteria 
through the fusing of the phagolysosome with cytotoxic granules and exposure to 
serine proteases and antimicrobial peptides (B) and exposure to reactive oxygen 
species in the phagolysosome (C). Neutrophils can also kill extracellular bacteria 
through release of granule contents (D) and NADPH oxidase-derived reactive 
oxygen species (E) into the extracellular milieu. Neutrophils may also release their 
nuclear contents as neutrophil extracellular traps (F). Release of cytokines and 



































1.1.2. Recruitment  
Neutrophil maturation and release from the bone marrow is predominantly driven 
through the activity of granulocyte colony-stimulating factor (G-CSF). G-CSF drives 
neutrophil release from the bone marrow in resting conditions, and can also drive 
enhanced neutrophil production and release from the bone marrow in infection. 
Endothelial cells respond to pathogen-associated molecular patterns (PAMPs) by 
releasing G-CSF, enhancing proliferation of haemopoietic stem cells in the bone 
marrow and skewing differentiation towards neutrophils (Boettcher et al., 2014).  
Following release from the bone marrow, circulating neutrophils are drawn to the 
site of infection and inflammation through the process of neutrophil recruitment. 
Recruitment is mediated through the activation of neutrophil receptors by ligands 
induced on the surface of the inflamed vascular endothelium. Endothelial cells react 
to stimuli such as TNFα, IL-1β and IL-17 generated during infection and express P- 
and E- selectins, as well as ICAMs and VCAMs on the luminal surface of the 
endothelium. Neutrophils bind these via PSGL-1 and L-selectin. The interactions 
between PSGL-1 and P- and E- selectins establish contact between the circulating 
neutrophils and the activated endothelial cell, and ESL-1 and E-selectin interactions 
mediate the deceleration of the circulating neutrophil and rolling along the 
endothelium. Rolling allows the cell to detect signals in the local microenvironment, 
including chemokines released by inflammatory cells in the site of inflammation. 
These secondary signals induce β1 and β2 surface integrins on the neutrophil 
membrane to unfold and interact with ICAM-1 and ICAM-2 ligands expressed on 
the inflamed endothelium. Integrin-ICAM interaction slows the rolling of the 
neutrophil along the endothelium and eventually arrests the cell. ICAM-2 
congregates at the endothelial cell junctions and guides neutrophils to these sites. 
Neutrophils then transmigrate through the basement membrane into the tissue, 
mediated by JAMs, PECAMs, and CD99. Once through the membrane, neutrophils 
travel towards the insult (Summarised in Borregaard 2010). 
1.1.3. Mediation of the inflammatory response 
 Although initially seen purely as obligate phagocytes, dedicated to clearance 




critical regulators of the immune response, allowing fine regulation of inflammation 
through the release of pro- and anti-inflammatory cytokines in response to damage-
associated molecular patterns (DAMPs), PAMPs and endothelial cell factors. In 
addition, neutrophils release an array of chemokines on activation which can recruit 
immune cells to the site of inflammation or infection (Zlotnik and Yoshie, 2012). 
Crucial neutrophil chemokines include potent neutrophil chemoattractants IL-8, 
CXCL1/KC and IL-1β that allow amplification of the initial immune response 
through an inflammatory “cascade”, recruiting more neutrophils to the site of 
inflammation. Other innate immune cell chemoattractants are released by 
neutrophils, including MIP-1α and MIP-1β, allowing recruitment of monocytes, 
macrophages, natural killer (NK) cells and immature dendritic cells (Scapini et al., 
2000). Neutrophils also release chemokines including IP-10 and MIG, which induce 
B- and T-cell recruitment, mediating the adaptive immune response. In vitro 
experiments have shown CCL2, CCL20 and CXCL10 release from neutrophils can 
recruit IFNy- and IL-17-producing T lymphocytes (Codolo et al., 2013). Tumour 
associated neutrophils can also release CCL17, a chemoattractant capable of 
recruiting Tregs, which is deleterious to the immune response to the tumour 
(Mishalian et al., 2014).  
Neutrophils are a source of both pro- and anti-inflammatory cytokines, including but 
not limited to IL-1, IL-6, IFNy, IL-17 and TNFα. TNFα can promote other cells to 
prime antiviral immune responses (Epaulard et al., 2014) and cause microvascular 
leakage (Finsterbusch et al., 2014). Neutrophils are also sources of other TNF 
superfamily members BAFF, APRIL and TRAIL. Expression of TRAIL also has 
antiviral properties and can mediate early bacterial killing in pneumonia (Stacey et 
al., 2014)(Steinwede et al., 2012). 
1.1.4. Neutrophil apoptosis and inflammation resolution 
As neutrophil activity can cause considerable damage to the host, rapid resolution of 
inflammation is essential. Resolution of inflammation is primarily mediated through 
a programme of constitutive neutrophil apoptosis and subsequent phagocytosis by 
macrophages (efferocytosis)(Perretti, Soehnlein and Ortega-Gómez, 2013). 




of cells without induction of pro-inflammatory pathways. Other forms of cell death, 
such as programmed pyroptosis and non-programmed necrosis, leads to loss of cell 
membrane integrity and subsequent release of toxic granule contents which can then 
cause further inflammation and tissue damage.  
Neutrophils undergo apoptosis spontaneously through an as-unknown mechanism. 
However, rates of neutrophil apoptosis can be influenced by other external factors. 
Pro-inflammatory cytokines, such as IL-1β, TNFα, Granulocyte-Macrophage-
Colony Stimulating Factor (GM-CSF), G-CSF and IFN-γ can all promote neutrophil 
survival (Colotta et al., 1992). Exposure to pathogens and pathogen-derived 
products, such as lipopolysaccharide (LPS) and inactivated bacteria, can also 
promote survival (Fox et al., 2010).  
The apoptosis and subsequent engulfment of neutrophils by macrophages is in itself 
an anti-inflammatory process, suppressing the expression of pro-inflammatory 
cytokines TNFα, GM-CSF, IL-12, IL-1β and IL-18, and activating release of the 
anti-inflammatory cytokines IL-10, TGF-β and prostaglandin E2 in in vitro studies 
(Fadok et al., 1998). Further studies in vivo showed addition of apoptotic neutrophils 
can actually protect against LPS-induced shock (Ren et al., 2008). Administration of 
apoptotic neutrophils reduced levels of pro-inflammatory cytokines IL-12, TNFα 
and IFN-γ in the blood of mice with LPS-induced sepsis, whereas levels of the anti-
inflammatory cytokine IL-10 were elevated. Timely apoptosis of neutrophils is 
therefore essential for resolution of the inflammatory response. 
Recruitment of neutrophils can also be regulated at least partially by the rate of 
apoptosis of neutrophils in the inflammatory tissue, as clearance of apoptotic 
neutrophils by macrophages and dendritic cells reduces IL-23 production, which in 
turn reduces the production of IL-17A by neutrophil regulatory T cells (Stark et al., 
2005). IL-17A is needed for the production of G-CSF; therefore, higher numbers of 
apoptotic neutrophils being phagocytosed in the tissue suppresses the production of 





1.1.5. Pathologies associated with neutrophil functional deficiency 
Defects in neutrophil phagocytosis and bacterial killing efficiency can lead to life-
threatening immune diseases. Patients with conditions where neutrophil abundance 
or function are compromised are particularly susceptible to bacterial and fungal 
infections. Diseases caused by defects in NADPH oxidase function (Chronic 
granulatomous disease) and cytotoxic granule formation and function (Chediak-
Higashi syndrome, neutrophil-specific granule deficiency) are all linked to more 
frequent bacterial infections (Lakshman and Finn, 2001). Chediak-Higashi syndrome 
is an autosomal recessive disorder also associated with a number of haematological 
and neurological symptoms, caused by a mutation in the lysosomal trafficking 
regulatory gene LYST, causing abnormal fusion of primary (azurophilic) granules 
with secondary (specific) granules. In this disease, an infection induces neutrophilia 
in the tissue, but the neutrophils lack elastase and cathepsin G and are unable to 
mount an effective response (Mackay and Rosen, 2000), with patients suffering 
recurrent S. aureus and Streptococci infections. Deficiencies in the capability of 
neutrophils to release NETs, for example in neutrophils isolated from neonates, can 
also lead to significant deficiencies in extracellular killing of S. aureus and E. coli, 
and can predispose the host to bacterial infections (Yost et al., 2009). 
1.1.6. Neutrophils and inflammatory disease 
Normal activity of neutrophils can cause bystander damage to tissues due to the 
activity of toxic granule contents on host tissue, and neutrophil presence in the tissue 
and activity is also associated with a number of inflammatory diseases caused by 
tissue destruction, including Chronic Obstructive Pulmonary Disease (COPD) and 
rheumatoid arthritis. In COPD, the degree of airway neutrophilia in patients 
correlates with decline in lung function and is consequentially associated with the 
severity of disease symptoms (Stǎnescu et al., 1996). The presence of neutrophils in 
chronic inflamed tissue is mediated in part by recruitment of neutrophils through 
release of pro-inflammatory cytokines IL-1, CCR1 and CXCR2 (Chou et al., 2010), 
although the exact reason as to why the inflammatory response does not resolve in 
these conditions has not been elucidated. 




the airways, but experience frequent bacterial infections known as exacerbations 
(Hoenderdos and Condliffe, 2013). Acute exacerbations are characterised by acutely 
enhanced inflammation of the peripheral airways, even greater neutrophil numbers in 
sputum and a profound deterioration in physiological wellbeing. Exacerbations are 
common despite enhanced neutrophil infiltration into the airway lumen, suggesting 
that neutrophils present in the lungs of COPD patients may also be functionally 
deficient. This is mirrored in cystic fibrosis patients, who experience frequent S. 
aureus and H. influenzae infections despite the observations that the airways of these 
patients have extremely high levels of neutrophils, neutrophil elastase and MPO, as 
well as enhanced oxidative stress as measured by glutathione concentration and 
redox ratios (Lyczak, Cannon and Pier, 2002)(Dickerhof et al., 2017). Understanding 
the regulation of neutrophil apoptosis and function will therefore be essential in 
understanding how to treat these chronic inflammatory conditions.  
1.2. Modulation of neutrophil lifespan and function by 
oxygen tension 
1.2.1. Hypoxia 
Oxygen is required by mammalian cells in order to produce ATP through oxidative 
phosphorylation. In the human body, arterial blood has an oxygen concentration of 
11.3-13.3kPa, whereas venous blood is around 5.5-6kPa (Woerlee, 1988). Systemic 
hypoxia (hypoxaemia) can occur in cases of lung dysfunction such as COPD and 
cystic fibrosis, or in situations where oxygen is limiting such as at altitude, or during 
sleep apnoea (Barry and Pollard, 2003)(Lévy et al., 2008)(Kent, Mitchell and 
McNicholas, 2011). Lower respiratory tract infections such as pneumonia are also 
associated with hypoxaemia; the degree of hypoxaemia is associated with adverse 
outcomes of infection in pneumonia patients (Majumdar et al., 2011) and in children 
with lower respiratory tract infections (Lazzerini, Sonego and Pellegrin, 2015), and 
adverse outcomes in chronic lung diseases such as COPD (Kent, Mitchell and 
McNicholas, 2011).  
Oxygen levels in the tissues are variable, and depend on metabolic rates of the 




oxygen requirement is high. A number of particularly hypoxic niches exist in the 
body as part of normal function, including the bone marrow, the intestinal mucosa 
and the placenta (Campbell, Kao and Colgan, 2016)(Beerman et al., 2017). These 
niches have adapted to low oxygen environments, and hypoxia is required for normal 
function of these tissues (Reviewed in Taylor & Colgan 2017). 
Acute hypoxia also occurs in pathology, most commonly in cases of myocardial or 
cerebral ischaemia or in the tumour microenvironment (Kominsky, Campbell and 
Colgan, 2010)(Lin et al., 2016). Hypoxia can occur at the site of infection or 
inflammation, where tissue oxygen demand is increased due to high concentrations 
of infiltrating immune cells. Oxygen concentrations at inflammatory sites, such as 
arthritic joints, can reach as low at 1kPa (Ng et al., 2010). Lack of oxygen in the 
tissue can result in ATP depletion and cell death, but also can profoundly alter the 
immune response (Michiels, 2004).  
1.2.2. The hypoxic response pathway 
Mammalian cells regulate their response to oxygen concentration in order to 
maintain metabolic homeostasis. The main molecular mechanism for mounting this 
response is through the hypoxic response pathway, specifically through the 
transcription factors HIF-1α, HIF-2α, and the recently described HIF-3α. These 
transcription factors mount a profound transcriptional response in hypoxic 
conditions, modulating a host of cell responses. HIF-1α, the most well-characterised 
component of this pathway, is ubiquitously expressed and is a crucial regulator of 
homeostasis through modulating metabolism, apoptosis and tissue vascularization 
(Semenza, 1998). HIF-1α allows for adaptation to hypoxia; however, many cancers 
overexpress HIF-1α, and overexpression encourages proliferation and 
vascularisation of tumours (Semenza, 2002). 
Regulation of HIF-1α and HIF-2α activity occurs at the level of transcription and 
protein stability. In normoxic conditions, HIF is transcribed and translated 
constitutively, then broken down through the activity of the prolyl hydroxylases 
PHD1, PHD2 and PHD3 (Schofield and Ratcliffe, 2004). PHD enzymes hydroxylate 




HIF-2α), promoting the interaction of the HIF-α subunit with Von-Hippel Lindau 
tumour suppressor protein (VHL)(Maxwell et al., 1999)(Furlow et al., 2009). VHL 
ubiquitinylates HIF-α, targeting it for rapid proteasomal degradation. Hydroxylation 
of HIFα by PHD enzymes requires molecular oxygen as a cofactor; therefore, in the 
absence of oxygen, the PHD enzymes are inactive and HIF-α remains stable and can 
go on to transcribe hypoxic response genes. This system allows a very rapid 
response to hypoxia. HIF activity is also regulated by another oxygen-dependent 
hydroxylase enzyme, Factor Inhibiting HIF (FIH), which blocks the transcriptional 
activity of HIF-1α subunits through hydroxylation of an asparagine residue, Asn803 
in human HIF-1α. The activity of PHD enzymes and FIH therefore regulate HIFs 
through degradation and inhibition of transcription when oxygen is available. A 
simplified version of the pathway is shown in Figure 1.2.2-1.  
HIF-1α and HIF-2α are both regulated by PHD proteins and have distinct 
transcriptional profiles. A list of HIF-1α and HIF-2α targets are shown in Table 
1.2.2-1. HIF-3α is structurally related to HIF-1α and HIF-2α, but does not have 
transcriptional activity, and expression is not regulated by oxygen tension at a 
transcriptional level (Hara et al., 2001). However, the alternative splicing of HIF-3α 
can produce a truncated form known as IPAS able to suppress HIF-1α and HIF-2α-
mediated activity through forming inactivate heterodimers with them (Makino et al., 
2001). Unlike HIF-1α, HIF-2α and HIF-3α are expressed in a limited selection of 
tissues including endothelial cells, renal interstitial cells and myeloid cells 
(Majmundar, Wong and Simon, 2010). 
In addition to molecular oxygen, PHD proteins also require free Fe2+ and the Krebs 
cycle intermediate 2-oxoglutarate (otherwise known as α-ketoglutarate, or α-KG). 
Metabolic flux can therefore regulate the activity of this pathway through 
modulating the efficiency of PHD in hydroxylating HIF targets (Schofield and 









Figure 1.2.2-1: The hypoxic response pathway. Oxygen, 2-oxoglutarate and Fe2+ 
are essential cofactors for the activity of the prolyl hydroxylase domain enzymes 
PHD1, 2 and 3. These enzymes hydroxylate HIF and target it for degradation by 
VHL. Lack of oxygen, Fe2+ or 2-oxoglutarate prevents the activity of PHD enzymes 
and leaves HIF-1α stable and able to bind to hypoxic response elements of target 






Protein Pathway Regulation Effectors  






PDK Upregulated PDK 
Angiogenesis Upregulated VEGF 
Glycolysis Upregulated HK1, HK2, PFKFB1-4, 
ALDOA, ALDOC, TPI1, 




Upregulated TKT, TKTL2 
Glycogen synthesis Upregulated GYS1 
Apoptosis Upregulated BNIP3, FAM162A, NOXA, 





Suppressed TMEM70, CYCS, ISCU 
Citric acid cycle Suppressed FH, ALDH4A1 
Red blood cell 
differentiation 
Upregulated EPO 
Cell differentiation Upregulated NOTCH 
Solute transporters  MCT4, CA9, NHE1 





Upregulated VEGF, TGF-α 
Angiogenesis Upregulated TGF-β1 
Table 1.2.2-1: The hypoxic response pathway. A list of critical pathways regulated 
by the hypoxic response transcription factors HIF-1α and HIF-2α (Benita et al., 





1.2.3. Modulation of neutrophil lifespan and function by oxygen 
tension 
In a normal neutrophil-mediated inflammatory response, neutrophils migrate to the 
site of infection or inflammation and then phagocytose invading bacteria. 
Neutrophils are cleared from the site of infection through a programme of 
constitutive apoptosis and subsequent phagocytosis of the apoptotic neutrophils by 
other immune cells such as resident macrophages (Perretti, Soehnlein and Ortega-
Gómez, 2013). In hypoxic conditions such as those found at sites of inflammation, 
constitutive neutrophil apoptosis and clearance are delayed (Hannah et al., 1995). 
This hypoxic survival phenotype is thought to be important in allowing neutrophils 
to remain in inflamed tissue long enough to clear infection through degranulation 
and phagocytosis of invading pathogens. Indeed, hypoxia can positively regulate 
neutrophil degranulation and potential for tissue injury (Hoenderdos et al., 2016). 
Inflammatory tissue tends to be hypoxic due to rapid tissue volume expansion 
increasing the distance between blood vessels and some areas of tissue, and the 
influx of large numbers of inflammatory cells, which then consume molecular 
oxygen. Neutrophils themselves can drive tissue hypoxia, through massive oxygen 
consumption after activation of NADPH oxidase activity, which acts as an 
inflammatory signal to nearby cells, as well as other neutrophils, through HIF-1α 
signalling (Colgan and Taylor, 2010)(Campbell et al., 2014). 
The exact mechanism of neutrophil persistence in chronic inflammatory conditions 
such as COPD is not known. However, dysregulation of this hypoxic survival 
phenotype and consequential lack of macrophage clearance may contribute to the 
accumulation of neutrophils in the airway lumen of COPD patients (Hoenderdos and 
Condliffe, 2013). Patients with moderate to severe COPD also experience alveolar 
hypoxia due to airway limitation and subsequently may develop hypoxaemia which 
can also influence the response of immune cells to infection (Kent, Mitchell and 
McNicholas, 2011). Pathways involved in the regulation of neutrophil hypoxic 
survival are associated with the modulation of intrinsic apoptosis and metabolic 
pathways, phagocytic capacity and redox potential, all of which may play a part in 
mediating neutrophil persistence and airway damage in inflammation (summarised 




The neutrophil response to hypoxia is dependent on the activity of the transcription 
factors HIF-1α and HIF-2α. HIF-1α is critical for neutrophil hypoxic survival 
(Walmsley et al., 2005) and for neutrophil infiltration and tissue destruction in 
models of inflammatory disease (Cramer et al., 2003). HIF-1α regulates neutrophil 
survival through an NF-κB-mediated mechanism, although downstream effectors of 
this pathway are unclear and require further elucidation (Walmsley et al., 2005). 
Macrophages isolated from HIF-1α-deficient mice were also shown to be 
functionally deficient, with aberrant bacterial killing, motility and ability to infiltrate 
into tissue (Cramer et al., 2003), implicating HIF-1α as a master regulator of 
myeloid cell function in hypoxic conditions. 
HIF-2α also regulates inflammation. Loss of HIF-2α is capable of suppressing 
neutrophilic inflammation and reducing the damage associated with lung injury 
induced by administration of LPS (Thompson et al., 2014). In a model of sterile lung 
inflammation, the expression of HIF-1α and HIF-2α appear to be temporally distinct, 
with HIF-1α expression induced early in the inflammatory response, and HIF-2α 
expression induced from 24 hours following inflammatory insult. In contrast to HIF-
1α knockouts, loss of HIF-2α was shown to accelerate constitutive neutrophil 
apoptosis even in normoxic conditions. 
Unsurprisingly, regulation of the PHD enzymes also has knock-on effects on 
inflammation through modulating neutrophil function. Loss of PHD2 in neutrophils 
reduces rates of constitutive apoptosis through stabilisation of HIF-1α and causes an 
exaggerated response to S. pneumonia infection, with more neutrophils at the site of 
inflammation (Sadiku et al., 2017). Conversely, loss of PHD3 in neutrophils causes 
loss of hypoxic survival and is beneficial for inflammation resolution (Walmsley et 
al., 2011). Further analysis of this pathway will be essential for understanding how 





1.3. Function and significance of neutrophil mitochondria 
1.3.1. Functions of neutrophil mitochondria 
As predominantly glycolytic cells, there has been some debate as to the role 
mitochondria play in the neutrophil. Early electron microscopy studies showed a 
small number of mitochondria in the neutrophil which are small and possess poorly 
defined cristae (Hirsch and Fedorko, 1968). However, more recent studies using 
mitochondria-specific fluorescent antibodies have found neutrophils possess an 
extensive network of mitochondria (Fossati et al., 2003), which has been confirmed 
by studies from our group (unpublished). These studies also found neutrophil 
mitochondria maintain mitochondrial membrane potential, suggesting they do 
undertake active electron transport (Fossati et al., 2003)(van Raam et al., 2008) 
although it is unclear whether this is used to generate ATP. Some studies suggest 
neutrophil mitochondria do not undergo oxidative metabolism; Maianski et al argue 
that neutrophil mitochondria do not participate in energy metabolism as inhibition of 
oxidative phosphorylation does not appear to significantly decrease the overall ATP 
found in the cell (Maianski et al., 2004). In addition, neutrophil oxygen consumption 
is minimal (Kramer et al., 2014) and neutrophil mitochondria seem to lack 
respiratory supercomplexes (van Raam et al., 2008), suggesting neutrophil 
metabolism is predominantly glycolytic. However, studies by Bao et al implicate 
mitochondrially-produced ATP in autocrine purinergic signalling of the neutrophils, 
suggesting some degree of physiologically-relevant oxidative phosphorylation (Bao 
et al., 2014).     
Fossati et al outline a number of non-energy functions of neutrophil mitochondria 
through the use of inhibitors of the electron transport chain (Fossati et al., 2003). 
Disruption of neutrophil mitochondrial membrane potential with the protonophore 
FCCP was found to have a profound effect on cell shape, respiratory burst capability 
and neutrophil chemotaxis. Furthermore, incubation with the ATP synthase inhibitor 
oligomycin was found to alter respiratory burst activation and chemotaxis of 
neutrophils with no effect on mitochondrial membrane potential and neutrophil 
apoptosis, indicating that while neutrophil mitochondria have limited respiratory 





1.3.2. The role of neutrophil mitochondria in apoptosis 
The involvement of mitochondria in the regulation of neutrophil apoptosis has been 
explored in a number of studies linking caspase activation and upstream regulators 
of caspases such as Bak, Bax, Bad and Mcl-1 to the regulation of the onset of 
constitutive neutrophil apoptosis. Neutrophils constitutively expressive pro-apoptotic 
Bcl-2 family proteins such as Bax, Bad, Bak, Bik and Bim, and also express anti-
apoptotic proteins such as Mcl-1, Bcl-XL and A1, but not Bcl-2 (reviewed in Milot & 
Filep 2011). Mcl-1 is known to be a profound survival signal as it antagonizes pro-
apototic Bax protein, and is thought to be an important factor in regulating 
neutrophil survival. Neutrophils are unusual in that they do not express Bcl-2, an 
anti-apoptotic protein found in almost all other tissues as well as other innate 
immune cells known to be a critical regulator of apoptosis (Akgul, Moulding and 
Edwards, 2001)(Chipuk et al., 2010). Neutrophils isolated from Mcl-1 conditional 
knockout mice were shown to have profoundly reduced survival when cultured ex 
vivo (Dzhagalov, St. John and He, 2007). Moreover, pro-survival stimuli such as 
GM-CSF, IL-1β, LPS and hypoxia increase Mcl-1 expression (Moulding et al., 
1998)(Dyugovskaya et al., 2012), implicating Mcl-1 in a link between regulation of 
constitutive apoptosis and delay of apoptosis in inflammation.. 
Maianski et al show accumulation of Bax in and loss of cytochrome c from the 
neutrophil mitochondria during apoptosis and suggest constitutive neutrophil 
apoptosis is mediated by the intrinsic apoptosis pathway (Maianski et al., 2004). 
This correlates with the profound survival effects of Mcl-1. A study by Scheel-
Toellner et al suggests constitutive apoptosis is dependent on an extrinsic pathway 
involving the formation of lipid rafts which can localise death receptors such as 
CD95 and death-inducing signalling complexes (DISCs) (Scheel-Toellner et al., 
2004). They hypothesise that generation of ceramide allows clustering of CD95, 
DISCs and other TNFR1 homologues, which mediates apoptosis through caspase-8 
activation and Bax insertion into the outer mitochondrial membrane. However, a 
study by Renshaw et al suggests blocking death receptors, in this case TRAIL-R2, 




effects of TRAIL (Renshaw et al., 2003). It is not entirely clear how the relative 
contribution of intrinsic and death receptor-mediated apoptotic pathways regulate 
constitutive neutrophil apoptosis or how these pathways are modulated in the 
hypoxic survival phenotype. Interestingly, treatment with desferoxamine, an 
inhibitor of hydroxyl radical production, was shown to reduce ceramide generation 
and CD95 clustering, and delay spontaneous neutrophil apoptosis, indicating ROS 
may be upstream regulators of this process and play an important role in the 
regulation of apoptosis.  
1.3.3. Mitochondrial reactive oxygen species 
It is well established that intact mitochondria produce reactive oxygen species. 
Production of mitochondrial reactive oxygen species (hereby referred to as mROS) is 
mediated through leak of electrons from the electron transport chain and subsequent 
reaction with molecular oxygen in the mitochondrial matrix or intracellular space to 
form superoxide, or O2- (Wulf, 2002). Superoxide can then be exported from the 
intracellular space to the cytoplasm, or rapidly dismutated to hydrogen peroxide 
(H2O2) which can freely diffuse across the mitochondria outer membrane and have 
far reaching effects in the cell (West, Shadel and Ghosh, 2011). Alternatively, 
superoxide can react with nitric oxide (NO) to produce peroxynitrite (ONOO-), a 
powerful oxidant. H2O2 is detoxified by antioxidant enzymes such as catalase or 
glutathione peroxidase, or can be reduced by metal ions to form a hydroxyl radical, 
OH (Figure 1.3.3-1).  
Traditionally, mROS have been thought of as an unwanted by-product of oxidative 
respiration, which can cause damage to the cell. Indeed, a wide range of pathologies 
are linked to enhanced oxidative stress, including rheumatoid arthritis and 
degenerative neurological disorders (Uttara et al., 2009). However, a number of 
studies have found roles for mROS in the healthy cell and describe ROS such as 
hydrogen peroxide as intracellular signalling molecules capable of modulating the 
activity of phosphatase and kinase enzymes through oxidation of residues in the 
active site (Rhee et al., 2000)(Banerjee et al., 2010). Interestingly, there is also 
mounting evidence that HIF-1α stability in hypoxia is dependent on the production 




Schumacker, 2006). Inhibition and deletion of complexes I and III of the electron 
transport chain are sufficient to completely block HIF-1α stability (Guzy and 
Schumacker, 2006).  
The mechanism for mROS-mediated HIF-1α is unclear, but it has been proposed this 
may be due to hydrogen peroxide radicals directly inhibiting PHD enzymes by 
oxidising non-heme-bound iron. Subsequent studies have suggested peroxide may 
also enhance HIF-1α stability through inhibition of the activity of FIH (Masson et 
al., 2012). 
There has been some prior investigation into the role of mROS in the context of 
neutrophil-mediated lung inflammation. Data suggests neutrophils have limited 
complex V activity, which may account for electron leak at other steps in electron 
transfer (Luo and Loison, 2008). Complex I is known to be a major source of 
electron leak and production of mROS (West, Shadel and Ghosh, 2011). In a study 
by Zmijewski, neutrophil complex I inhibition was shown to increase ROS 
production, inhibit NF-κB activation, and diminish pro-inflammatory cytokine 
production in neutrophils activated by LPS (Zmijewski et al., 2008). The study went 
on to show inhibitors of complex I administered to mice with LPS-induced lung 
inflammation significantly decreased neutrophil counts in bronchoalveolar lavage 
(BAL) fluid and significantly lessened lung damage induced on addition of LPS. 
This correlates with studies suggesting HIF-1α requires ROS derived from complex I 
and III for stability (Guzy and Schumacker, 2006). Studies by van Raam have 
suggested neutrophil mitochondrial membrane potential and mROS production could 
be maintained by transfer of electrons to complex III via the glycerol 3-phosphate 
shuttle, suggesting the high level of glycolysis in the neutrophil can maintain 
mitochondrial membrane potential itself (van Raam et al., 2008). These data 
therefore implicate neutrophil mROS as potential modulators of neutrophil function, 
and further investigation is required to understand how mROS may affect neutrophil 







Figure 1.3.3-1: Reactive oxygen species in the cell. A schematic showing the 
various reactive oxygen and nitrogen species in the cell and cellular antioxidant 
mechanisms. A) Molecular oxygen is converted to superoxide through the activity 
of the mitochondrial respiratory chain complexes or through oxidase enzymes such 
as xanthine oxidase and NADPH oxidase. B) Reactive nitrogen species such as NO 
may react with superoxide to produce toxic radicals such as peroxynitrite that can 
cause cell damage. C) Superoxide may be dismutated by mitochondrial SOD into 
hydrogen peroxide. Hydrogen peroxide can freely diffuse out of the mitochondria 
and modulate mitochondrial and cytoplasmic signalling. It may be neutralised by the 
activity of antioxidant enzymes such as catalase or glutathione peroxidase. It may 
also cause cellular damage either directly or through it’s oxidised intermediate, OH. 






























1.3.4. Neutrophil reactive oxygen species and apoptosis 
The modulation of apoptotic pathways in hypoxic conditions or in patients with 
chronic lung disease has not been studied in much detail, especially in the context of 
ROS signalling. Mcl-1 has been under scrutiny as a downstream target of HIF-1α in 
other cell types. Studies have indicated Mcl-1 expression is closely linked with 
expression of HIF-1α at the transcriptional level (Liu et al., 2006) but little 
information exists in the context of neutrophil apoptosis. Studies from our group 
have also implicated a HIF-1α-independent, PHD3-dependent hypoxic survival 
signal mediated via the balance between the pro-apoptotic protein Siva1 and the 
survival protein Bcl-XL (Walmsley et al., 2011). 
Reactive oxygen species may be influential in driving neutrophil apoptosis, both 
constitutive and following phagocytosis of pathogens via a caspase-dependent 
pathway (Yamamoto et al., 2002)(Sim et al., 2005). Neutrophils from patients with 
Chronic Granulatomous Disease (CGD), a disease characterised by a defect in 
NADPH oxidase, were found to experience a profound delay in constitutive 
apoptosis when cultured ex vivo (Kasahara et al., 1997). Sim et al posit that 
apoptosis is mediated through ROS interacting with the ERK1/2 signalling pathway, 
and from oxidative damage to the cell inducing caspase-dependent apoptosis. 
However, there is also evidence that indicates ROS may have a pro-survival role. 
ROS are thought to stabilise HIF-1α, and stabilisation of HIF-1α allows for a 
profound survival response (Walmsley et al., 2005). Other studies have shown 







1.4. Neutrophil metabolism and regulation of apoptosis 
and function 
Glucose metabolism is closely linked with immune cell function both at the site of 
inflammation and infection. High glucose levels in the blood are known to be 
proinflammatory; chronic hyperglycemia associated with diabetes has been linked to 
increased levels of chronic inflammatory markers including IL-1β, IL-6 and TNF-α 
(Chang and Yang, 2016). Hyperglycaemia can also profoundly modulate neutrophil 
function and apoptosis. Neutrophils isolated from patients with type 1 diabetes have 
been shown to have functional defects in adhesion, migration, phagocytosis and 
survival (summarised Huang et al., 2016).  
The regulation of carbohydrate metabolism in innate immune cells has given rise to 
the field of Immunometabolism. Immune cell functions are closely related to their 
metabolic regulation and substrate use. Enhanced glycolytic flux is a hallmark of 
immune cell activation on ligation of TLR receptors, occurring during pro-
inflammatory macrophage activation and dendritic cell activation, and activation of 
B and T cells (Krawczyk et al., 2010)(Rodriguez-Prados et al., 2010). Pro-
inflammatory M1 classical macrophage activation with bacterial LPS is 
characterised by an increase in HIF-1α expression and glycolytic flux, whereas anti-
inflammatory M2 macrophages activated with IL-4 and IL-13 instead rely on 
oxidative phosphorylation for energy production (Kelly and O’Neill, 2015). This 
upregulation of glycolysis is though to occur through LPS-induced activation of 
HIF-1α and NF-κB; similarly, hypoxia can acts as a potent pro-inflammatory 
stimulus through HIF-1α, and HIF-1α is essential for inflammatory macrophage 
activation (Kelly and O’Neill, 2015)(Wang et al., 2017).  
These data perhaps explain why fasting and administration of inhibitors of glycolysis 
have had some success in vivo as treatments against inflammatory diseases (Lee et 
al., 1999)(Gasior, Rogawski and Hartman, 2006). A study by Wang et al elegantly 
showed that the glucose hexokinase inhibitor 2-deoxyglucose (2-DG) and fasting 
could actually reverse morbidity associated with Listeria monocytogenes infection or 
LPS-induced sepsis, whereas nutrient deprivation or inhibition of glucose utilisation 




(I:C) (Wang et al., 2016). Glucose supplementation was also detrimental in a model 
of LPS-induced sepsis – indicating glucose could fuel detrimental pro-inflammatory 
functions of the immune system. Similarly, hypoxia is capable of sensitizing cells to 
2-DG due to an increase in glycolytic flux after exposure to hypoxia (Liu et al., 
2002)(Xintaropoulou et al., 2015). 
Metabolism can also regulate hypoxic signalling. The PHD enzymes require oxygen 
and the Krebs cycle metabolite α-KG to hydroxylate HIFs. Flux through the Krebs 
cycle can modulate HIF activity through the availability of α-KG (Majmundar, 
Wong and Simon, 2010). Recent studies have implicated other Krebs cycle 
metabolites as critical immune regulators. Succinate generated in the Krebs cycle 
can inhibit PHDs and mediate a pro-inflammatory, HIF-1α driven macrophage 
response (Tannahill et al., 2013). Hypoxia itself can modulate Krebs cycle 
metabolism, with hypoxia causing the production of L-2-hydroxyglutarate, a Krebs 
cycle byproduct which can competitively inhibit PHD enzymes (Xu et al., 
2011)(Intlekofer et al., 2015). Glycolytic flux also feeds back to HIF-1α expression, 
with lactate and pyruvate production stimulating the accumulation of HIF-1α even in 
aerobic conditions (Lu, Forbes and Verma, 2002). Pharmacological manipulation of 
these pathways can therefore modulate immune cell function; for example, 
suppression of CARKL, an enzyme that limits flux through the pentose phosphate 
pathway, is sufficient to push macrophages to an M1-like state by increasing 
glycolytic flux (Haschemi et al., 2012).  
As neutrophils have long been thought of as metabolically “simple” cells, mainly 
glycolytic with little capacity for aerobic respiration, there has been little focus on 
metabolism in mediating neutrophil function. Recent studies by Sadiku et al in 
neutrophils have shown an exaggerated inflammatory response caused by myeloid 
specific knockout of PHD2 is caused by enhanced glycolytic flux and can be rescued 
on treatment with 2-DG (Sadiku et al., 2017). This parallels similar observations in 
macrophages that link glycolytic metabolism to function. Through giving C13-
labeled glutamine, Sadiku et al were able to show neutrophils are capable of both 
reductive Krebs cycle activity and gluconeogenesis, as labeled carbon was found to 




activity was profoundly increased in PHD2 knockout cells.  
Hypoxia and the HIF-1α pathway can therefore profoundly modulate immune cell 
function through carbohydrate metabolism. However, there have been few studies 
investigating the role of metabolism in regulating neutrophil function and apoptosis 
specifically. 
1.5. Aims of the thesis 
Hypoxia has been shown to be a profound stimulus for neutrophil survival and 
persistence in tissues. Oxygen sensing mechanisms, including HIF-1α and HIF-2α, 
are essential for the adaptation of neutrophils to the hypoxic niche of inflamed sites. 
Modulation of HIF-1α expression is predominantly caused by the absence of oxygen 
substrate for PHD enzymes. However, alternative regulators of HIF activity can 
finely tune the hypoxic response of the cell. One of these regulators is mitochondrial 
ROS, which can be released in response to acute hypoxia. Direct targeting of HIF-1α 
is not a desirable approach for reducing inflammation in chronic inflammatory 
diseases for the reason that HIF-1α is required for many processes including 
motility, invasiveness and bacterial killing.  However, attenuation of inappropriate 
HIF activity in the context of hypoxia may prevent over-exaggerated immune 
reactions. Therefore, targeting pathways that augment the HIF-1α transcriptional 
response, such as mROS, may be useful in limiting HIF-1α-mediated chronic 
inflammation. Previous studies using the mitochondrial inhibitors metformin and 
rotenone have both been shown to limit LPS-driven lung injury, indicating targeting 
neutrophil mitochondrial may be a potential treatment for neutrophil inflammation 
(Zmijewski et al., 2008). The PHD enzymes are also profound regulators of the HIF 
proteins. PHD2 has been well characterized as able to modulate HIF-1α stability and 
glucose metabolism in neutrophils in a way which augments their function (Sadiku 
et al., 2017). The contribution of other PHD enzymes to neutrophil function and 
apoptosis, especially in the inflammatory environment in vivo, is less well 
established.  
My thesis therefore has two distinct questions regarding the regulation of reactive 




cytosolic reactive oxygen species produced by NADPH oxidase. My hypotheses are: 
1. That neutrophils mitochondrial function regulates neutrophil apoptosis not 
through generation of ATP, but via signaling through the production of 
mitochondrial ROS, which can stabilize HIF-1α and enhance neutrophil 
survival. 
2. That the prolyl hydroxylase enzyme PHD3 is a metabolic regulator that can 
suppress reactive oxygen species production through regulating metabolism, 
and loss of this enzyme may be beneficial in resolving bacterial infection 
through enhancing production of reactive oxygen species and consequently, 
enhancing bacterial killing and encouraging rapid neutrophil apoptosis and 
clearance. 
The aims of this thesis are therefore as follows: 
1. To understand if, despite being predominantly glycolytic cells, neutrophils 
maintain a mitochondrial membrane potential and release mitochondrial ROS 
uaing fluorescent probes which can measure mitochondrial function in live 
cells. 
2. To examine how hypoxia affects neutrophil mitochondrial function; in 
particular, whether neutrophil mitochondria release ROS in response to 
hypoxia, and whether ROS modulate the stability of HIF-1α with 
downstream effects on survival and function. 
3. To interrogate the mechanism of hypoxic mROS release using neutrophils as 
a model of cells with little mitochondrial ATP production, using mass 
spectrometry to measure metabolic flux. 
4. To use a model of PHD3 knockout to understand whether loss of PHD3 is 
beneficial for the resolution of bacterial infection as it is in models of sterile 
inflammation. 
5. To measure how the metabolic profiles of neutrophils are altered by loss of 







2.1. Ethical approval 
2.1.1. Healthy volunteers 
Phlebotomy of healthy volunteers was approved by the Lothian Local Research 
Ethics committee. Volunteers gave full informed consent to participate. 
2.1.2. SDHBx patients 
20 patients with rare heterogenous germ-line mutations in SDHB (SDHBx) were 
recruited. Individuals with loss-of-function frameshift, splice, missense or nonsense 
mutations were included in the study.  
2.2. Human neutrophil isolation 
Neutrophils were isolated from peripheral blood through dextran sedimentation 
followed by discontinuous Percoll centrifugation. This method yields >95% pure 
neutrophils with minimal activation (Haslett et al., 1985). 	
6% w/v dextran stocks were made up from 3g of sterile 500kDa dextran (Sigma-
Aldrich Company Ltd., UK) and 50ml 0.9% Baxter’s saline. The dextran stock was 
then passed through a 0.22um filter and warmed to 37°C prior to use. Peripheral 
blood was drawn from healthy volunteers using a 21 gauge needle and aliquoted into 
a 50ml falcon tube containing 4.4ml 3.8% sodium citrate (Sigma-Aldrich Company 
Ltd., UK) as an anti-coagulant. Tubes were gently mixed, then centrifuged at 270g 
for 20 minutes. The plasma phase was aspirated and removed. To the remaining 
lower cell-rich layer, 6ml of 6% dextran was added and the tube topped up to 50ml 
with sterile 0.9% saline (Baxter Healthcare Ltd.). The tube was then mixed by gentle 
inverting and rolling, air bubbles removed using a sterile Pasteur pipette, then left to 
settle for 20-30 minutes at 37°C with the lid loosely fitted to allow red cell 
sedimentation to occur. The upper leukocyte-rich layer was transferred to sterile 
falcon tubes and spun at 185g for 6 minutes. Discontinuous plasma-Percoll gradients 
were prepared by overlaying 2ml of 68% Percoll/32% Dulbecco’s Phosphate 




Percoll/19% DPBS in 15ml tubes (Percoll® from Sigma-Aldrich Company Ltd., UK). 
The upper fraction was run gently down the side of the tube to avoid mixing the two 
layers. Leukocytes from 40ml of whole blood (1 Percoll gradient per tube) were re-
suspended in 2ml 51% Percoll/49% DPBS and overlaid on top of the gradient. These 
tubes were then centrifuged at 1200g for 30 minute, with acceleration 1 and no 
brake, producing three distinct layers of cells. Erythrocytes were pelleted at the 
bottom of the tube. Between the 81% and 68% Percoll fractions, a band containing 
polymorphonuclear (PMN) cells (neutrophils and eosinophils) formed. Between the 
68% and 51% fractions, a band comprised of peripheral blood mononuclear cells 
(PBMCs) formed. The PBMC layer was removed using a Pasteur pipette with care 
taken not to transfer cells to the lower layer. The granulocytes were transferred to a 
fresh falcon tube and the tube made up to 40ml with 1x DPBS, centrifuged at 350g 
for 5 minutes to pellet the cells, then resuspended again in 40ml with 1x DPBS and 
counted via microscopy using C-Chip disposable haemocytometer slides (Cambridge 
Bioscience, UK). Neutrophil purity was assessed through examination of slides 
prepared by cytocentrifuge immediately following isolation and samples with >95% 
purity used for subsequent assays. 
2.3. Human neutrophil culture 
Neutrophils isolated from whole blood were resuspended at 5x106 ml-1 in RPMI 
1640 (Sigma-Aldrich Company Ltd., UK) supplemented with 1% 100x 
penicillin/streptomycin (Gibco™, ThermoFisher Scientific, UK) and 10% foetal 
bovine serum (FBS)(Gibco™, ThermoFisher Scientific, UK) and pre-warmed to 
37°C and cultured on 96-well non-tissue culture treated polyvinylchloride plates (BD 
Falcon™, BD Biosciences, Becton Dickinson Ltd., Oxford, UK). Normoxic cell 
culture was carried out at 37°C in a humidified incubator with 5% supplemental CO2 
(Sanyo). Hypoxic cell culture was established by re-suspending cells in media which 
had been pre-equilibrated overnight at 1% O2, 5% CO2 in an Invivo2 400 hypoxic 




2.4. Gas analysis of equilibrated culture media  
The oxygen tension of re-equilibrated complete RPMI used for neutrophil culture 
was measured using a RAPIDLab® 348EX blood gas analyser. A 1ml aliquot was 
removed from RPMI equilibrated in either normoxia or hypoxia as described above 
into a 1ml syringe and the syringe capped. The sample was then fed into the blood 





 Normoxia (n=4) Hypoxia (n=15) 
pO2 18.5 (0.195) 4.082 (0.4916) 
pCO2 3.63 (0.2517) 4.329 (0.0572) 
pH 7.43 (0.00673) 7.38 (0.0200) 
Figure 2.4-1: Confirmation of hypoxic culture conditions. A: The oxygen 
cascade. Oxygen levels in the body range from 19kPa in inspired air to less that 5kPa 
in inflamed tisue. B: pO2, pCO2 and pH values of media equilibrated in normoxia 




2.5. Assessment of apoptosis via morphology 
Microscope slides (ThermoFisher Scientific, UK) were prepared through 
cytocentrifugation. 100µl of 5x106ml-1 neutrophil suspension was centrifuged onto a 
microscope slide using a Thermo Shandon Cytospin 3 (Harlow Scientific®) for 3 
minutes at 300rpm. Slides were aired dried for 10 minutes, fixed with 100% 
methanol, then dipped in Diff-Quik staining solutions 1 and 2 for 30 seconds each to 
stain and then rinsed under the tap. Slides were left to dry for 1 hour before 
mounting. Coverslips were attached with DPX synthetic resin mountant (Sigma-
Aldrich Company Ltd., UK). Slides were counted via oil-drop microscopy at 1000x 
magnification. Purity was assessed through counting visible eosinophils, monocytes 
and erythrocytes, and polymorphonuclear cell populations with <95% neutrophils 
excluded from further experiments. At least 300 neutrophils per slide were counted 
and apoptosis calculated as % of total counted neutrophils exhibiting nuclear 







Figure 2.5-1: Identification of apoptotic cells via morphology. Apoptotic cells 
were identified through nuclear condensation and fragmentation. Apoptotic cells are 
indicated by black arrows. A: An apoptotic neutrophil with a single, highly 






2.6. Flow cytometry 
2.6.1. Assessment of apoptosis via Annexin V/TO-PRO-3 staining 
Cultured neutrophils were removed from the culture plate and transferred to sterile 
1.5ml eppendorffs, then centrifuged for 2 minutes at 350g at 4°C, resuspended in 
1ml ice-cold 1xDPBS then centrifuged again. 1x Annexin Binding Buffer (ABB) 
was prepared from 1ml 10x ABB (Abcam®) and 9ml dH2O. Neutrophils were 
resuspended in 95µl 1x ABB. 5µl Annexin V-PE (BD Biosciences) was added to 3 
of the cell suspensions from each condition and incubated on ice in the dark for 10 
minutes. 4 FACS tubes were prepared, 1 as a blank containing 100µl 1x ABB and 3 
containing 100µl of a 1:20000 dilution of 1mM TO-PRO-3 (Invitrogen®) (5ml 
1xABB, 1µl 1mM TO-PRO-3). Annexin stained cells were added to the 1:20000 
TO-PRO-3 and unstained cells were added to the 1xABB as a negative control. 
Apoptosis was analysed using a BD FACSCalibur flow cytometer (Becton 
Dickinson®). Neutrophil populations were gated using side scatter (SSC) against 
forward scatter (FSC). Annexin V-PE binding was assessed through excitation with 
a 488nm laser filtered through a 585nm dichroic bandpass filter (FL2 channel). TO-
PRO-3 binding was assessed through excitation with the 635nm laser and detection 
of fluorescence through a 661nm dichroic bandpass filter (FL4 channel). Apoptosis 
was determined as percentage of Annexin V-PE positive or Annexin V-PE/ TO-
PRO-3 positive cells. Populations were gated using an unstained control. 
2.6.2. Assessment of mitochondrial reactive oxygen species 
production using MitoSOX™ Red 
Neutrophils were cultured in normoxia and hypoxia with and without 100µM 
MitoTEMPO (Sigma-Aldrich Company Ltd., UK), 10µM Rotenone (Sigma-Aldrich 
Company Ltd., UK), or 10µM Oligomycin (Sigma-Aldrich Company Ltd., UK), and 
5 minutes from the end of incubation, normoxic and hypoxic cells were stimulated 
through the addition of 100nM N-Formlylmethionine-leucyl-phenylalanine 
(fMLP)(Sigma-Aldrich Company Ltd., UK) to cell suspension. MitoSOX™ Red 
(Life Technologies) stock solution was made up through dissolving one 50µg vial in 
26µl in dimethyl sulfoxide (DMSO)(Sigma-Aldrich Company Ltd., UK). A working 




2µl of working solution was added to each well and plates loosely covered in tin foil 
and left to incubate for 30 minutes. Cells were then harvested, washed once in ice-
cold PBS, and resuspended in 1x Hank’s balanced salt solution (HBSS) ready for 
analysis. Cells were analysed via flow cytometry on the FACSCalibur using a 






         
Figure 2.6.2-1: Assessment of mitochondrial reactive oxygen species production 
by MitoSOX™ Red staining. Neutrophils were gated based on forward-scatter 
(FSH-H) and side-scatter (SSC-H) and MitoSOX™ Red fluorescence assessed 











2.6.3. Assessment of mitochondrial membrane potential using Tetra 
Methyl Rhodamine, Methyl Ester 
Neutrophils were cultured in normoxia and hypoxia with and without 10µM 
carbonyl cyanide m-chlorophenyl hydrazone (CCCP)(Sigma-Aldrich Company Ltd., 
UK) and 100µM MitoTEMPO (Sigma-Aldrich Company Ltd., UK). After 
incubation, normoxic and hypoxic cells were harvested and transferred into 1.5ml 
eppendorffs. Cells were centrifuged for 2 minutes at 350g at 4°C. 10mM 
tetramethylrhodamine methyl ester (TMRM)(Sigma-Aldrich Company Ltd., UK) 
stock solution was diluted 1/1000 in 1x DPBS and then 3ul added to 1ml of 1x 
DPBS to make a working solution with a final concentration of 30nM. Cells were 
resuspended in TMRM working solution and incubated at room temperature for 30 
minutes. Cells were analysed via flow cytometry on the FACSCalibur using a 








Figure 2.6.3-1: Assessment of mitochondrial membrane potential by TMRM 
staining. Neutrophils were gated based on forward-scatter (FSC-H) and side-scatter 
(SSC-H) and TMRM fluorescence assessed through the FL2-H channel. A: 









2.6.4. Assessment of cellular reactive oxygen species production 
using CM-H2DCFDA 
Neutrophils isolated from whole blood via dextran sedimentation and discontinuous 
percoll gradient were cultured in a 96-well plate for 30 minutes in complete RPMI in 
normoxia and hypoxia at 5x106 cells/ml. CM-H2DCFDA (DCF)(Life Technologies) 
stock solution was made up through dissolving one vial in 5µl DMSO and a working 
solution made up through diluting stock by a factor of 100. 3µl of working solution 
was adding per well of cells and incubated for 30 minutes. Cells were incubated for a 
further 30 minutes with and without 100nM of fMLP (Sigma-Aldrich Company Ltd., 









Figure 2.6.4-1: Assessment of neutrophil reactive oxygen species production 
through DCF staining. Neutrophils were gated based on forward-scatter (FSC-H) 
and side-scatter (SSC-H) and DCF fluorescence assessed through the BL-1A channel. 








2.7. Measurement of redox intermediates and redox ratios 
 Neutrophils were cultured in normoxia and hypoxia with and without 100nm 
LPS. Following incubation, cells were centrifuged for 2 minutes at 350g at 4°C and 
washed once in ice-cold 1xDPBS. Neutrophil pellet was lysed in 100µl Lysis Buffer 
(Abcam) and incubated for 15 minutes before assaying 25µl of lysate using a 
fluorimetric NAD+/NADH Assay Kit (ab176723)(Abcam) or NADP+/NADPH 
Assay Kit (ab176724)(Abcam). Fluorescence was read at 530/590nm using a 
TECAN infinite M1000 plate reader. 
2.8. Assessment of protein expression via western blotting 
2.8.1. Protein isolation from neutrophils 
Whole cell lysates were prepared from neutrophils through sonication. Protease 
inhibitor cocktail was made up before harvest through dissolving a complete 
protease inhibitor tablet (Roche) in 1ml dH2O. Neutrophils were harvested and 5x106 
cells (7 150µl wells) were pelleted at 350g for 2 minutes at 4°C, then resuspended in 
500µl complete lysis buffer made up from a stock of 1.5ml sonication lysis buffer 
(100 mM Tris-HCl, pH 7.8, 1.5 mM EDTA, 10 mM KCl, 0.5mM dithiothreitol 
(DTT), 1 mM sodium orthovanadate, 2 mM levamisole) with 75µl protease inhibitor 
cocktail (Roche), 15ul EDTA-Free Protease inhibitor cocktail 3 (Merck Millipore) 
and 15µl phenylmethanesulfonylfluoride (PMSF)(Sigma-Aldrich Company Ltd., 
UK). Cells were spun again at 350g for 2 minutes at 4°C, resuspended in 50µl 
complete lysis buffer and placed on ice for 10 minutes. Cells were sonicated in a 
Bioruptor® Plus sonication device (Diagenode) in 30 second bursts for 10 minutes. 
Cells were centrifuged for 10 minutes at 12,000g at 4°C and the supernatant 
transferred to a clean eppendorff. 50µl 2x Sodium Dodecyl Sulphate 
(SDS)/Bromophenol blue solution was added to each aliquot and samples boiled for 
5 minutes at 100°C before freezing at -80°C until use.   
2.8.2. Western blotting 
BioRad® Mini-PROTEAN Tetra-cell kits were used to set gels. 1.5mm 8% SDS gels 




tetramethylethlyenediamine (TEMED) (Appendix 7.1). BioRad® mini-PROTEAN 
1.5mm separating plates and short plates, and BioRad® 1.5mm 10-well combs were 
cleaned with 70% IMS before use. 
APS and TEMED were added immediately before the resolving gel was poured 
between two upright plates. The resolving gel was then overlaid with 0.5ml 
isopropanol and allowed to set. Once set, isopropanol was rinsed from the membrane 
with water and dried, and stacking gel overlaid onto the gel, a comb added, and the 
gel left to set.  
Electrophoresis was carried out in a tank filled with 1x running buffer (recipes for 
western reagents in Appendix 7.2). Plates were submerged in running buffer and 
combs removed gently. Samples were heated to 100°C for 5 minutes before loading 
and 50µl of lysate loaded per lane. A lane was loaded with 15µl New England 
Biolabs® Colorplus™ broad range protein ladder (10-230kDa). Samples were run 
through the stacking gel at 100V, then through the resolving gel at 150V. Protein 
was not run off the gel as the proteins of interest were at the extreme of the protein 
ladder, at 15kDa. Instead, protein front was run approximately 1 inch from the end of 
the gel. 
Gels were removed and transferred to a polyvinylidene fluoride (PVDF) membrane 
(Immobilon Transfer membrane, Millipore) via wet transfer. 
1 square of PVDF membrane was cut per gel and soaked in 100% methanol for 5 
minutes. Transfer cassettes were assembled in a bath of 1x transfer buffer (Appendix 
7.2) with stacks of sponge, filter paper, gel and PVDF membrane. Cassettes were 
placed in a tank and submerged in 1x transfer buffer, and protein transferred at 100V 
for 70 minutes on ice. Membranes were then blocked in blocking buffer (Appendix 
7.2) for 60 minutes. Membranes were incubated with primary antibody diluted in 
blocking buffer at an appropriate solution overnight at 4°C (See Appendix 7.8 for a 
summary of primary antibodies used). Membranes were washed 3 times in 10ml 1x 
TBS-Tween (Appendix 7.2) for 10 minutes per wash and incubated for 1 hour with 
Horseradish Peroxidase-coupled Goat Anti-Rabbit IgG (Dako) diluted 1:2000 in 




Western ECL subtrates (Biorad®) were equilibrated for 5 minutes and membranes 
treated with ECL subtrates for 5 minutes before exposure to X-ray film and 
development in dark room.  
2.8.3. Stripping and re-probing 
After development, membranes were washed in water for 7 minutes, soaked in 0.2M 
NaOH for 15 minutes and washed again for 7 minutes in water before reprobing with 
Rabbit anti-p38 MAPK diluted 1:2000 in milk (Cell Signaling Technology) for 1 
hour. Membranes were then washed, probed with secondary antibody and developed 
as described previously. 
2.9. Murine study approval 
 Animal experiments were conducted in accordance with the UK Home 
Office Animals (Scientific Procedures) Act of 1986. All animal studies were 
approved by The University of Edinburgh Animal Welfare and Ethical Review 
Board. 
2.10. Murine colonies  
2.10.1. Wild-type animals 
C57BL/6 mice were purchased from Harlan (Oxford, UK), aged 8 weeks. They were 
then rested in standard housing conditions for 1 week prior to experiments. 
2.10.2. PHD3flox/flox LysMCre+/- colony 
Breeding stocks were kindly donated by Peter Carmeliet and Max Mazzone, VIB-
KU Leuven Centre for Cancer Biology. A myeloid cell lineage-specific Cre-loxP 
system was used to delete PHD3. Experimental animals were homozygous for the 
floxed PHD3 allele targeted to myeloid cells via a lysozyme M-drived Cre 
recombinase (LysMCre+/- PHD3flox/flox)(Clausen et al., 1999)(Figure 2.10.2-1). All 
experiments were performed with sex and age-matched wild-type mice. 
2.10.3. Genotyping 




100μl of sterile lysis buffer (5ml 1M NaCl, 5ml 10mM EDTA, 5ml 10% SDS, 500ul 
1M Tris HCl pH 7.5, 10mg Proteinase K, 35ml sterile H2O) was added to mouse ear 
clips and incubated for 50°C for 2 hours. After incubation, 200μl of phenol-
chloroform was added, samples vortexed to mix and then centrifuged for 10 minutes 
at 11,000g. Supernatant was removed and stored at 4°C until used for PCR. 
Amplified cDNA was separated on a 2% agarose gel, run at 100V for 1 hour and 
read on a Gel Doc 2000 system (Biorad, UK). Primers used for genotyping are 






Figure 2.10.2-1: Schematic showing myeloid-specific knockout of PHD3 using 
the LysM promoter. A) Diagram showing location of flox sites within the Phd3 
allele in PHD3flox/flox mice. B) PHD3flox/flox mice were crossed with heterozygous 
LysM Cre/Lox mice to generate PHD3flox/flox LysMCre+/- and PHD3flox/flox LysMCre-/- 
mice. PHD3 expression is controlled by expression of the LysM promoter, targeting 
knockout specifically to cells of the myeloid lineage. LysM is expressed in 
granulocytes and mature macrophages. Figure A adapted from Takeda et al, 2006. 
Mice kindly donated by the Carmeliet group. 
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2.11. Murine lung inflammation model 
2.11.1. Induction of sterile lung injury 
100mg of bacterial lipopolysaccharide from Pseudomonas aeruginosa (Sigma-
Aldrich Company Ltd., UK) was dissolved in 10ml of 0.9% saline to make a 
10mg/ml stock and stored at 4°C for up to 2 months before use. 300µl stock was 
diluted in 2.7ml sterile Baxter’s saline to make a 1mg/ml solution. Mice were 
nebulised with 3ml 1mg/ml solution using a custom-made nebulisation rig and then 
housed in either room normoxia (21% O2) or in a Coy™ Model 3 hypoxic chamber 
set at physiological hypoxia (10% O2). The oxygen concentration in the hypoxic 
chamber was reduced gradually over the course of one hour to 10% oxygen/90% 
nitrogen using an oxygen sensing control unit (Coy Labs, Michigan, USA). Oxygen 
concentration was then steady at 10%. Carbon dioxide generated by animal 
respiration was removed using fresh soda lime placed in the chamber. At the 
indicated time points, mice were assessed for sickness and then culled via an 
overdose of pentobarbital administered interperitoneally.  
2.11.2. Bronchoalveolar lavage  
Inflammatory cells were harvested from the lung via bronchoalveolar lavage with 5 
washes of 0.8ml ice-cold 0.9% saline. Cell counts per ml of BAL were determined 
using the Sartorius™ NucleoCounter™ NC-100™ Automatic Cell Counter. Total 
BAL cell counts were determined through cell counts per ml multiplied via total 
BAL volume returned. Cell purity and differential cell counts were performed 
through identifying the percentage abundance of each constituent cell on the slides. 
2.11.3. Murine neutrophil isolation 
Whole BAL was centrifuged at 300g for 10 minutes and supernatant removed and 
frozen at -80°C. Cells were washed once in 1ml ice-cold 1xDPBS before use. 
2.11.4. Percoll purification of murine bronchoalveolar lavage 
neutrophils 
Neutrophils isolated from mouse BAL were purified by discontinuous Percoll 




Discontinuous Percoll gradients were prepared through adding 3ml 78% Percoll/22% 
1xDPBS into a 15ml falcon tube and then carefully overlaying 3ml of 69% 
Percoll/31% 1xDPBS on top using a sterile Pasteur pipette, running the upper 
fractions gently down the side of the tube to avoid mixing. Neutrophils were 
resuspended in 3ml 52% Percoll/48% 1xDPBS, and then gently layered on top of the 
gradient. The gradient was centrifuged at 1200g for 30mins at acceleration 1, brake 
0.  The PBMC layer was carefully removed using a Pasteur pipette. The granulocytes 
were transferred to a fresh 15ml falcon tube, topped up to 15ml with 1x DPBS, and 
then centrifuged at 300g for 10 minutes. Cells were then resuspended in 1ml of PBS 
and transferred to a fresh eppendorff. 100μl of sample was removed and diluted in 
100μl 2% FCS/PBS for haemocytometer counts and cytospins. Neutrophils were 








 Mean SEM Minimum Maximum 
Pre-
gradient 
93.7 0.398 85.8 97.6 
Post-
gradient 
98.9 0.353 97.2 100 
Figure 2.11.4-1: Increase in neutrophil purity following percoll density 
centrifugation. Neutrophils were isolated from mouse BAL 24 hours after mice 
were exposed to nebulized LPS and further purified via Percoll density 
centrifugation. A,B: Cytospins of neutrophils directly from the BAL (A) and post- 
Percoll density centrifugation (B). C: Purity counts from cytospins pre- and post-







2.11.5. Murine neutrophil culture 
Neutrophils isolated from mouse BAL were resuspended at 1x106 ml-1 in RPMI 1640 
(Sigma-Aldrich Company Ltd., UK) with 1% 100x penicillin/streptomycin (Gibco®) 
and 10% FBS pre-warmed to 37°C and cultured on 96-well non-tissue culture treated 
polyvinyl chloride plates (BD Falcon™, BD Biosciences, Becton Dickinson Ltd., 
Oxford, UK). Normoxic cell culture was carried out at 37°C in a humidified 
incubator with 5% supplemental CO2 (Sanyo). Hypoxic cell culture was established 
by re-suspending cells in media which had been pre-equilibrated in 1% O2, 5% CO2 
in an Invivo2 400 hypoxic workstation (Ruskinn, Bridgend, UK).   
2.12. Analysis of cytokines in the bronchoalveolar fluid 
Albumin levels in the bronchoalveolar lavage fluid were analysed via ELISA. Before 
analysis, mouse BAL was centrifuged at 300g for 5 minutes at 4°C to pellet cells and 
supernatant was transferred to a 15ml falcon tube and frozen at -80°C for up to 1 
month before analysis. Before running these ELISAs, the sample was thawed at 4°C. 
2.12.1. IgM ELISA 
IgM levels in the bronchoalveolar lavage fluid were analysed via ELISA. 25µl of 
BAL supernatant was diluted in 25µl PBS for a 1:2 dilution and assayed via the 
Abcam® IgM Mouse ELISA Kit (ab133047). IgM BAL concentration was 
multiplied by total BAL volume for total IgM per BAL. 
2.12.2. Albumin ELISA 
10μl of BAL supernatant was added in 990μl 1xDPBS, and 2μl of this solution 
added to 798μl 1xDPS for a final dilution of 1:40000. 50μl was assayed via the 
Abcam® Albumin Mouse ELISA Kit  (ab108792). Albumin BAL concentration was 
multiplied by total BAL volume for final albumin amount per BAL. 
2.12.3. Elastase  
Elastase levels in the bronchoalveolar lavage fluid were analysed via fluorimetric 
assay. 50μl of BAL supernatant was assayed via the EnzChek™ Elastase Assay 




volume for final elastase amount per BAL. 
2.12.4. Myeloperoxidase 
 Myeloperoxidase (MPO) levels in the bronchoalveolar lavage fluid were 
analysed via fluorimetric assay. 50ul of BAL supernatant was assayed via the 
EnzChek™ MPO Assay (ThermoFisher Scientific). MPO concentration was 
multiplied by total BAL volume for final MPO amount per BAL. 
2.13. Growth and storage of Staphylococcus aureus strain 
SH1000 
2.13.1. Growth of SH1000 S. aureus from stock 
 SH1000, derived from the clinical isolate NCTC 8325, was used for 
subcutaneous infection models. Initial SH1000 master stocks were kindly donated by 
the David Dockrell group (University of Edinburgh Centre for Inflammation 
Research). Before use, vials of SH1000 bacteria were thawed for 10 minutes at room 
temperature. Bacteria were streaked onto ready-made Columbia horse blood agar 
plates (VWR). A single colony of SH1000 was inoculated into 30ml brain heart 
infusion (BHI) in a 50ml falcon tube for 15 hours at 37°C. The culture was 
centrifuged for 10 minutes at 500g and washed in 50mls of PBS, then centrifuged for 
10 minutes at 500g and resuspended in 25ml PBS. 1ml PBS aliquots were frozen at -
80°C for future use. 
2.13.2. Determination of bacterial concentration 
 Stock concentrations were determined via Miles-Misra counts. 100µl of 
culture was serially diluted in 900ul PBS aliquots. 3 10µl aliquots of each dilution 
were pipetted onto Columbia horse blood agar plates (VWR) and incubated 
overnight. Aliquots of the stock solution were frozen at -80°C. Bacterial colonies 
were counted to determine CFU/ml (CFU = colony forming units) of the stock vial. 






2.14.1. 12 hour model of acute infection and hypoxia 
Mice were shaved on the right flank and left to recover for 24 hours in standard 
housing conditions before the experiment. On the day of injection, stocks of SH1000 
were defrosted for 10 minutes, centrifuged at 5000g for 5 minutes and made up with 
PBS into a 1x109 CFU/ml solution. Mice were administered with 50ul 1x109 CFU/ml 
(5x107) SH1000 subcutaneously into the right flank before being housed in either 
room normoxia (21% O2) or in a Coy™ Model 3 hypoxic chamber set at 
physiological hypoxia (10% O2) for 12 hours. The oxygen concentration in the 
hypoxic chamber was reduced gradually over the course of one hour to 10% 
oxygen/90% nitrogen using an oxygen sensing control unit (Coy Labs, Michigan, 
USA). Oxygen concentration was then steady at 10%. Carbon dioxide generated by 
animal respiration was removed using fresh soda lime placed in the chamber. 
Sickness scores, weight and temperature were assessed at 0 and 12 hours (see 
Appendix 7.4 for sickness scoring criteria). By 12 hours, a noticeable abscess had 
formed at the site of injection. Mice were culled via an overdose of pentobarbital 
administered intraperitoneally, and the abscess (overlying scab and pustule) was 
excised with a scalpel, weighed and snap frozen at -80°C. 
2.14.2. 7 day model of prolonged inflammation 
Mice were inoculated as above and then housed in room normoxia (21% O2) for 7 
days. Systemic effects of bacterial infection were measured. Mice were weighed 
every day. Temperatures were taken daily using a rectal probe (BAT-2, Physitemp 
Instruments Inc., USA) and photographs taken with a ruler for scale to calculate 
abscess size. Mice were scored on sickness based on gross external appearance, 
including assessment of fur ruffling, activity, perioptic exudate and dehydration. 
Following the 7 days, mice were culled via an overdose of pentobarbital 
administered intraperitoneally, and the abscess (overlying scab and pustule) excised 
with a scalpel and weighed. Abscesses were then dissected into 3 equal pieces, and 
the pieces weighed and either snap frozen at -80°C for bacterial counts and MPO 




2.14.3. Measuring bacterial load at the site of infection 
Abscess tissue was placed in a sterile dish and cut into small pieces with a sterile 
scalpel blade. Contents were placed into a sterile bijou and forceps and scalpel blade 
rinsed with 1ml PBS into the petri dish. The scalpel was used to remove any flesh 
stuck to the plate and the flesh added to the bijou. The plate was then washed with a 
further 1ml PBS and liquid transferred to bijou. The mixture was vortexed for 1 
minute and left on ice for 1 hour to allow the scab to dissolve, before vortexing again 
for 1 minute. 1:10 serial dilutions were made on the homogenate and 3 10μl aliquots 
of each dilution plated onto Columbia Blood Agar plates (VWR). Plates were 
incubated at 37°C overnight before counting resultant colonies to determine colony 
forming units per lesion and per gram of lesion. 
2.14.4. Measuring myeloperoxidase activity 
The abscess was transferred to a sterile screw-cap tube with 6 homogenisation beads 
and 0.5ml cold HTAB buffer (Appendix 7.5) and the abscess homogenised in a 
bullet blender for 5 minutes. The homogenate was sonicated for 10 minutes in 30 
second bursts in a Bioruptor® Plus sonicator (Diagenode Europe SA, Belgium) and 
then freeze-thawed on dry-ice once to ensure cell lysis. The solution was centrifuged 
at 14,000g for 10 minutes at 4°C and the supernatant transferred to a new sterile 
eppendorff tube. 100µl of supernatant was added to 1.9ml of O-dianisidine solution 
(0.167mg/ml O-dianisidine hydrochloride (Sigma-Aldrich Company Ltd., UK) and 
the change in absorbance at 450nm from 30 seconds to 90 seconds after addition of 
supernatant was read on a spectrophotometer (Jenway 6310, Barloworld Scientific, 
UK) to give relative MPO activity.  
2.14.5. Abscess histology 
Sections of abscess were excised and immediately fixed in 10% buffered formalin. 
Tissue was removed from the 10% buffered formalin and placed into a cassette. A 
Leica TP1020 processor (Leica Microsystems, UK) was used to place samples into 
wax and tissues then embedded into paraffin blocks before cutting with a microtome 
and mounting onto glass slides (Superfrost plus, ThermoFisher Scientific, UK). 




xylene for 2 minutes, then rehydrated through submerging in 100% ethanol two 
times, then 95% ethanol and 75% ethanol for 2 minutes before rinsing in H20 for one 
minute. Dewaxed and rehydrated slides were staining in Gill’s haematoxylin for 2 
minutes and then rinsed for 1 minute. Slides were then placed in Scott’s tap water for 
10 seconds and rinsed, before staining with eosin for 5 minutes and rinsing again. 
Slides were then dehydrated by dipping in 75%, then 95% and 100% ethanol three 
times each, mounted and then air dried. Sections were stained with Rabbit polyclonal 
anti-MPO antibody (ab9535, Abcam). 
2.15. In vivo model of fulminant Streptococcal pneumonia 
Pneumococci (Streptococcus pneumonia type 2, D39) were prepared to a 
concentration of 2x108/ml in PBS. Mice were anesthetised with ketamine (76mg/kg, 
Willows Francis Veterinary, UK) and medetomidine (1mg/kg, Orion Pharma, UK) 
intraperitnoeally. While under anaesthetic, mice were suspended by the upper 
incisors and a blunt needle passed into the trachea orally. Mice were instilled with 
50μl 2x108/ml pneumococci (1x107/ml total). Twenty minutes after anaesthaesia, 
mice were administered with atipamezole (2mg/kg, Orion Pharma, UK) to reverse 
anaesthesia. Mice were recovered for 6 hours and housed for 12 hours in room 
oxygen. 
2.16.  Measurement of neutrophil phagocytic capacity 
2.16.1. Growth of human D39 Streptococcus Pneumoniae 
Before culture, stocks of D39 was removed from the -80°C freezer and defrosted at 
room temperature. Stocks were streaked onto Colombia Horse Blood Agar plates 
and incubated at 37°C overnight. The following day, 10 colonies of D39 from the 
blood agar plate were inoculated into 5ml BHI broth and mixed in an incubator at 
37°C for 4.5 hours. Absorbance of the culture was read at 600nm. Culture was 
incubated until 0.5 OD600nm.  
2.16.2. CFSE-labelling of D39 Streptococcus Pneumoniae 
Aliquots of bacteria were centrifuged at 4000g for 5 minutes and then resuspended in 




incubated at room temperature for 1 hour in the dark while gently rocking to mix. 
After 1 hour, the culture was centrifuged at 4000g for 5 minutes and the pellet 
resuspended in 15ml PBS. Wash was repeated twice more. After the final wash, the 
pellet was resuspended in 5ml PBS and culture adjusted to OD600. Bacteria were 
heated at 65°C for 10 minutes to heat-kill and stored at 4°C for up to 1 month before 
use. 
2.16.3. In-vitro phagocytosis assay 
Heat-killed bacteria were vortexed (3x15 second burst at highest settings) to separate 
clumps. The suspension was diluted 100-fold and 10μl of diluted suspension added 
to a haemocytometer slide and examined using an inverted fluorescent microscope 
(EVOS FL Cell Imaging System)(ThermoFisher Scientific) on the GFP channel. If 
not a consistent single cell suspension, the cells were further vortexed and imaged 
again. This process was repeated until the bacteria were evenly dispersed. 50μl FBS 
was added to bacterial suspensions, vortexed and incubated at 37°C for 1 hour to 
opsonize, then washed twice with 1ml ice-cold 1xDPBS. Concentration of bacterial 
particles was determined through counting in a haemocytometer using an inverted 
fluorescent microscope and concentration of bacteria adjusted to 1x109. Neutrophils 
were isolated from murine BAL and resuspended in RPMI +10% FBS at a 
concentration of 2x106ml-1 and 100μl suspension plated and incubated in either 
normoxia (21%) or hypoxia (1%) for 25 minutes. 10μM cytochalasin D was added to 
cells and incubated for a further 5 minutes. 2μl of 1x109 CFUml-1 bacterial 
suspension was then added to cells for an MOI of 10:1. Cells were incubated for a 
further 30 minutes at 37°C before being aspirated and transferred into 1.5ml 
eppendorffs, washed in ice-cold 1xDPBS once, and then resuspended in ice-cold 
1xDPBS. Cells were analysed via flow cytometry on the Attune NxT cytometer 
(ThermoFisher Scientific) using a 405nm laser filtered through a 533/30nm dichroic 
bandpass filter (BL1 channel). Uptake was measured based on BL-1 positivity 






Figure 2.16.3-1: Gating strategy for murine phagocytosis assay. Neutrophils were 
gated out based on forward and side scatter (A) then single cells gated on through 
FCS-A/FCS-H (B) and SSC-A/SSC-H (C). Percentage uptake of cells was 
determined through gating against an unstained neutrophil population not cultured 
with bacteria. D: BL1-A plot showing two populations representing BL1-A-negative 
neutrophils (left) which have not taken up CFSE-labelled D39 S. pneumonia and a 







2.17. Liquid-chromatography/Mass Spectrometry analysis 
of intracellular metabolites in murine inflammatory 
neutrophils 
2.17.1. Preparation of cells for Liquid Chromatography/Mass 
Spectrometry 
Ultrapure BAL neutrophils were lysed in 100μl 80% methanol pre-cooled to -80°C 
and samples snap frozen at -80°C. 
2.17.2. Protein quantification for normalisation 
Samples were thawed and centrifuged at 10,000g for 5 minutes to pellet protein 
contents of the cell and supernatant removed for Liquid Chromatography-Mass 
Spectrometry analysis. Protein content of the pellets were analysed by Pierce™ BCA 
Protein Assay (ThermoFisher Scientific). The pellet was resuspended in 100μl of 
PBS and 25μl of sample and standards added to a 96-well microplate. 200μl of 
Pierce™ BCA Protein Assay working reagent was added to each well and mixed 
thoroughly on a plate shaker for 30 seconds. Plate was incubated at 37°C for 30 
minutes, cooled to room temperature and absorbance measured at 562nm using a 
TECAN infinite M1000 plate reader.  
2.17.3. Liquid-chromatography/Mass Spectrometry analysis 
 Measurements of relative levels of analyte abundance were carried out in 
collaboration with the Carmeliet lab (VIB Leuven, Belgium). Analysis was 
performed using a Dionex UltiMate 3000 LC System (ThermoFisher Scientific) 
coupled with a Q Exactive Orbitrap Mass Spectrometer (ThermoFisher Scientific) 
operated in negative mode (Figure 2.17.3-1). 25μl of sample was injected on a 
SeQuant ZIC/pHILIC Polymeric column (Merck Millipore). The gradient started 
with 10% solvent B (10mM NH4-acetate in mqH20, pH 9.3) and 90% solvent A 
(acetonitrile) and remained thus until 2 minutes following injection. Next, a linear 
gradient to 80% B was carried out until 29 minutes. At 38 minutes, the gradient 
returned to 40% B, followed by a decrease to 10% B at 42 minutes. The 




the column kept at 25°C. The mass spectrometer operated in full scan-SIM mode 
using a spray voltage of 3.2kV, capillary temperature 320°C, sheath gas at 10.0, 
auxiliary gas at 5.0. AGC target was set at 1e6 using a resolution of 140,000, with a 
maximum IT of 500ms. Data collection and analysis were performed using Xcalibur 
Software (ThermoFisher Scientific) with a Genesis peak-picking algorithm 
identifying predicted peaks. Peaks were manually checked individually to ensure 







Figure 2.17.3-1: Analysing metabolite abundance via liquid-
chromatography/mass-spectrometry. Neutrophil lysates dissolved in -80°C 
methanol were run through an LC-MS setup. The SeQuant® ZIC®-pHILIC HPLC 
column separates analytes based on the affinity of the analytes to the stationary phase 
of the column (hydrophobicity). The column is optimised for separation of polar 
hydrophilic compounds, including metabolites of anaerobic and oxidative respiration, 
through containing a polymeric stationary phase bonded to true zwitterionic 
functional groups. The mass spectrometer determines the size of analytes as they 
arrive from the Liquid Chromatography column. 
Samples dissolved in 
liquid phase 
LC column 
Samples separated into 
individual molecules based on 
affinity to stationary phase 
Ion source 
Mass Spectrometer 
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Figure 2.17.3-2: Analyte abundance determined using Xcalibur® software. A: 
Analytes of interest can be determined by their mass to charge ratio (m/z) and 
expected retention times determined by reference standards run through the set-up. 
B: Peaks were automatically determined using the Genesis peak integration 
software. Peaks were picked based on size due to small changes of measured 
retention time compared to reference analytes. C: Chromatogram showing the 
abundance of lactate (predicted RT 3.39). Abundance was measured as area under 







2.18. Real-time qPCR 
2.18.1. RNA extraction 
Inflammatory neutrophils isolated from mouse bronchoalveolar lavage were cultured 
for 4 hours in normoxia and hypoxia. Following culture, 1x106 neutrophils were 
transferred to 1.5ml eppendorff tubes, centrifuged at 300g for 5 minutes and washed 
in 1ml 1xDPBS. Cells were then centrifuged at 300g for 5 minutes and lysed in 
400μl mirVANA™ lysis/binding buffer (Invitrogen™, Waltham MA, US), pipetting 
up and down 5 times to aid lysis. Lysates were frozen for up to 3 months before 
further extraction. Before extraction, samples were thawed on ice and 40μl of 
miRNA Homogenate Additive added before vortexing for 30 seconds. Samples were 
incubated on ice for 10 minutes. 400μl of Acid-Phenol:Chloroform was added to the 
sample before vortexing for 30 seconds to mix, and the mixture centrifuged for 5 
minutes at 10,000g at room temperature. The aqueous phase was removed from the 
sample and put in a sterile RNAse-free tube. A volume of 100% ethanol 1.25 times 
that of the extracted aqueous phase was then added. Lysates was added to a filter 
cartridge over a clean collection tube and centrifuged for 15 seconds at 10,000g. 
Flow-through was discarded and 700μl miRNA Wash Solution 1 was added to the 
filter and centrifuged for 30 seconds at 10,000g. Flow-through was discarded and 
500μl Wash Solution 2/3 was added to the filter and centrifuged for 15 seconds at 
10,000g. Flow through was discarded and a second wash was repeated using 500μl 
Wash Solution 2/3. Following the second wash, the filter and collection tube were 
centrifuged for 1 minute at 10,000g to remove residual fluid from the filter. The 
filter cartridge was transferred to a fresh collection tube and 40μl of pre-heated 
(95°C) RNAse-free H20 added to the filter, and the assembly centrifuged for 30 
seconds at 13,000g to recover RNA. Flow-through was run through the filter again 
for 30 seconds at 13,000g to ensure maximum recovery. RNA purity and abundance 
was measured using a NanoDrop Spectrophotometer (ThermoFisher Scientific). 
DNA and protein contamination was ascertained through ratio of absorbance at 
260nm/280nm and 260nm/230nm, respectively.  Samples were treated with 1μl 
TURBO™ DNAse (Invitrogen™) and incubated at 37°C in the heat block for 30 




centrifuged at 10,000g for 90 seconds at 4°C to pellet inactivation beads. Samples 
were then reanalysed with the NanoDrop for final RNA concentration. 
2.18.2. cDNA preparation 
At least 250ng of RNA from each sample was added to a PCR tube and made up to 
12.4µl with RNase-free water. A mastermix was prepared based on number of 
samples for reverse transcription (Per sample: 16µl 10mM dNTPs (#U1240), 1.2µl 
RNasin (#N2115), 1.2µl random primers (#C1181), 1.2µl AMV (avian 
myeloblastosis virus) reverse transcriptase and 8µl 5x AMV buffer (both #M9004) 
(all Promega®)). 27.6µl mastermix was added to each sample and mixed by 
pipetting. Samples were then placed in a 3Prime thermal cycler (Techne®) and 
cycled through 23°C for 5 minutes, 42°C for 2 hours and 99°C for 2 minutes, then 
held at 4°C. Resultant cDNA was then frozen at -80°C. 
2.18.3. Taqman 
cDNA were was thawed at 4°C. For each primer, a standard curve was prepared in 
0.5ml PCR tubes from cDNA derived from pooled mouse BAL. cDNA was 
amplified in polymerase chain reactions using commercial primers (Appendix 7.6.2) 
and GoTaq Flexi DNA polymerase (Promega UK, UK). 19μl of mastermix 
(Appendix 7.6.1) was added to 1μl of cDNA and the plate was analysed using an 
ABI 7900HT Fast Real-Time PCR System (ThermoFisher Scientific). Cycling was 
set as 2 minutes at 50°C, 10 minutes at 95°C, then 40 cycles of 15 seconds at 95°C 
and 1 minute at 60°C before holding at 4°C. Data was analysed within the 
proprietary SDS software. All reads were normalised to the expression of β-actin in 
corresponding samples. 
2.19. Apoptosis and functional assays: Statistics 
Results are expressed as mean +/- SEM of the number (n) of independent 
experiments. In human studies, each independent experiment was performed from 
cells from separate donors and each experiment performed in triplicate. In murine 
studies, independent experiments were performed in separate mice or on cells pooled 




were performed using GraphPad Prism 7 for Mac (GraphPad Software Inc. USA). 
For comparing 2 groups, unpaired or paired Student’s T-tests were used. For 
comparing the effects of two independent variables, 2-way ANOVA was performed 
with Sidak’s post-hoc test for multiple comparisons. For comparing abscess size, 






3. The role of mitochondrial ROS in regulating 
neutrophil survival 
3.1. Introduction 
3.1.1. The role of mitochondrial reactive oxygen species as 
signalling molecules 
Mitochondrial reactive oxygen species have long been known as toxic by-products 
of normal respiratory chain function, capable of inducing pathology through damage 
to cellular components including lipid peroxidation, oxidation of proteins thiols and 
oxidative damage to chromosomal DNA (Martínez-Cayuela, 1995). As such, 
mitochondrial free radicals have been implicated in the pathology of a number of 
disease states, with an extensive literature linking atherosclerosis (Napoli et al., 
2003), rheumatoid arthritis (Yoo et al., 2016), ischaemia-reperfusion injury 
(Ambrosio et al., 1993) and cancer (Sullivan and Chandel, 2014) to mROS 
production. 
Despite the evident harmful nature of ROS, a growing body of literature has 
implicated reactive oxygen species as important signalling molecules in their own 
right, capable of modulating a host of cellular responses. Early studies showed that 
release of H2O2 by the mitochondria is essential for the proliferation of Balb/3T3 
embryonic fibroblasts in response to platelet-derived growth factor in vitro and 
treatment of cells with exogenous catalase can prevent proliferation. This mechanism 
was shown to be due to the capacity of ROS to enhance PDGF- and EGF-induced 
tyrosine phosphorylation and subsequent MAPK activation (Sundaresan et al., 
1995)(Rhee et al., 1997). Reactive oxygen species inhibit protein tyrosine 
phosphatase activity through oxidation of cysteine thiol residues, leading to 
enhanced phosphorylation of downstream effector proteins (Lee et al., 1998). Key 
signal transduction pathways involved in proliferation and survival, including PI3K-
AKT and RAS-MEK-ERK, are negatively regulated by protein tyrosine phosphatase 
activity, and as such ROS been implicated in the induction of these pathways. 
Subsequent studies have shown ROS mediates the activity of a number of proteins 




enhancing p53 DNA binding activity (Tishler et al., 1993) and NF-κB signalling 
(Suzuki, Forman and Sevanian, 1996)(Lluis et al., 2007), as well as positively 
regulating the activity of calcium channels voltage-dependent Ca2+ channels in the 
plasma membrane through oxidation of cysteine residues (Hudasek, Brown and 
Fearon, 2004).  
3.1.2. Induction of mitochondrial ROS release in hypoxia 
Studies from the Chandel group suggest that mitochondria act as cellular oxygen 
sensors and somewhat paradoxically, that oxidative stress can increase in cells in 
physiological (1.5% O2) hypoxia (Chandel et al., 1998). The study shows that 
hypoxia induces the production of ROS, which mediate the transcription of a number 
of hypoxic response genes in Hep3B cells such as EPO, VEGF and PGK1 (Chandel 
et al., 1998). There have also been a number of in vivo studies that confirm hypoxia 
induces the release of ROS. Independent studies show mice exposed to chronic 
intermittent hypoxia have enhanced ROS levels in the cerebral cortex as measured 
by analysis of thiobarbituric acid reactive substances (Peng et al., 2006) and DCF 
staining of cortical neuronal cells (Xu et al., 2004).  
The mechanism by which hypoxia causes the release of reactive oxygen species 
from the mitochondrion is unclear. In studies in isolated mitochondria, ROS 
production decreased as oxygen concentration was lowered to anoxia (Hoffman, 
Salter and Brookes, 2007), indicating that a decrease in oxygen itself does not cause 
the increase in superoxide directly by altering stability of the ubisemiquinone radical 
at complex III. It suggests that secondary effects must modulate mROS production. 
One possible model is that changes in the concentration of oxygen availability and 
NO abundance can modify the redox state of cytochrome c oxidase to favour the 
release of mROS (Palacios-Callender et al., 2004). Hypoxic release of mROS has 
been implicated in the regulation of a host of cellular processes, including myocyte 
contraction (Duranteau et al., 1998), p38 MAP kinase activation (Kulisz et al., 
2002), endocytosis of Na, K-ATPase by alveolar epithelial cells (Dada et al., 2003) 
and adipocyte differentiation (Carrière et al., 2004). The modulation of immune 
response has also been linked to hypoxic mROS release, including leukocyte 




(Pearlstein et al., 2002). 
3.1.3. Regulation of HIF-1α stability by mitochondrial ROS 
Further studies from the Chandel group identify HIF-1α as a major mediator of 
ROS-dependent signalling pathways in hypoxia. Addition of exogenous H2O2 is 
sufficient to stabilise HIF-1α in normoxia, and the overexpression of catalase 
abolishes hypoxic response-element luciferase expression in hypoxic cells (Chandel 
et al., 2000). Contemporaneous studies supported the involvement of the electron 
transport chain in HIF-1α stabilisation using in vivo experiments where the precursor 
to the potent complex I inhibitor MPP+, MPTP, was administered to mice and HIF-
1α levels measured in the mouse striatum and cortex. Addition of MPTP is sufficient 
to block HIF-1α accumulation in the mouse striatum, as well as HIF-1α stabilisation 
in neuronal CATH.a and PC12 cells exposed to hypoxia in vitro (Agani et al., 2000).  
The role of mROS in regulating HIF-1α was controversial for some time, following 
conflicting studies which suggest loss of a mitochondrial respiratory chain in p0 cell 
lines derived from a number of different tissues does not influence HIF-1α stability 
(Vaux et al., 2001)(Srinivas et al., 2001). However, more recent studies confirmed 
these findings using more advanced genetic and biochemical techniques. A study in 
143B cells used a FRET-based sensor sensitive to redox conditions (Guzy et al., 
2005). Cells transfected with a plasmid expressing a redox-sensitive HSP-FRET 
probe and exposed to transient hypoxia (1% pO2) have a profound increase in 
oxidative stress on exposure to hypoxia, which is attenuated in p0 cells lacking 
mitochondrial DNA and a functional respiratory chain. Subsequent studies have 
confirmed an induction of ROS release in hepatocellular carcinoma HepG2 cells, 
neuroblastoma SH-SY5Y, cells and adenocarcinoma DLD-1 cells through the use of 
the ROS-sensitive fluorescent probe DCF (Lluis et al., 2007).. 
Complex III has been identified as the site of mROS release in hypoxia. Addition of 
the complex III inhibitor stigmatellin blocks the release of mROS in hypoxia (Guzy 
et al., 2005).  Furthermore, cells containing a cytochrome b-deficient bc1 complex 
are unable to undergo oxidative respiration, but can generate mitochondrial ROS and 




HIF-1α stability in hypoxia, indicating the Q0 site of complex III specifically is the 
main source of hypoxia-induced mROS (Bell et al., 2007). Complex III inhibition 
also reduces HIF-1α stabilisation, showing activity at complex III augments HIF-1α 
stability in hypoxia (Brunelle et al., 2005)(Mansfield et al., 2005). RNA interference 
against complex III, and cells transfected with SOD1 and SOD2-expressing 
adenoviruses have suppressed HIF-1α stabilisation in hypoxic conditions (Brunelle 
et al., 2005).  Moreover, loss of cytochrome c, which oxidises cytochrome c1 and 
keeps the Rieske iron sulphur protein subunit of complex III oxidised and capable of 
producing ROS, decreases ROS production and prevents stabilisation of HIF-1α in 
hypoxia (Mansfield et al., 2005). Interestingly, anoxia (0% O2) was sufficient to 
stabilize HIF-1α in cytochrome c-deficient cells, which emphasises the sensitivity of 
this response on the degree of hypoxia experienced by the cell. 
These studies suggest a subtler model of HIF-1α stabilisation where mROS can 
augment HIF-1α stabilisation in hypoxia and modulate the hypoxic response in a 
mechanism complementary to oxygen availability for the hydroxylation of HIF-1α 
by PHD enzymes and FIH.  
A number of studies have highlighted the paradoxical nature of mitochondrial 
reactive oxygen species, and shown that the degree of oxidant production can 
produce a spectrum of effects, with low levels of ROS capable of stabilising pro-
survival proteins, but higher levels of ROS in cells depleted of mitochondrial 


















and cell death 
Figure 3.1.3-1: Balance of mitochondrial reactive oxygen species in the cell. Cells 
produce a low degree of mitochondrial ROS as part of normal electron chain function 
which are involved in signalling. Higher amounts of ROS, induced by cellular stress, 











The mechanisms by which ROS stabilise HIF-1α are controversial. Early studies 
from Bell implicate the oxidation state of cytoplasmic iron as a modulator of HIF-1α 
through altering substrate availability for the PHD enzymes (Bell et al., 2007). They 
suggest that cytosolic H2O2 may oxidise Fe2+ to Fe3+, depleting the amount of 
available Fe2+ that PHDs can then use as a cofactor to hydroxylate and break down 
HIF-1α. This mechanism of PHD stabilisation was also seen in other studies in cells 
lacking the antioxidant junD-/- which have enhanced H2O2 production (Gerald et al., 
2004). Other studies have described the inhibition of PHD function on addition of S-
nitroglutathione, a source of bioavailable NO, indicating NO may have a direct 
influence on inhibiting the PHD enzymes (Metzen et al., 2003). Subsequent studies 
have implicated FIH as the main redox-sensitive regulator of HIF-1α activity 
(Masson et al., 2012)., and an alternative model of HIF-1α stabilisation by ROS is 
proposed by Du et al where ROS mediates HIF-1α expression through Rac1 and 
activation of the PI3-ERM pathway (Du et al., 2011). Secondary signalling via 
calcium release has also been implicated, as hypoxia and mROS can both stimulate 
calcium release, and HIF stabilisation is regulated by calcium signalling (Hui et al., 
2006).  
It is unclear why HIF-1α	stabilisation	is	specifically	due	to	mitochondrial	ROS	as	
opposed	 to	 cytoplasmic	 ROS. Localisation of HIF-1α to the mitochondrial may 
explain why HIF-1α is more sensitive to mitochondrial ROS than other cellular 
sources of ROS. There have been studies suggesting HIF-1α localises to the 
mitochondria and therefore mitochondrial ROS may act as an extra signal to 
encourage stabilisation after translocation of the stable protein (Briston, Yang and 
Ashcroft, 2011). However, less than 5% of HIF-1α associates with the mitochondrial 
fraction of the cell, so alternative pathways may be intermediate between the release 
of ROS and their stabilisation of HIF-1α. Additional downstream targets of ROS 
which may regulate the hypoxic response pathway include NF-κB via the regulation 
sensitive activity of c-SRC (Bonello et al., 2007)(Lluis et al., 2007). 
3.1.4. Innate immune cell regulation by mitochondria ROS 
mROS have been implicated in the regulation of the innate immune system, 




Antibacterial responses are promoted by mROS through a number of different 
pathways, including through direct activation of NF-κB and MAPK signalling 
pathways, augmenting pro-inflammatory cytokine production. Endothelial cells can 
release IL-6 in response to hypoxia through mROS signalling to NF-κB (Pearlstein 
et al., 2002). Recent studies have shown mROS can activate NLRP3 inflammasome 
activity and enhance the processing and activation of IL-1β and IL-18 precursors in 
bone-marrow derived macrophages (BMDMs) (Tschopp and Schroder, 2010)(Zhou 
et al., 2011). Subsequent studies from Luke O’Neill’s group have implicated 
mitochondrial membrane hyperpolarisation and subsequent increase in ROS 
production as essential mediators of pro-inflammatory activity of M1 macrophages 
(Tannahill et al., 2013)(Mills et al., 2016). Induction of mROS in pro-inflammatory 
macrophages is dependent on a more glycolytic phenotype, where mitochondrial 
metabolism is disrupted, whereas alternative polarisation of macrophages was 
characterised by a metabolic profile dependent on oxidative phosphorylation and 
normal Krebs cycle function.  
Recent studies have also described how ionising radiation induces mROS, which is 
essential for induction of pro-inflammatory cytokines in BMDMs in the tumour 
microenvironment (Kim et al., 2017). Blocking the production of mROS has been 
show to alleviate inflammatory symptoms through downregulating macrophage 
activation (Hall et al., 2018).  
Antiviral activities are also enhanced through mROS-mediated signalling through 
RIG-I-like receptor (RLR) mitochondrial antiviral signalling protein (MAVS) and 
downstream signalling to NF-κB and interferon regulatory factors IRF3 and 
IRF7(Tal et al., 2009). 
Neutrophil-derived mROS have been implicated in the control of pro-inflammatory 
neutrophil functions, such NADPH oxidase activation (Kröller-Schön et al., 2014), 
degranulation (Vorobjeva et al., 2017). A number of studies looking at the 
modulation of neutrophil function by neutrophil mitochondrial ROS have focused on 
metabolic diseases. Patients with diabetes and anorexia nervosa have defective 
neutrophil mitochondrial function as determined by reduced oxygen consumption 




2013)(Victor et al., 2014). Therefore, close control of neutrophil mitochondrial 
function may be required for proper control of neutrophilic inflammation.  
Recent studies have shown mitochondrial antioxidants are capable of treating 
inflammatory conditions. MitoQ has had some success in treating an experimental 
autoimmune encephalomyelitis (EAE) mouse model of multiple sclerosis. MS is 
typified by high numbers of activated microglia, causing unsheathing and 
demyelination in the cerebral cortex. Lipid and DNA oxidation correlates with 
inflammation in MS brain lesions, indicating mitochondrial ROS may play a role in 
MS pathology (Haider et al., 2011). MitoQ reduced both neurological disability and 
physiological inflammatory effects of EAE such as inflammation of the spinal cord 
and TNF-α expression. MitoTEMPO has also been shown to reduce the severity of 
diabetic cardiomyopathy in mice (Ni et al., 2016). MitoTEMPO has been shown as 
effective in reducing inflammation in models of periodontitis (Li et al., 2016) and 
renal fibrosis (Liu et al., 2018). 
Conditions associated with hypoxia and mediated by release of reactive oxygen 
species, including ischaemia/reperfusion injury, have also been addressed using 
mitochondrial antioxidants. MitoQ has been showed to protect against mitochondrial 
DNA damage and subsequent loss of intestinal mucosa integrity in a mouse of 
ischaemia/reperfusion through suppression of mtDAMP release, partially through an 
Nrf2/ARE-dependent mechanism (Hu et al., 2018).  
MitoQ has been through a number of clinical trials in humans. Double-blind clinical 
studies of MitoQ as a potential therapy for Parkinson’s disease have shown no 
benefit in slowing disease progression as measured by the Unified Parkinson’s 
Disease Rating Scale (UPDRS). Moreover, doses of MitoQ up to 80mg were shown 
to induce nausea and vomiting in volunteers in a dose-dependent way (Snow et al., 
2010). Caution must be exercised, as off-target effects, including somewhat 
alarmingly acute swelling and depolarisation of mitochondria in cells in the kidney 





3.1.5. Measuring mitochondrial ROS 
The induction of ROS in hypoxia is a controversial field due to conflicting reports in 
the literature and also because of the current limitations in studying mitochondrial 
ROS production. A review studying hypoxia-induced reactive oxygen species 
highlights that measurements of oxidative stress, especially in vivo, can be 
obfuscated by other factors such as oxygen consumption, acidity and shear stress, 
and that the degree of hypoxia may also not correlate linearly with reactive oxygen 
species release and redox stress (Clanton, 2007). Indeed, other studies have 
suggested that changes in the flux through the electron transport chain can change 
oxygen concentrations in the cytoplasm due to changes in the consumption of O2 via 
oxidative phosphorylation, and this can have a knock-on effect on HIF stability, in 
this case HIF-2α in an adrenomedullary cell line (Brown and Nurse, 2008). 
3.1.6. Regulation of ROS by anaerobic metabolism 
Mitochondrial ROS production and function is closely linked with metabolism 
through a number of metabolic pathways, including the tricarboxylic acid cycle, the 
DHAP shuttle, and the action of antioxidant pathways including the pentose 
phosphate pathway (Liemburg-Apers et al., 2015).  
The primary link between energy metabolism and ROS is through the mitochondrial 
electron transport chain. Complexes I and III of the mitochondrial electron transport 
chain are major sources of mitochondrial reactive oxygen species (Figure 3.1.7-1), 
although complex II is also capable of producing mitochondrial ROS through the 
forward and reverse reactions from succinate and the QH2 pool (Quinlan et al., 2012) 
and modulation of complex II activity influences ROS release from other complexes 
(Dröse, Hanley and Brandt, 2009). Complex I and II both directly link the Krebs 
cycle to the mitochondrial respiratory chain. Complex I uses mitochondrial NADH 
as a substrate to transfer electrons to the Q pool. Complex II converts succinate to 
fumarate, transferring an electron to FAD in the SDHA subunit of complex II. 
Unsurprisingly, Krebs cycle activity is closely linked to mROS production. 
Increased TCA cycle flux can results in accumulation of oxidative phosphorylation 
substrates and elevated NADH/NAD+ levels, which in turn can increased mROS 




cycle intermediates can reduce mitochondrial ROS production in cells (Sawa et al., 
2017). Similarly, a functional mitochondrial electron transport chain is needed for 
TCA cycle function (Martínez-reyes et al., 2016). Krebs cycle activity can also 
influence HIF-1α activity in other ways; succinate can inhibit HIF-1α and SDH 
mutations are capable of stabilising HIF through the build-up of succinate (Selak et 
al., 2005).  
Increased glycolytic flux can also correlate with an increased flux into the 
mitochondrial respiratory chain via shuttling through glycerol 3-phosphate (Ishihara 
et al., 1996). The glycerol 3-phosphate shuttle itself is an important site of ROS 
generation and is prone to electron leak (Mracek, Drahota and Hou, 2013). 
Therefore, glycolytic flux into the TCA cycle can influence mROS production. This 
mechanism has been observed in innate immune cells; in pro-inflammatory 
macrophages, glycolytic ATP production causes an increase in mitochondrial 
membrane potential, which in turn is needed for pro-inflammatory effects of LPS 
and also drives increased generation of mitochondrial ROS, driving the production 
of IL-1β (Mills et al., 2016). Neutrophils can maintain mitochondrial membrane 
potential by oxidation of glycerol 3-phosphate (Figure 3.1.7-2), as isolated 
mitochondria from neutrophils treated with glycerol phosphate can recover a 
membrane potential as measured by TMRM, suggested that mGDP is present in 
neutrophil mitochondria and is functional (van Raam et al., 2008). Inhibition of 
complex III correlates with increased lactate production, suggesting flux from 
glycolysis into the DHAP shuttle, and transfer of electrons to complex III from 
mGPDH, is occurring in the neutrophils in in vitro culture. However, whether this 
has functional consequences or is a physiologically relevant source of mROS in the 
neutrophil is unclear. 
The pentose phosphate pathway can also modulate the activity of mROS through 
generation of antioxidants NADPH and GSH. Enhanced flux through the pentose 
phosphate pathway can protect against peroxide-induced cytotoxicity through an 
enhanced NADPH/NADP+ ratio and regeneration of oxidised glutathione (GSSG) to 
reduced glutathione (GSH) (Le Goffe et al., 2002). Skin fibroblasts with enhanced 




preventing NADPH increase induced ROS production and subsequent cell death 







Figure 3.1.6-2: The DHAP shuttle. The DHAP shuttle acts as a way of transferring 
electrons into the electron transport chain directly from glycolysis. GPD2 is a 
significant source of mitochondrial ROS. 
Figure 3.1.6-1: The electron transport chain. Electrons are passed from Krebs 
cycle products NADH (Complex I) or succinate (Complex II). Loss of electrons and 




3.1.7. Aims of this chapter 
Neutrophils are an interesting candidate for study of mitochondrial ROS signalling 
as they have a phenotype of delayed apoptosis in hypoxia, and the role of the 
neutrophil mitochondria is poorly understood, as neutrophils are predominantly 
glycolytic cells with little capacity for oxidative phosphorylation. As neutrophils do 
not use their mitochondria for ATP production, it is possible their mitochondria are 
used predominantly in a signalling role through release of reactive oxygen species. 
Given that HIF-1α profoundly regulates neutrophil apoptosis and function, it will be 
critical to understand whether there is an interaction between the neutrophil 
mitochondria and HIF-1α. In addition to understanding the basic biology of these 
non-proliferative cells, as neutrophils are implicated in a number of inflammatory 
diseases associated with localised and systemic hypoxia, understanding the 
regulation of the neutrophil hypoxic response pathway and ascertaining whether 
neutrophil mitochondria are capable of influencing neutrophil HIF-1α stability and 
survival may be essential in the study of potential treatments for chronic 
inflammatory diseases. 
As stated in section 1.5., my hypothesis for this chapter is that: 
Neutrophils mitochondrial function regulates neutrophil apoptosis not 
through generation of ATP, but via signaling through the production of 
mitochondrial ROS, which can stabilize HIF-1α and enhance neutrophil 
survival. 
The aims of this section are therefore as follows: 
1. To understand if, despite being predominantly glycolytic cells, neutrophils 
maintain a mitochondrial membrane potential and release mitochondrial ROS 
uaing fluorescent probes which can measure mitochondrial function in live 
cells. 
2. To examine how hypoxia affects neutrophil mitochondrial function; in 
particular, whether neutrophil mitochondria release ROS in response to 
hypoxia, and whether ROS modulate the stability of HIF-1α with 




3. To interrogate the mechanism of hypoxic mROS release using neutrophils as 
a model of cells with little mitochondrial ATP production, using mass 






3.2.1. Confirmation of neutrophil hypoxic survival in in vitro culture 
conditions 
As previously described, neutrophils experience delayed apoptosis in vitro when 
cultured in hypoxic conditions (Hannah et al., 1995)(Sarah R Walmsley et al., 2005). 
To confirm the effectiveness of our culture conditions, apoptosis of neutrophils 
isolated from healthy volunteers and cultured for 20 hours in normoxia (21% O2) or 
hypoxia (1% O2) was assessed through morphology and by staining with Annexin V 
and TO-PRO-3 and analysed by flow cytometry. 
Culture in hypoxia significantly delays the constitutive apoptosis of neutrophils after 
20 hours in culture as measured via morphology (mean (±SEM), N = 39.71 
(10.45)%, H = 21.83 (16.13)%, n = 6, p*<0.05)(Figure 3.2.1-1, A-C) and Annexin 
V/TO-PRO-3 staining and analysis via flow cytometry (mean (±SEM), N = 47.1 




















Figure 3.2.1-1: Hypoxia prolongs neutrophil survival as determined through 
morphological analysis of nuclear condensation and fragmentation in vitro. 
Neutrophils isolated from peripheral blood were cultured for 20 hours in normoxia 
(21% O2) or hypoxia (1% O2) and apoptosis assessed via morphology (A-C). B: 
Normoxic cells. C: Hypoxic cells. Data expressed as mean±SEM and analysed with 











Figure 3.2.1-2: Hypoxia prolongs neutrophil survival as determined through 
Annexin V/TO-PRO-3 staining and analysis via flow cytometry. Neutrophils 
isolated from peripheral blood were cultured for 20 hours in normoxia (21% O2) or 
hypoxia (1% O2) and apoptosis assessed via Annexin V/TO-PRO-3 staining and 
flow cytometry (A-C). B: Normoxic cells. C: Hypoxic cells. Apoptosis was 
determined as % Annexin V +ve cells. Data expressed as mean±SEM and analysed 


















































3.2.2. Acute hypoxia stimulates production of neutrophil 
mitochondrial reactive oxygen species  
To determine whether hypoxia induces release of mROS as it does in other cell 
types, neutrophil mROS production was measured using the mitochondria-targeted 
redox probe MitoSOX™ Red and fluorescence intensity measured via flow 
cytometry. 
By 1 hour in hypoxic culture, neutrophils have significantly enhanced production of 
mROS as measured via MitoSOX™ Red staining (mean (±SEM), normoxia (black 
bar) 1 hour = 78.9 (10.2), hypoxia (white bar) 1 hour = 131 (41.0) gMFI, n = 7, 
p*<0.05)(Figure 3.2.2-1, A). Cells cultured for 4 hours in hypoxia still have elevated 
mROS production (normoxia (black bar) 4 hours = 71.8 (10.2), hypoxia (white bar) 
4 hours = 145 (59.5) gMFI, p*<0.05, n = 7)(Figure 3.2.2-1, A). Mitochondrial ROS 
levels are at baseline levels in normoxic culture equivalent to freshly isolated 
neutrophils (mean (±SEM), 0 hours = 66.6 (17.0), normoxia (black bar) 1 hour = 
78.9 (9.15), normoxia (black bar) 4 hours = 71.8 (10.2) gMFI, n = 7)(Figure 3.2.2-1, 
A). This indicates exposure to high glucose culture media does not induce 
production of mitochondrial ROS. 
Treatment with the potent activation stimulus 100nM fMLP does not alter neutrophil 
mROS levels (mean (±SEM), normoxia (black bar) untreated 1 hour = 78.9 (9.15), 
normoxia (black bar) treated 1 hour = 81.7 (12.4), hypoxia (white bar) untreated 1 
hour = 167 (41.0), hypoxia (white bar) treated 1 hour = 188 (50.9) gMFI)(Figure 
3.2.2-1, B). However, fMLP does significantly induce the production of overall 
cellular ROS as measured by DCF fluorescence, enhancing the production of ROS 
by over a factor of 3 (mean (±SEM), untreated = 1.36x104 (1.52x103), treated = 
4.18x104 (5.8x103) gMFI, n = 8. p***<0.001)(Figure 3.2.2-1, C). These data indicate 
the MitoSOX™ Red probe is specific for mitochondria-derived ROS and not 
sensitive to cytoplasmic or lysosomal ROS produced by NADPH oxidase, and the 
increase in MitoSOX™ Red fluorescence in hypoxia is induced by the induction of 
mROS specifically. 
Treatment with the complex I inhibitor rotenone and the complex V/ATP synthase 




(black bar) untreated = 74.7 (5.18), normoxia (black bar) rotenone = 97.3 (1.00), 
normoxia (black bar) oligomycin = 110 (19.0), hypoxia (white bar) untreated = 143 
(23.4), hypoxia (white bar) rotenone = 178 (26.9), hypoxia (white bar) oligomycin = 
215 (29.4) gMFI, n = 5, *p<0.05, **p<0.01)(Figure 3.2.2-1, D, E), indicating 
neutrophils possess a functional respiratory chain which can be blocked by 
mitochondrial inhibitors. However, inhibition in hypoxia does not produce a greater 
degree of mROS release in hypoxia, indicating flux through the electron transport 
chain is equivalent in normoxia and hypoxia (mean (±SEM), normoxia rotenone = 
1.30 (0.134), hypoxia rotenone = 1.24 (0.188), normoxia oligomycin = 1.48 (0.254), 
hypoxia oligomycin = 1.5 (0.206), n = 5)(Figure 3.2.2-1, F). The data therefore show 
neutrophils have some respiratory chain activity and hypoxia, but not exposure to 
high glucose culture medium or activation via the fMLP receptor, is a potent 
stimulus for release of reactive oxygen species from the mitochondrial electron 
transport chain. 

















































































































Normoxia vs Hypoxia 
p**<0.01
Untreated vs Rotenone 
10µM ns by 2-way 
ANOVA
Figure 3.2.2-1: Hypoxia, but not neutrophil activation, induces production of 
mitochondrial ROS. Freshly isolated neutrophils or neutrophils cultured for 1 or 4 
hours in normoxia or hypoxia were stained with the mitochondria-targeted redox 
probe MitoSOX™ Red to assess production of mitochondrial reactive oxygen species 
(A, B). Neutrophils were cultured with and without 100nM fMLP for 1 hour and 
stained with MitoSOX™ Red (B) or stained with DCF (C). Neutrophils were 
cultured for 1 hour with and without 10µM rotenone or 10µM oligomycin (D,E). 
fMLP = formyl Met-Leu-Phe peptide. DCF = dichlorofluorescein.. Data expressed 
as mean±SEM and analysed with paired two-tailed student’s T tests (C, F) corrected 
for multiple comparisons with the Holm-Sidak method (F) or by 2-way ANOVA (A, 







































































3.2.3. Mitochondria-targeted antioxidants are pro-apoptotic to 
neutrophils and inhibit HIF-1α stabilisation 
To determine the effects of mitochondrial ROS on neutrophil apoptosis, neutrophils 
were treated with 100µM MitoTEMPO, a mitochondria-targeted analogue of the 
antioxidant TEMPO (Figure 3.2.3-1, A). Mitochondrial ROS production measured 
via MitoSOX™ Red staining was significantly suppressed in neutrophils cultured for 
1 hour in hypoxia (mean (±SEM), hypoxia untreated = 125 (10.2), hypoxia (white 
bar) MitoTEMPO = 105 (10.9) gMFI, n = 7, p*<0.05)(Figure 3.2.3-1, B). 
MitoTEMPO significantly increased the rate of apoptosis of neutrophils cultured for 
20 hours as measured by morphology (mean (±SEM), normoxia (black bar) 
untreated = 45.3 (4.45), normoxia (black bar) MitoTEMPO = 56.9 (6.21), hypoxia 
(white bar) untreated = 27.1 (5.07), hypoxia (white bar) MitoTEMPO = 39.5 
(7.38)%, n = 8, p*<0.05,)(Figure 3.2.3-1, C) and also increased apoptosis as 
measured by Annexin V/TO-PRO-3 staining and flow cytometry, although is result 
was not significant (mean (±SEM), normoxia (black bar) untreated = 53.4 (4.94), 
normoxia (black bar) MitoTEMPO = 58.7 (5.06), hypoxia (white bar) untreated = 
36.4 (3.56), hypoxia (white bar) MitoTEMPO = 42.0 (4.62)%, n = 7, ns by 2-way 
ANOVA)(Figure 3.2.3-1, D). 
To assess the effect of MitoTEMPO on HIF-1α stabilisation, neutrophils were 
cultured with MitoTEMPO for 4 hours and HIF-1α stability assessed by western blot 
and densitometry performed. MitoTEMPO modestly but significantly inhibited 
stabilisation of HIF-1α protein after co-incubation for 4 hours (mean (±SEM), 
normoxia (black bar) untreated = 0.145 (0.0593), normoxia (black bar) MitoTEMPO 
= 0.181 (0.0956), hypoxia (white bar) untreated = 3.08 (0.515), hypoxia (white bar) 
MitoTEMPO = 2.47 (0.161), n = 3, p**<0.01)(Figure 3.2.3-2, C). Neutrophils 
treated with the non-mitochondria targeted analogue TEMPOL for 4 hours have 
equivalent HIF-1α stabilisation in hypoxic conditions, indicating mitochondrial ROS 
specifically augment HIF-1α stabilisation in hypoxia (Figure 3.2.3-2, D). 






























Figure 3.2.3-1: Addition of the mitochondria-targeted anti-oxidant 
MitoTEMPO blocks production of mitochondrial ROS and is pro-apoptotic. 
Neutrophils were cultured for 1 hour with and without 100μM MitoTEMPO (A) and 
stained with MitoSOX Red (B), or cultured for 20 hours and apoptosis measured via 
morphology (C) and Annexin V/TO-PRO-3 staining and flow cytometry (D). Data 
expressed as mean±SEM and analysed with paired two-tailed Student’s T tests (B) 
and 2-way ANOVA (C, D), n = 7 p*<0.05. 
 
 






































































Figure 3.2.3-2: Addition of the mitochondria-targeted antioxidant MitoTEMPO 
inhibits HIF-1α stability in hypoxia. Neutrophils were cultured for 4 hours with 
and without 100μM MitoTEMPO, lysed in SDS lysis buffer and then lysates probed 
for HIF-1α expression via western blot (A,B). Data expressed as mean±SEM and 
analysed with paired two-tailed Student’s T tests, n = 3, p**<0.01. Whole blot is 
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3.2.4. Acute hypoxia enhances neutrophil mitochondrial membrane 
potential through mechanism independent of enhanced Krebs cycle 
flux 
To ascertain the mechanism of mitochondrial ROS release, we measured 
mitochondrial membrane potential (ΔΨm) in cultured neutrophils. Mitochondrial 
membrane potential is closely linked to ROS production and is an indication of 
electron transport chain activity. 
Neutrophils have significantly increased mitochondrial membrane potential when 
cultured in hypoxic conditions compared to normoxia (mean (±SEM), 0 hours = 214 
(78.7), normoxia (black bar) 1 hour = 263 (33.1), hypoxia (white bar) 1 hour = 456 
(89.9), normoxia (black bar) 4 hours = 327 (58.6), hypoxia (white bar) 4 hours = 569 
(71.8) gMFI, n = 6, p*<0.05)(Figure 3.2.4-1, A). Maintenance of mitochondrial 
membrane potential, however, is not required for survival, as collapse of 
mitochondrial membrane potential does not induce apoptosis. The protonophore 
CCCP significantly reduces mitochondrial membrane potential (mean (±SEM), 
normoxia (black bar) untreated = 263 (33.1), normoxia (black bar) treated = 227 
(26.5), hypoxia (white bar) untreated = 456 (89.9), hypoxia (white bar) treated = 247 
(32.9) gMFI, n = 6, p*<0.05)(Figure 3.2.4-1, B) but does not affect neutrophil 
apoptosis (mean (±SEM), normoxia (black bar) untreated = 63.4 (4.41), normoxia 
(black bar) treated = 63.5 (4.50), hypoxia (white bar) untreated = 43.0 (5.01), 
hypoxia (white bar) treated = 39.1 (5.59) gMFI, n = 3, p*<0.05)(Figure 3.2.4-1, C). 
Neutrophil mitochondrial membrane potential increase in hypoxia is not dependent 
on an increase in Krebs cycle flux. Neutrophils have equivalent levels of Krebs cycle 
intermediates in normoxia and hypoxia as measured via Liquid 
Chromatography/Mass Spectrometry (LC-MS)(mean (±SEM), citrate normoxia = 
5.39x108 (3.68x107), citrate hypoxia = 5.82x108 (6.01x107), αKG normoxia = 
7.13x106 (1.75x106), αKG hypoxia = 8.21x106 (8.73x105), succinate normoxia = 
1.51x107 (2.92x106), succinate hypoxia = 1.78x107 (4.63x106), fumarate normoxia = 
2.91x106 (4.87x105), fumarate hypoxia = 4.04x106 (1.63x106), malate normoxia = 
1.13x108 (1.56x107), malate hypoxia = 1.53x108 (2.43x107), oxaloacetate normoxia 




3.2.4-2, A). Neutrophil mitochondrial membrane potential increase in hypoxia is also 
not dependent on greater availability of NADH. Neutrophils have equivalent levels 
of total NAD+/NADH in normoxia and hypoxia (mean (±SEM), normoxia = 
1.58x108 (2.39x107), hypoxia = 1.78x108 (3.54x107), n = 4)(Figure 3.2.4-2,B) and 
have an equivalent NAD+/NADH ratio (mean (±SEM), normoxia = 14.2 (2.20), 
hypoxia = 11.6 (1.38), n = 4)(Figure 3.2.4-2, C).  
Addition of Krebs cycle intermediates can supplement the mitochondrial pool of 
substrate for the mitochondrial electron transport chain and has been shown to 
enhance mitochondrial activity (Hinke et al., 2007). Addition of the complex I 
substrate malate and the membrane-permeable complex II substrate methyl succinate 
(MSucc) does not affect mitochondrial membrane potential, indicating minimal 
activity of complex I and II (mean (±SEM), normoxia untreated = 123 (37.6), 
normoxia CCCP = 49.2 (10.7), normoxia malate = 107 (28.8), normoxia MSucc = 
118 (35.4), normoxia malate + MSucc = 106 (34.4), normoxia malate + MSucc + 
CCCP = 45.5 (9.45), hypoxia untreated = 217 (38.3), hypoxia CCCP = 60.2 (10.2), 
hypoxia malate = 186 (35.2), hypoxia MSucc = 202 (37.5), hypoxia malate + MSucc 
= 169 (40.0), hypoxia malate + MSucc + CCCP = 51.0 (6.35) gMFI, n = 4, 
p*<0.05)(Figure 3.2.4-3, A). 
These data show neutrophil mitochondrial electron chain activity is enhanced in 
hypoxia via a mechanism independent of mitochondrial glucose oxidation and 






























































Figure 3.2.4-1: Neutrophils maintain a mitochondrial membrane potential that 
is enhanced in hypoxic conditions. Neutrophils were cultured for 1 and 4 hours in 
normoxia and hypoxia (A,B,) or 20 hours (C) with and without 10μM CCCP (B, C) 
and mitochondrial membrane potential determined via staining with TMRM dye 
(A,B) or apoptosis determined by staining with Annexin V and TO-PRO-3 (C) and 
analysis via flow cytometry. Apoptosis was determined as % Annexin V +ve cells. 
Data expressed as mean±SEM and analysed with 2-way ANOVA with Sidak’s post 




































































































Figure 3.2.4-2: Neutrophils cultured in hypoxia have no change in Krebs cycle 
flux or NADH availability.  Neutrophils were cultured for 4 hours in normoxia and 
hypoxia and lysed in methanol before LC-MS analysis. Relative abundance of 
tricarboxylic acid cycle intermediates (A) and total NADH and NAD+ (B) in 
neutrophils cultured in normoxia and hypoxia C: NAD+/NADH ratios of neutrophils 
cultured for 4 hours in normoxia and hypoxia.  Data expressed as mean±SEM and 








































Figure 3.2.4-3: Addition of cell permeable Krebs cycle intermediates has no 
effect on mitochondrial membrane polarisation.  Neutrophils were cultured for 1 
hour in normoxia and with and without the krebs cycle intermediates malate, 
glutamate and methyl succinate, then stained with TMRM and analysed via flow 
cytometry. Data expressed as mean±SEM and analysed with 2-way ANOVA with 
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3.2.5. Neutrophils cultured in hypoxia have reduced cellular ROS but 
equivalent capacity to mount a respiratory burst 
To study whether this uplift in cellular ROS was specific to the mitochondria, we 
studied overall cell oxidant production in neutrophils using the cellular ROS probe 
dichlorofluorescein (DCF). 
Neutrophils cultured in hypoxia have reduced baseline cellular ROS (mean (±SEM), 
normoxia = 1.36x104 (1.52x103), hypoxia = 9.84x103 (1.27x103) gMFI, n = 8, 
p**<0.01)(Figure 3.2.5-1, A). The majority of the ROS produced in stimulated 
neutrophils is mediated through the pentose phosphate pathway as determined 
through treatment with the OxPPP inhibitor 6AN. 6AN blocks cellular ROS 
production in fMLP-treated cells (Mean (±SEM), normoxia (black bar) untreated = 
4.18x104 (5.80x103), normoxia (black bar) 6AN = 2.85.104 (5.22x103), hypoxia 
(white bar) untreated = 3.00x104 (7.02x103), hypoxia (white bar) 6AN = 2.41x104 
(3.35x103) gMFI, n = 8, p=0.09)(Figure 3.2.5-1, B).  
Hypoxia does not alter the capacity for neutrophils to mount a respiratory burst as 
measured by fold increase in DCF fluorescence following stimulation with fMLP 
(mean (±SEM), normoxia (black bar) untreated = 3.11 (0.377), normoxia (black bar) 
6AN = 1.92 (0.148), hypoxia (white bar) untreated = 2.95 (0.418), hypoxia (white 



































Figure 3.2.5-1: Neutrophils cultured in hypoxia have diminished ROS 
production but equivalent capability of mounting a respiratory burst.  
Neutrophils were cultured for 1 hour without (A) or with (B) 100nM fMLP and with 
or without the OxPPP inhibitor 6AN (B, C) and ROS production assessed through 
staining with the ROS-sensitive dye DCF (A, B, C). Respiratory burst was calculated 
as fold increase in DCF fluorescence after stimulation with 100nM fMLP (C). Data 
expressed as mean±SEM and analysed with paired two-tailed Student’s T tests (A) 

































































3.2.6. A model of mitochondrial dysfunction: blockade of complex II 
As a model of mitochondrial dysfunction, we had at our disposal a pool of patients 
with a rare deficiency in the mitochondrial protein succinate dehydrogenase. The 
patients have heterozygous loss-of-function mutations in SDHB. SDHB is a subunit 
of succinate dehydrogenase and is needed for transfer of electrons from FADH2 to 
the Q pool (Figure 3.2.6-1). Neutrophils isolated from patients with mutations in 
SDHB have reduced succinate dehydrogenase activity and are functionally different 
to healthy control neutrophils in that they have diminished rates of constitutive 
apoptosis when cultured in vivo (Jones et al., 2016). We examined whether loss of 
Kreb’s cycle enzyme activity in this case had a significant effect on mitochondrial 
function, specifically mitochondrial membrane potential and release of 
mitochondrial reactive oxygen species. 
Neutrophils isolated from patients with heterozygous SDHB mutations were found to 
have equivalent mROS levels to neutrophils isolated from healthy control blood 
directly after isolation (mean (±SEM), T0 HC = 98.0 (46.1), T0 HC MT = 49.5 
(10.0), T0 SDH = 83.4 (28.7), T0 SDH MT = 46.4 (4.83) gMFI, n = 3, ns)(Figure 
3.2.6-2, A). After culture in glutamine and glucose-rich media with and without LPS, 
mROS levels of neutrophils isolated from patients with heterozygous SDHB 
mutations were still equivalent (mean (±SEM), N6 HC = 97.7 (30.4), N6 HC MT = 
60.4 (1.48), N6 SDH = 103 (31.3), N6 SDH MT = 53.7 (5.43), N6 HC LPS = 79.3 
(41.7), N6 HC LPS MT = 46.9 (10.7), N6 SDH LPS = 56.2 (18.3), N6 SDH MT LPS 
= 48.4 (8.99) gMFI, n = 3, ns)(Figure 3.2.6-2, B-C). Likewise, freshly isolated 
neutrophils from patients with heterozygous SDHB mutations have equivalent 
mitochondrial membrane potential to neutrophils from healthy controls (mean 
(±SEM), T0 HC = 577 (71.7), T0 HC CCCP = 242 (38), T0 SDH = 557 (64.3), T0 
SDH CCCP = 246 (28) gMFI, n = 3, ns)(Figure 3.2.6-2, D). The same is true for 
neutrophils cultured in media with and without LPS (mean (±SEM), N6 HC = 596 
(20.0), N6 HC CCCP = 240 (1.32), N6 SDH = 566 (31.5), N6 SDH CCCP = 248 
(5.36), N6 HC LPS = 491 (9.43), N6 HC CCCP LPS = 233 (5.06), N6 SDH LPS = 
490 (14.4), N6 SDH CCCP LPS = 231 (13.5) gMFI, n = 3, ns)(Figure 3.2.6-2, E-F). 




respiratory chain function, neutrophils with heterozygous SDHB mutations do have a 
greater NAD+/NADH ratio compared to healthy control neutrophils (mean (±SEM), 
T0 HC = 0.240 (0.178), T0 SDH = 1.05 (0.543), N6 HC = 0.183 (0.107), N6 SDH = 
3.13 (1.32), N6 HC LPS = 0.624 (0.240), N6 SDH LPS = 1.36 (0.835), n = 4)(Figure 
3.2.6-3, A) but equivalent total NADt (T0 HC = 0.0687 (0.0209), T0 SDH = 0.0816 
(0.0250), N6 HC = 0.149 (0.0307), N6 SDH = 0.132 (0.00956), N6 HC LPS = 0.685 
(0.144), N6 SDH LPS = 0.699 (0.0735), n = 4)(Figure 3.2.6-3, B). 
Neutrophils with heterozygous SDHB mutations have an equal NADP+/NADPH 
ratio compared to healthy control neutrophils (mean (±SEM), T0 HC = 1.11 (0.204), 
T0 SDH = 1.02 (0.0630), N6 HC = 0.887 (0.109), N6 SDH = 0.996 (0.0671), N6 HC 
LPS = 0.578 (0.100), N6 SDH LPS = 0.575 (0.0745), n = 3)(Figure 3.2.6-3, C) and 
an equivalent amount of total NADPt in all conditions (mean (±SEM), T0 HC = 
0.0846 (0.0283), T0 SDH = 0.0726 (0.0237), N6 HC = 0.101 (0.0144), N6 SDH = 
0.0942 (0.0178), N6 HC LPS = 0.217 (0.0271), N6 SDH LPS = 0.224 (0.0332), n = 
3)(Figure 3.2.6-3, D). 
Neutrophils cultured with the complex II inhibitor 3-NP have significantly reduced 
apoptosis consistent with SDHB patients (mean (±SEM), 0.5mM vehicle control = 
64.5 (4.25), 0.5mM 3NP = 55.7 (1.46), 1mM vehicle control = 64.8 (2.85), 1mM 
3NP = 49.8 (3.62), 2mM vehicle control = 65.0 (3.01), 2mM 3NP = 51.3 (5.67)%, n 
= 4, p*<0.05)(Figure 3.2.6-4, A). 3-NP significantly reverses apoptosis induced by 
rotenone inhibition, indicating anti-apoptotic effects of 3-NP are not due to 
inhibition of the electron transport chain. (mean (±SEM), untreated =  48 (2.52), 












Figure 3.2.6-1: The role of SDHB in the tricarboxylic acid cycle and 
mitochondrial electron transport chain. SDHB is one of four subunits of the 
protein complex succinate hydrogenase (SDH). The SDHA subunit of succinate 
dehydrogenase catalyses the oxidation of succinate to fumarate, a key step in the 
krebs cycle. This reaction reduces FAD to FADH2. Electrons from FADH2 are 
transferred to the SDHB iron clusters, which in turn transfer these electrons to 
ubiquinone via SDHC/SDHD, reducing the ubiquinone to ubiquinol which can then 










































































































Figure 3.2.6-2: Neutrophils with succinate-dehydrogenase deficiency have 
equivalent mitochondrial ROS release and mitochondrial membrane potential. 
Neutrophils were isolated from healthy volunteers (black bars) or patients with 
germline mutations in SDHB (grey bars). Freshly isolated neutrophils ((A, D) and 
neutrophils cultured in normoxia for 6 hours with (B, E) and without (C, F) LPS 
were stained with MitoSOX™ Red (A-C) or TMRM (D-F) and fluorescence 
analysed via flow cytometry to assess production of mROS and mitochondrial 
membrane potential. Data expressed as mean±SEM and analysed with 2-way 

















































































 	Figure 3.2.6-3: Neutrophils isolated from patients deficient in succinate-
dehydrogenase B have higher NAD+/NADH ratios but similar NADP+/NADPH 
ratios. Neutrophils were isolated from healthy controls (black bars) and SDHBx 
patients (grey bars). Freshly isolated (FI) and neutrophils cultured for 6 hours with 
and without LPS were lysed and NAD+/NADH (A,B) and NADP+/NADPH (C,D) 
levels analysed via fluorimetric assay.  NAD+/NADH ratio (A), total NAD+ and 
NADH (B), NADP+/NADPH ratio (C) and total NADP+ and NADPH (D) were 
calculated from observed values. Data expressed as mean±SEM and analysed via 2-































































































p*<0.05 by 2-way 
ANOVA
Figure 3.2.6-4: Inhibition of succinate dehydrogenase with 3-nitropropionic 
acid prolongs neutrophil lifespan and reverses rotenone-induced apoptosis. 
Neutrophils cultured for 20 hours were treated with 3NP (A) or 3NP and rotenone 
(B) and apoptosis assessed via morphology. Data expressed as mean±SEM and 
analysed by 2-way ANOVA with Sidak’s post hoc multiple comparison test (A, B), 
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3.2.7. Neutrophils cultured in hypoxia have significantly enhanced 
anaerobic respiration 
Neutrophil metabolism is closely linked to mitochondrial electron chain function 
through the activity of the tricarboxylic cycle and availability of high-energy 
molecules such as ATP and NADH derived from glycolysis and the krebs cycle.  
Neutrophils have significantly more ATP, ADP and AMP in hypoxia and a lower 
energy status (ATP/ADP), indicating a greater energy demand and use of ATP in 
hypoxic conditions. Neutrophils have more ATP after culture in hypoxia for 4 hours 
compared to normoxic controls (mean (±SEM), normoxia = 2.71x108 (3.21x107), 
hypoxia = 4.11x108 (3.55x107), n = 4, p*<0.05)(Figure 3.2.7-1, A). Other 
phosphorylation states are also upregulated in hypoxia. ADP levels are significantly 
higher in hypoxia (mean (±SEM), normoxia = 1.64x107 (3.01x106), hypoxia = 
3.13x107 (5.70x106), n = 4, p*<0.05)(Figure 3.2.7-1, B). AMP is also upregulated in 
hypoxia (mean (±SEM), C, normoxia = 1.49x107 (6.08x105), hypoxia = 2.38x107 
(2.76x106), n=4, p*<0.05)(Figure 3.2.7-1, C). Neutrophils have a lower energy status 
(ATP/ADP) in hypoxia (mean (±SEM), normoxia = 17.2 (1.87), hypoxia = 14.1 
(2.12), n=4, p*<0.05)(Figure 3.2.7-1, D). 
Glycolysis regenerates NAD+ to NADH via glycolysis and can also make the 
mitochondrial-substrate DHAP (Figure 3.2.7-2, A). Neutrophils have significantly 
more flux through glycolysis in hypoxia (mean (±SEM), glucose 6-P normoxia = 
5.31x107 (8.53x106), glucose 6-P hypoxia = 1.20x108 (3.50x107), fructose 1,6-BP 
normoxia = 1.19x107 (1.29x106), fructose 1,6-BP hypoxia = 2.19x107 (3.34x106), 
DHAP normoxia = 4.27x106 (9.51x105), DHAP hypoxia = 7.47x106 (1.58x106), 
GAP normoxia = 7.57x106 (2.75x106), GAP hypoxia = 1.63x107 (3.13x106), 2-PG 
normoxia = 1.07x107 (3.38x106), 2-PG hypoxia = 1.98x107 (6.93x106), pyruvate 
normoxia = 8.63x106 (5.66x105), pyruvate hypoxia = 1.14x107 (5.34x105), lactate 
normoxia = 6.66x108 (5.11x107), lactate hypoxia = 7.91x108 (4.82x107), n = 4, 
p*<0.05)(Figure 3.2.7-2, B). 
Neutrophils require exogenous glucose for hypoxic survival. Neutrophils cultured 
without glucose in hypoxia lose hypoxic survival, whereas in normoxic conditions 




normoxia (black bar) FBS = 47.5 (3.07), normoxia (black bar) DFBS (dialysed FBS) 
= 53.4 (2.16), normoxia (black bar) DFBS-Gluc = 44.7 (2.83), hypoxia (white bar) 
FBS = 12.3 (2.53), hypoxia (white bar) DFBS = 36.0 (8.03), hypoxia (white bar) 
DFBS-Gluc = 93.4 (2.63), n = 8, p***<0.001)(Figure 3.2.7-3, A). Neutrophils 
cultured without glutamine have no change in apoptosis from DFBS controls, 
indicating glutamine is not necessary for maintaining neutrophil survival in hypoxia 
(mean (±SEM), normoxia (black bar) DFBS = 53.4 (2.16), normoxia (black bar) 
DFBS-Glut = 54.5 (3.13), hypoxia (white bar) DFBS = 36.0 (8.03), hypoxia (white 
bar) DFBS-Glut = 38.6 (6.06), n=8)(Figure 3.2.7-3, A). Neutrophils cultured with 
the hexokinase-inhibitor 2-deoxyglucose (2-DG) have accelerated apoptosis (mean 
(±SEM), normoxia (black bar) untreated = 52.8 (5.09), normoxia (black bar) 2-DG = 
70.6 (10.3), hypoxia (white bar) untreated = 31.3 (8.75), hypoxia (white bar) 2-DG = 
83.0 (3.31), n = 4, p*<0.05)(Figure 3.2.7-3, B). 2-DG-treated neutrophils cultured in 
hypoxia have a significantly greater degree of apoptosis compared to their untreated 
control than normoxic cells compared to their untreated control, indicating induction 
of hypoxic survival is dependent on the augmentation of glycolytic flux (mean 







































































Figure 3.2.7-1: Neutrophils have significantly more ATP/ADP/AMP, but 
reduced energy status indicating higher energy requirement in hypoxia. 
Neutrophils were cultured for 4 hours in normoxia and hypoxia and ATP (A), ADP 
(B) and AMP (C) abundance measured via LC-MS. Energy status (ATP/ADP) (D) 
was calculated as a measure of energy demand in the cell. Data expressed as 







Figure 3.2.7-2: Neutrophils have significantly increased abundance of glycolytic 
intermediaries in hypoxic conditions. Neutrophils were cultured for 4 hours in 
normoxia and hypoxia and lysed in methanol before LC-MS analysis. A: Schematic 
showing anaerobic glycolysis. Measured metabolites are highlighted. B: Relative 
metabolite abundance in cells cultured in normoxia and hypoxia. Data expressed as 





































































































Figure 3.2.7-3: Hypoxic neutrophils require extracellular glucose for survival. 
Neutrophils were cultured for 20 hours in normoxia and hypoxia in either complete 
RPMI with 10% FBS, complete RPMI with 10% dialysed FBS, RPMI without 
glucose with 10% dialysed FBS, or RPMI without L-glutamine with 10% dialysed 
FBS (A), or with and without the glucose hexokinase-inhibitor 2-deoxy-D-glucose 
(B, C). Data expressed as mean±SEM and analysed by paired Student’s two-tailed T 
tests (A, C) corrected for multiple comparisons with the Holm-Sidak method (A), 








































3.2.8. Neutrophils cultured in hypoxia have significantly enhanced 
flux through the pentose phosphate pathway 
Cellular antioxidant buffering capacity is primarily controlled through flux through 
the pentose phosphate pathway (Figure 3.2.8-1, A). We examined pentose phosphate 
pathway flux using LC-MS analysis in normoxia and hypoxic conditions. 
Neutrophils have significantly more flux through the pentose phosphate pathway in 
hypoxia (mean (±SEM). Ribulose 5-P normoxia = 6.27x105 (9.20x104), Ribulose 5-P 
hypoxia = 1.22x106 (2.79x105), Ribose 5-P normoxia = 3.06x106 (3.55x105), Ribose 
5-P hypoxia = 5.11x106 (7.78x105), Sedoheptulose 7-P normoxia = 6.37x106 
(8.85x105), sedoheptulose 7-P hypoxia = 1.16x107 (2.18x106), Erythrose 4-P 
normoxia = 7.06x104 (5.95x104), erythrose 4-P hypoxia = 1.78x105 (8.28x104), n = 
4, p**<0.01 by 2-way ANOVA)(Figure 3.2.8-1, B). 
Despite enhanced flux through the pentose phosphate pathway, neutrophils maintain 
an equivalent NADP+/NADPH ratio and GSH/GSSG ratio. Total NADP+ levels are 
equivalent between normoxic and hypoxic conditions. LPS was used as a control for 
NADPH oxidase activity and enhanced NADPt production (mean (±SEM), 
normoxia untreated = 0.154 (0.0305), hypoxia untreated = 0.177 (0.0142), normoxia 
LPS = 0.268 (0.0410), hypoxia LPS = 0.296 (0.0328), n = 3, p**<0.01)(Figure 3.2.8-
2, A). NADP+/NADPH levels are equivalent between normoxia and hypoxia (mean 
(±SEM), normoxia = 0.194 (0.0199), hypoxia = 0.241 (0.0359), normoxia LPS = 
0.382 (0.0722), hypoxia LPS = 0.286 (0.0409), n = 3)(Figure 3.2.8-2, B). Total 
glutathione levels are equivalent between normoxia and hypoxia (mean (±SEM), 
normoxia = 2.25 (0.215), hypoxia = 2.32 (0.217), normoxia LPS = 2.07 (0.207), 
hypoxia LPS = 2.16 (0.316), n = 3)(Figure 3.2.8-2, C) as are glutathione redox ratios 
(mean (±SEM), normoxia = 17.3 (4.21), hypoxia = 17.22 (4.016), normoxia LPS = 
21.2 (8.31), hypoxia LPS = 24 (1.97), n = 3)(Figure 3.2.8-2 D). This indicates an 
enhanced pentose phosphate flux is needed to maintain redox status. Consistent with 
these findings, blocking the pentose phosphate pathway with the G6PD inhibitor 
6AN is pro-apoptotic to neutrophils cultured in normoxia or hypoxia (mean (±SEM), 
normoxia untreated = 55.8 (2.22), normoxia 6AN = 68.8 (0.454), normoxia LPS = 
31.8 (6.23), normoxia LPS 6AN = 66.7 (4.00), hypoxia untreated = 35.6 (4.34), 




(0.442)%, n = 3)(Figure 3.2.8-3, A), with stimulated cells and cells cultured in 
hypoxia having a significantly higher degree of apoptosis induced by 6AN than 
unstimulated, normoxic cells (mean (±SEM), normoxia = 1.24 (0.0648), hypoxia = 
1.42 (0.0575), normoxia LPS = 2.59 (0.588), hypoxia LPS = 3.79 (0.781), n = 
3)(Figure 3.2.8-3, B). 
The addition of the antioxidant catalase significantly reduces apoptosis in both 
normoxia and hypoxia (mean (±SEM), normoxia untreated = 76.5 (1.25), normoxia 
catalase = 14.2 (3.31), hypoxia untreated = 35.4 (7.56), hypoxia catalase = 3.30 
(1.01)%, n = 3)(Figure 3.2.8-4,A). Addition of catalase was also sufficient to reverse 
the apoptosis caused by culture in hypoxia without exogenous glucose (mean 
(±SEM), hypoxia untreated = 35.4 (7.56), hypoxia untreated –glucose = 82.7 (5.94), 
hypoxia catalase –glucose = 15.3 (9.23)%, n = 3)(Figure 3.2.8-4, A, B). 
These data indicate that in hypoxia, oxidative stress is increased and glucose is 
needed to prevent oxidant-induced apoptosis in hypoxia through regeneration of 


















































Hypoxia p**<0.01 as 
determined by 2-way 
ANOVA
Figure 3.2.8-1: Neutrophils cultured in hypoxia have significantly higher levels 
of pentose phosphate pathway metabolites. Neutrophils were cultured for 4 hours 
in normoxia and hypoxia and lysed in methanol before LC-MS analysis. A: 
Schematic showing the oxidative pentose phosphate pathway. Measured metabolites 
are highlighted. B: Relative metabolite abundance in cells cultured in normoxia and 














































Figure 3.2.8-2: Neutrophils cultured in hypoxia have no difference in amounts 
or redox ratios of NADPH or glutathione. Neutrophils were culture for 4 hours in 
normoxia and hypoxia and lysed before glutathione and NADP levels measured via 
fluorimetric assay. A: Total NADP+/NADPH B: NADP+/NADPH ratio C: Total 
glutathione D: GSH/GSSG ratio. Data expressed as mean±SEM and analysed via 








































   	
Figure 3.2.8-3: Blockade of the oxPPP is pro-apoptotic with a significantly greater 
effect on stimulated and hypoxic cells. Neutrophils were cultured with and without 
1mM 6AN or 100ng/ml LPS and apoptosis assessed at 20 hours via morphology (A,B). 
Data expressed as mean±SEM and analysed via 2-way ANOVA (A, B) with Sidak’s 
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Figure 3.2.8-4: Catalase promotes neutrophil survival in both normoxia and 
hypoxia and the pro-apoptotic effects of glucose depletion in hypoxia can be 
reversed by exogenous addition of catalase. Neutrophils were cultured with and 
without 1mg/ml catalase in normoxia (A) and hypoxia (A,B) either in complete 
RPMI media or RPMI without glucose and apoptosis assessed at 20 hours via 
morphology. Data expressed as mean±SEM and analysed via paired two-tailed 










3.3.1. Neutrophils use their mitochondria for signalling via 
mitochondrial ROS production 
Neutrophils do not rely on electron transport chain function for ATP production, but 
still have extensive mitochondrial networks which maintain a mitochondrial 
membrane potential and can release ROS (Fossati et al., 2003)(Maianski et al., 
2004). The role of mitochondria in the neutrophil is unclear. As neutrophils maintain 
a mitochondrial membrane potential, it seemed likely that the neutrophil respiratory 
chain is at least partly functional and may produce mitochondrial ROS in the absence 
of ATP production.  
I investigated whether hypoxia induces the production of mitochondrial ROS in 
neutrophils as it does in other cell types. From the data it is clear that neutrophils do 
maintain a mitochondrial membrane potential (Figure 3.2.4-1, A-B) and produce 
mitochondrial ROS (Figure 3.2.2-2), and acute hypoxia, but not pro-inflammatory 
stimuli or exposure to high glucose culture media, is a potent inducer of 
mitochondrial ROS production (Figure 3.2.2-2). 
The data also show the hypoxic release of mitochondrial ROS in neutrophils 
promotes survival and positively regulates the stability of HIF-1α as blockade of 
mROS production using mitochondrial inhibitors is pro-apoptotic (Figure 3.2.3-1) 
and inhibits HIF-1α stabilisation (Figure 3.2.3-2, A-B).  
Interestingly, although the release of mROS is induced in hypoxia, overall cellular 
redox stress is reduced in hypoxic conditions (Figure 3.2.5-1, A), and non-
mitochondrial antioxidants such as TEMPOL do not influence HIF-1α stability, 
suggesting HIF-1α stabilisation is mediated specifically by mROS release in hypoxia 
(Figure 3.2.3-2, B). The reason for this effect being specific to ROS produced in the 
mitochondria is unclear. ROS-induced HIF-1α stabilisation has been suggested to be 
dependent on AMPK signalling via JNK and JAK2 (Jung et al., 2008). Cellular 
stress, including ROS, can cause JNK localisation to the mitochondria which can 
then amplify mROS production in a positive feedback loop (Chambers and 




loop may explain why mROS specifically are capable of stabilising HIF-1α over 
NADPH-oxidase derived ROS. Indeed, these studies indicated inhibition of 
NADPH-oxidase activity with apocynin did not affect JNK-mediated upregulation of 
ROS production. Additional studies have suggested that a small percentage of 
cellular HIF-1α associates with the mitochondria (Briston, Yang and Ashcroft, 
2011), which may explain why HIF-1α is more sensitive to mROS over cytoplasmic 
ROS. However, the precise mechanism remains unclear. 
Further downstream functional effects of hypoxia-induced mROS have yet to be 
elucidated. Neutrophil mitochondrial function has been implicated in the regulation 
of chemotaxis induced by fMLP as treatment with the uncoupler CCCP can inhibit 
neutrophil chemotaxis (Fossati et al., 2003)  Recent studies have specifically 
implicated the release of neutrophil mROS in the regulation of neutrophil 
degranulation and extracellular ROS (Vorobjeva et al., 2017). The addition of the 
mitochondrial antioxidant SkQ1 was shown to inhibit neutrophil degranulation in 
response to fMLP, and also induced apoptosis in fMLP-stimulated cells. Neutrophil 
degranulation is upregulated in hypoxic conditions through a HIF-1α-independent, 
PI3Kγ-dependent mechanism, and hypoxic supernatants produce a greater degree of 
injury on human tissues (Hoenderdos et al., 2016). Whether hypoxic mROS release 
influences this regulation of degranulation is unknown, although as mROS is known 
to positively modulate PI3K pathways, it is possible mROS may play a role in 
enhanced degranulation in hypoxia (Sullivan and Chandel, 2014).  
Neutrophil mROS have also been shown to be important for the calcium-dependent 
induction of NETosis through the activity of the mitochondrial channel SK3 (Douda 
et al., 2015). Moreover, mROS have been implicated in the release of pro-
inflammatory NETs comprised of oxidized mitochondrial DNA in patients with 
systemic lupus erythematous disease (SLE), with mitochondrial ROS scavengers 
capable of suppressing lupus-like disease in vivo (Lood et al., 2016). NETosis is 
indeed modulated by hypoxia and HIF-1α stabilisation, with hypoxia limiting the 
capacity of neutrophils to undergo NETosis (Branitzki-Heinemann et al., 2016).  
Our data is therefore in agreement with studies in other cell types that suggest mROS 




mediator of pro-inflammatory neutrophil activities. This parallels studies in pro-
inflammatory macrophages implicating glycolysis and a subsequent increase in 
mitochondrial membrane potential as a mediator of pro-inflammatory macrophage 
functions such as IL-1β production (Mills et al., 2016). Targeting neutrophil 
mitochondria may have potential for reducing neutrophilic inflammation in acute 
and chronic inflammatory disease. The increased importance of neutrophil 
mitochondrial ROS in hypoxia may suggest a way in which hypoxia can promote 
inflammation, which may be targeted by mitochondrial inhibitors or antioxidants. 
3.3.2. Mechanism of hypoxia-induced mitochondrial ROS is 
independent of Krebs cycle flux, NADH availability and oxidative 
glucose metabolism 
The mechanism for hypoxia-induced mROS release is not entirely clear, although 
our data show it is not due to changes in mitochondrial electron chain substrate 
availability via altered flux through the Krebs cycle (Figure 3.2.4-2, A), nor the 
enhanced availability of NADH or NADPH reducing intermediates (Figure 3.2.4-2, 
B-C) which can transfer electrons to the mitochondrial electron transport chain. 
Neutrophils lacking a functional complex II have changes in NAD+/NADH ratio 
(Figure 3.2.6-3, A) yet maintain mROS production (Figure 3.2.6-2, A) and a 
mitochondrial membrane potential (Figure 3.2.6-2, B), indicating that either they 
make up for deficit through flux through complex I, or complex II in neutrophils 
does not contribute to electron transport chain flux. The latter hypothesis is likely as 
our data show loss of SdhB does not influence mROS production in neutrophils, 
whereas studies in Hep3B cells have shown pharmacological inhibition or genetic 
knockdown of SdhB enhances mROS production which stabilises HIF-1α (Guzy et 
al., 2008). Furthermore, addition of cell-permeable complex II substrate 
methylsuccinate does not increase mitochondrial membrane potential, indicating 
minimal complex II activity (Figure 3.2.4-3, A). 
It has been noted that maintenance of mitochondrial membrane potential by 
neutrophils is primarily caused by complex III; however, it is unclear whether this 
mechanism is the cause of this enhanced membrane potential in hypoxia (Guzy et 




and oligomycin did induce the production of mROS (Figure 3.2.2-2, D), indicating 
transit of electrons through the electron transport chain. However, the degree of 
mROS increase produced through treatment with these compounds was equivalent in 
normoxia and hypoxia (Figure 3.2.2-2, E), suggesting increased electron flux 
through these complexes of the electron transport chain was not the cause of this 
increased ROS production. Therefore, the mechanism of enhanced mROS and 
membrane potential may be due to either fundamental physiological changes to the 
mitochondria in hypoxia, or an increase in the use of alternative mitochondrial 
electron transport pathways that contribute to mitochondrial electron release which 
bypass complex I, such as the glycerol 3-phosphate shuttle. Electrons can be 
introduced into the electron transport chain at sites independent of complexes I and 
III, and then travel back to these complexes through reverse electron transport 
(RET), so an increase in mROS through complex I inhibition may reflect inhibition 
of reverse transit rather than acceptance of electrons from TCA cycle-derived 
NADH. Reverse electron transport allows cells to regenerate NADH through transfer 
of an electron to NAD+ via complex I. Early studies showed isolated mitochondria 
can produce NADH from NAD+ after supplementation with succinate, a complex II 
substrate (Chance and Hollunger, 1961). We have limited conclusive evidence for 
physiologically relevant RET in our model; however, it is interesting that neutrophils 
in vitro lacking complex II have a drastically higher NAD+/NADH ratio (Figure 
3.2.6-3, A), which may indicate this occurs in the neutrophil mitochondrial electron 
chain.  
Regardless of direction of flow, electrons must be introduced into the respiratory 
chain through metabolic intermediates. As Krebs cycle activity is extremely limited 
and hypoxia does not change NAD+/NADH ratio or Krebs cycle flux, it is unlikely 
hypoxic mROS upregulation is mediated through enhanced flux into the electron 
transport chain via complex I and II. One possible mechanism for entry of electrons 
into the electron transport chain is the glycerol 3-phosphate shuttle, which is a direct 
link between glycolysis and the electron transport chain. The shuttle is composed of 
a cytosolic glycerol 3-phosphate dehydrogenase enzyme, cGPDH, or GPD1, which 
converts the glycolytic intermediate DHAP to glycerol 3-phosphate, oxidising one 




dehydrogenase, mGPDH, or GPD2, which converts glycerol 3-phosphate back to 
DHAP, reducing a molecule of FAD to FADH2 which can then reduce the 
mitochondrial Q pool. This allows the reducing power of cytosolic NADH to transfer 
to the mitochondrial electron transport chain. Glycerol 3-phosphate can also be 
dephosphorylated to produce glycerol by G3PP, a reaction which controls the rate of 
glycolysis and lipogenesis (Mugabo et al., 2016). 
As neutrophils have enhanced flux through glycolysis and more DHAP abundance, 
enhanced flux through this pathway may allow neutrophils to maintain a 
mitochondrial membrane potential for redox signalling without investing Krebs 
cycle intermediates into oxidative phosphorylation. This may also explain higher 
rates of mROS production as the mitochondrial GPD is a significant source of ROS, 
equivalent to Complex III during maximal electron flux (Vrbacký et al., 2007). 
Other highly glycolytic cells use this pathway, such as some malignant cancers, have 
high rates of mROS release mediated by GPD2 (Mracek, Drahota and Hou, 2013) 
and GPD2 activity has been shown to be essential for survival of prostate cancer 
cells in vitro (Singh, 2014). There has been some evidence that neutrophil 
mitochondria primarily use this pathway, as mitochondria isolated from neutrophils 
can fully regenerate their mitochondrial membrane potential if treated with glycerol 
3-phosphate (van Raam et al., 2008). Addition of glycerol phosphate had a greater 
effect on regenerating mitochondrial membrane potential than complex I and II 
substrates malate and succinate, respectively. Other studies in neutrophils have 
shown glycerol metabolism is important in neutrophilic inflammation and survival 
(Moniaga et al., 2015). Further study into whether this pathway is active in 
neutrophils and modulated by oxygen tensions is needed to ascertain whether this is 
indeed the mechanism behind enhanced neutrophil mROS production in hypoxia.  
3.3.3. Neutrophil mitochondrial energy production is minimal and is 
not modulated by hypoxia  
Concurrent with previous studies (Fossati et al., 2003)(Maianski et al., 2004), our 
data suggest neutrophil mitochondria are not required or needed for oxidative 
respiration and ATP production. We found that demand for ATP, and ATP 




Glycolytic flux is also upregulated in hypoxia (Figure 3.2.7-2), but not oxidative 
respiratory pathways such as the Krebs cycle (Figure 3.2.4-2). This suggests that the 
increase in ATP demand in hypoxia is not met through mitochondrial oxidative 
respiration, and instead up-regulation of glycolytic flux or regulation of alternative 
energy pathways is needed to satisfy increased hypoxic energy demand. In keeping 
with this concept, treatment of neutrophils with the mitochondrial inhibitor CCCP 
which collapses the membrane potential and capacity for ATP production through 
complex V of the respiratory chain, does not modulate neutrophil apoptosis either 
normoxic or hypoxic conditions (Figure 3.2.4-1), indicating neutrophils are not 
dependent on oxidative phosphorylation. 
The reliance of neutrophils on glycolysis is paralleled by their metabolic response to 
hypoxia. The fact that ATP production and demand is enhanced in hypoxia in 
neutrophils in vitro is in stark contrast to a number of other studies in proliferative 
cells where hypoxia decreases ATP production as the cells lose respiratory chain 
function due to lack of available molecular oxygen (Heerlein et al., 2005)(Kioka et 
al., 2014). Perhaps consequently, lack of ATP availability in severe or chronic 
hypoxia in proliferative cells can induce apoptosis (Santore et al., 2002)(Kioka et al., 
2014), whereas hypoxia or even a total lack of oxygen, is a potent survival stimulus 
to neutrophils (Figure 3.2.1-1, Figure 3.2.1-2)(Walmsley et al., 2005). It is unclear 
whether this survival response is ATP-mediated. Previous studies have shown 
neutrophil apoptosis is inhibited by ATP in a way dependent on the activity of the 
P2Y11 receptor (Vaughan et al., 2007), although our data does not show if enhanced 
glycolytic flux and ATP production in the neutrophils directly translates to increased 
release of ATP into the extracellular milieu. Inhibition of glycolysis by 2-DG or 
culturing neutrophils in glucose-free culture medium is more pro-apoptotic in 
neutrophils cultured in hypoxia to the extent that normoxic neutrophils show no 
change in apoptosis after 20 hours in culture, whereas hypoxic neutrophils are 
completely non-viable at the same time-point (Figure 3.2.7-3). This indicates the 
pro-survival effect in hypoxia is dependent on glucose metabolism via glycolysis, 





3.3.4. The neutrophil antioxidant response is induced by hypoxia, 
mediated by flux through the pentose phosphate pathway and required 
for survival  
 Neutrophils can modulate mitochondrial reactive oxidant species levels not only 
through altering flux through the electron transport chain, but also through the 
expression of small molecules and proteins which act as antioxidants, removing 
reactive oxygen species from the cell. 
Glutathione is a major antioxidant buffer and glutathione levels decrease in 
neutrophils over time while in culture, significantly declining within an hour of 
culture. This effect was reversed on addition of exogenous catalase to the culture 
medium (Ogino, Packer and Maguire, 1997). Ogino et al argue that ROS can 
irreversibly oxidise glutathione, potentially through the generation of chloramine by 
MPO, and that glutathione protects against the ROS produced by the neutrophils 
themselves. Glutathione is regenerated by the activity of the pentose phosphate 
pathway, which uses metabolites from glycolysis (Figure 3.2.8-1, A). 
We measured glutathione levels after 2 hours in culture and found no difference in 
either glutathione levels or GSH/GSSG ratio (Figure 3.2.8-2, A-B), or NADPH 
levels or NADP+/NADPH ratio. However, pentose phosphate activity was 
significantly enhanced in hypoxia (Figure 3.2.8-1, B), which suggests the neutrophils 
have to regenerate glutathione at a more rapid rate to compensate for an increase in 
redox stress in the cell. This indicates neutrophils maintain a steady overall redox 
ratio potentially through upregulating pentose phosphate activity in response to 
enhanced ROS production in hypoxia. Blocking hypoxic upregulation of pentose 
phosphate pathway activity using the GPD inhibitor 6-AN induces neutrophil 
apoptosis (Figure 3.2.8-3, A), and more so in hypoxic cells (Figure 3.2.8-3, B), 
suggesting neutrophils rely more on the pentose phosphate pathway in hypoxia. 
Addition of 6AN was sufficient to prevent the upregulation of ROS after 
administration of fMLP, indicating efficient inhibition of the pentose phosphate 
pathway (Figure 3.2.5-1, B-C), although interestingly in unstimulated cells, levels of 
reactive oxygen levels were unchanged. It is possible this is because residual 




Similarly, blocking glucose availability or depriving neutrophils of glucose induces 
apoptosis as mentioned previously. This is either because neutrophil energy demand 
is higher in hypoxia so blocking the primary source of ATP induces apoptosis, or 
because glucose uptake is needed to induce upregulation of the pentose phosphate 
pathway and prevent oxidative damage in hypoxia. To ascertain which was the case, 
we added the antioxidant catalase to the culture medium to see if reducing oxidative 
stress of the neutrophils could prevent apoptosis caused by glucose starvation. 
Catalase is an antioxidant which is distributed throughout the cytoplasm of cells and 
is capable of converting H2O2 to H2O and O2 (Ballinger et al., 1994). Previous work 
has shown catalase, but not superoxide dismutase, can reduce neutrophil apoptosis in 
vitro (Hannah et al., 1995), and neutrophils actively transcribe and translate large 
amounts of endogenous catalase, in contrast to monocytes that express GPx in 
preference over catalase as their primary antioxidant defense mechanism (Pietarinen-
Runtti et al., 2000). Neutrophils also express MnSOD (Pietarinen-Runtti et al., 
2000). We found addition of catalase to the culture medium significantly prevents 
glucose-starved neutrophil cell death in hypoxia (Figure 3.2.8-4, A-B), indicating 
that upregulation of glucose metabolism is at least partially needed to protect against 
enhanced redox stress in hypoxia, and that protection against redox stress can 
prolong survival even in the absence of available energy substrates. 
Hypoxia neutrophils also mount a transcriptional and translational antioxidant 
response to hypoxia. Neutrophils increase catalase expression in hypoxia in vitro 
(Thompson et al., 2014) and also in response to apnoea (Sureda et al., 2004). 
Apnoea was also shown to modulate the activity of thioredoxin reductase, an enzyme 
that is capable of reducing protein disulphides and therefore reversing the effect of 
oxidants on protein thiol residues.  
Interestingly, even in hypoxic conditions, cells cultured with glucose also 
experienced a pro-survival effect on treatment with catalase. It is clear neutrophils 
employ a number of antioxidant defenses in response to hypoxia. 
3.3.5. Summary 




ROS. In hypoxia, mitochondrial ROS production is increased in a way that augments 
hypoxic HIF-1α in hypoxia. Enhanced release of mitochondrial ROS in hypoxia is 
not due to enhanced Krebs cycle flux or oxidative phosphorylation. It is possible that 
glycolysis is moderating this release of ROS as we show glycolysis is profoundly 
upregulated in hypoxic conditions. Upregulation of glycolytic flux is also linked to 
enhanced pentose phosphate pathway flux essential for neutrophil survival. 
Antioxidants can completely rescue neutrophil survival in hypoxia following 
removal of glucose, indicating antioxidant molecules are essential for modulating 
neutrophil survival over energy production. Therefore, our data describe duel roles 
for mitochondrial and cellular ROS as both signalling molecules and critical 
regulators of neutrophil apoptosis that are modulated by hypoxia through modulation 





4. Regulation of neutrophil function and killing by 
PHD3  
4.1. Introduction 
4.1.1. Regulation of PHD3 in inflammation 
Neutrophil metabolism and function is intrinsically linked by the hypoxic response 
pathway (Chapter 1.4). This pathway is composed of HIF proteins, and the PHD 
enzymes. These enzymes represent an intersection between hypoxia, inflammation, 
metabolism and cell function as they are sensitive to oxygen and Krebs cycle 
metabolite concentrations, and can also regulate both anaerobic and aerobic 
metabolism via the HIF proteins. 
PHD3 is expressed by a number of cells involved in the innate immune response, 
and loss of PHD3 has been shown to have conflicting effects depending on the 
context of infection and oxygen tension. In a model of sepsis, loss of PHD3 has been 
shown exacerbate symptoms and contribute to an exaggerated inflammatory 
response. Whole-animal knockout of PHD3 (PHD3-/-), but not PHD1 (PHD1-/-) or 
PHD2 (PHD2+/-) shortened the survival of mice subjected to abdominal sepsis 
because of an overwhelming innate immune response typified by Systemic 
Inflammatory Response Syndrome (SIRS)(Kiss et al., 2012). Bone marrow transfer 
to wild-type mice from PHD3-/- mice induced this phenotype in the recipient mice, 
indicating PHD3 knockout in innate immune cells specifically exacerbates this 
inflammatory response. This correlates with an increase in HIF-1α expression, 
increased expression of pro-inflammatory cytokines IL-6 and IL-1β, enhanced 
migration, and enhanced phagocytosis of zymosan and apoptotic cells in BMDMs 
derived from PHD3-deficient bone marrow.  
These data suggest that PHD3 suppresses immune cell activation and HIF-1α 
activity in a model of extreme inflammation. In contrast, in other models of 
inflammation not typified by immune dysfunction, PHD3 is highly expressed by 
proinflammatory M1 macrophages, implicating a pro-inflammatory role for PHD3 




in BMDMs does not change HIF-1α-dependent target gene expression as it does in 
sepsis, but does protect BMDMs against apoptotic cell death after serum starvation 
(Swain et al., 2014), stressing the inflammatory context is key in understanding 
PHD3 responses.  
Neutrophils express PHD3 and transcription of PHD3 is upregulated in peripheral 
blood neutrophils isolated from rheumatoid arthritis patients (Walmsley et al., 2011). 
Moreover, loss of PHD3 enhances the resolution of an LPS-induced lung injury 
model in hypoxic animals (Walmsley et al., 2011) through increased neutrophil 
apoptosis. Subsequent studies have shown that myeloid-specific loss of PHD3 can 
also dampen the immune response in a model of hind-limb ischemia (Beneke et al., 
2017), indicating PHD3 activity can exacerbate immune responses in the context of 
hypoxia and PHD3 knockdown is beneficial for inflammation resolution. Therefore, 
data from models of non-septic inflammation identify PHD3 as an attractive target 
when examining the immune response to hypoxia and infection. 
 It is important to note that as loss of PHD3, but not PHD2, has been implicated in 
encouraging tumour growth (Henze et al., 2014), studies must consider the  potential 
side effects of PHD3 inhibition. Furthermore, COPD patients have been associated 
with an increased incidence in single-nucleotide polymorphisms in PHD3, 
suggesting PHD3 deletion is involved in the pathogenesis of COPD (Fang et al., 
2017). 
4.1.2. Regulation of PHD3 by oxygen tension 
 PHD3 transcription and protein expression is up-regulated in hypoxia in a 
number of cancer cell lines (Appelhoff et al., 2004), and subsequent studies have 
shown hypoxia also up-regulates PHD3 in neutrophils (Walmsley et al., 2011) and 
macrophages (Escribese et al., 2012). Hypoxia induces PHD3 protein expression in 
cancer cells by over 30 fold, compared to a 3 fold induction of expression of PHD2 
(Place and Domann, 2013), although in normoxia, PHD2 protein levels are far higher 
than that of PHD3. It is possible this is partially to compensate for a loss of activity, 
as hydroxylase activity of PHD3 is dependent on molecular oxygen being available 




PHD3 maintain some hydroxylase activity in hypoxia, even at oxygen concentrations 
as low as 0.2%, with PHD3 more capable of hydroxylation at low oxygen 
concentrations (Stiehl et al., 2006). The regulation of PHD3 activity by oxygen 
tension is further complicated by recent findings describing novel non-HIF targets of 
PHD3 hydroxylation (Köditz et al., 2007), as well as non-hydroxylase enzymatic 
activity of PHD3 that occurs independent of oxygen tension. Therefore, it is likely 
that PHD3 has multiple different roles depending on oxygen tension due to 
modulation of both expression and hydroxylase activity. Oxygen tension may also 
change the cellular localisation of PHD3, with oxygen inducing the aggregation of 
PHD3 in oxidative conditions in a p62-dependent manner (Rantanen et al., 
2007)(Rantanen et al., 2013). 
4.1.3. PHD3 and regulation of HIF-1α and HIF-2α 
Traditionally, PHD3 has been thought to act through hydroxylation of HIF-1α (see 
chapter 1.1.3).  However, a number of studies investigating PHD3 deletion have 
failed to show modulation of HIF-1α signalling on loss of PHD3. Recent work has 
instead implicated PHD3 in the regulation of HIF-2α. SiRNA gene silencing of 
PHD1, PHD2 and PHD3 in HeLa cells showed HIF-1α levels are regulated only by 
silencing of PHD2 and that PHD2 is the dominant regulator of HIF-1α expression 
(Berra et al., 2003). Work from Chris Pugh’s lab has shown HIF-2α, but not HIF-1α, 
is stabilised at protein level in normoxia in PHD3 knockdowns, with even higher 
levels in hypoxic knockdowns, suggesting HIF-2α is dominantly regulated by PHD3. 
In neutrophils, loss of PHD3 does not appear to regulate HIF-1α expression, as 
hypoxic upregulation of HIF target genes is not affected by Phd3 deletion 
(Walmsley et al., 2011). In vivo evidence also suggests control of HIF-1α stability by 
PHD3 is limited. Embryos of PHD3-/- mice do not show abnormalities in the 
placenta, which requires proper control of HIF-1α expression for normal 
development (Dunwoodie, 2009). This is echoed by the finding that PHD2-/- 
embryos have severe placental defects and die between 12.5 and 14.5 days of 
embryonic development (Takeda et al., 2006).  
Expression of PHD3 blocks HIF-1α and HIF-2α CODD-linked fusion protein GAL 




terminal oxygen degradation domain (NODD). By contrast, PHD2 prefers the C-
terminal oxygen degradation domain (CODD) over the NODD by a factor of 20 
(Pektas and Knapp, 2013). This preference for CODD hydroxylation may account 
for the apparent specificity of PHD3 in controlling the stability of HIF-2α over HIF-
1α. 
PHD3 expression itself is positively regulated by the activity of HIF proteins. This is 
evident as deletion of VHL induces PHD3 at a transcriptional level in Hep3B cells   
Enhanced expression of HIF-2α specifically, but not HIF-1α, is enough to enhance 
PHD3 mRNA expression in Hep3B cells (Aprelikova et al., 2004). However, 
enhanced expression of either HIF-1α or HIF-2α enhances PHD3 expression in 
U2OS cells, indicating that the regulation of this pathway is cell-type specific.  
A further level of complexity is implied as PHD3 has been shown to bind to HIF-1α 
C-terminal activation domain (CTAD) and act as a co-activator for HIF-1α in 
hypoxia (Schoepflin et al., 2017). Therefore, PHD3 hydroxylase activity appears to 
regulate HIF-2α through hydroxylation of the NODD, but can also augment HIF-1α 
gene transcription through acting as a co-activator. This adds a further level of 
complication to the regulation of the hypoxic response pathway in different oxygen 
tensions, but also stresses the importance of investigating each component of the 
hypoxic response pathway as a functionally distinct target for manipulating cellular 
responses to hypoxia.  
HIF-2α is a critical mediator of innate immunity. HIF-2α were shown to have limited 
expression of IL-1β, CXCK8 and VEGF through an NF-κB-independent 
mechanism, indicating HIF-2α mediates a pro-inflammatory response to hypoxia 
(Fang et al., 2009). Moreover, HIF-2α has been shown to be a critical regulator of 
neutrophil inflammation, with HIF-2α prolonging neutrophil lifespan and 
contributing to neutrophil persistence at the site of inflammation (Thompson et al., 
2014). Neutrophils from PHD3-deficient animals were shown not to influence HIF-
2α target gene expression in neutrophils, indicating PHD3 does not regulate HIF-2α, 
although as this regulation is often context specific, this does not preclude the 




4.1.4. Non-HIF PHD3 targets: Advances and controversy  
Although the role of PHD3 has traditionally been confined to the hydroxylation of 
HIF proteins, recent studies have shown PHD3 can interact with a diverse array of 
proteins, both through oxygen and 2-oxoglutarate-dependent hydroxylation and 
through interactions where protein-protein signalling is not dependent on 
hydroxylase activity.  
Initial studies showed PHD3 can hydroxylate and suppress the activity of the 
transcription factor ATF-4 (Köditz et al., 2007). ATF-4 is the point where many 
stress response pathways converge, and is involved in the protection of the cell from 
oxidant stress following ER stress (Harding et al., 2003). Contemporaneous studies 
by Nakayama et al suggest PHD3 can form complexes with other PHD isotypes and 
Siah2, and formation of these complexes is enriched in hypoxia (Nakayama et al., 
2007). These complexes were found to modulate the effectiveness of PHD3 to 
hydroxylate HIF-1α. 
Following these studies, it was clear PHD3 had a very distinct role in regulating cell 
processes aside from the regulation of HIF proteins. There was growing interest in 
understanding how PHD3 can interact with target proteins. A number of studies 
described a non-hydroxylation role for PHD3 in negatively regulating the NF-κB 
pathway (Xue et al., 2010)(Fu and Taubman, 2010)(Fu and Taubman, 2013). These 
studies have described a role for PHD3 as able to inhibit differentiation of C2C12 
myoblasts in a HIF-independent manner through inhibition of the NF-κB pathway 
via inhibition of IKKγ (Fu and Taubman, 2010). A catalytic-inactive mutant of 
PHD3 was shown to be capable of inhibiting IKKγ, and PHD3 inhibition of IKK-
NF-κB signalling requires interaction with IKKγ (Fu and Taubman, 2013). NF-κB 
controls a host of genes involved in inflammation and is upregulated in a host of 
inflammatory diseases (Lawrence, 2009).  
Studies from Henze show PHD3 can inhibit hypoxic tumour growth in a 
hydroxylase-independent manner (Henze et al., 2014). PHD3 was shown to be 
silenced in glioma progression, and loss of PHD3 enhanced tumour cell survival and 




was inhibited were transfected with a hydroxylase-deficient mutant PHD3-HI96A. 
Expression of the hydroxylase-deficient protein was sufficient to suppress tumour 
growth, indicating hydroxylase activity was not needed for the tumour suppression 
activity of PHD3. More recent studies have also described hydroxylation and 
stabilization of the tumour suppressor gene p53 by PHD3 (Rodriguez et al., 2018). 
An incomplete list of PHD3 binding proteins discovered so far is shown in Table 
4.1.4-1. 
The complexity of PHD3 activity and transcription activation may contribute to the 
context-specific and cell-specific effects on PHD3 deletion, and explain why loss of 





PHD3 target Role Hydroxylation/Non-
hydroxylation 
Interaction 





PKM2 (Luo et al., 
2011) 
Glycolysis Hydroxylation Enhancement 
hCLK2 (Xie et al., 
2012) 
Cell cycle Hydroxylation Enhancement 







Nakayama, 2010)  
Apoptosis Non-hydroxylation Enhancement 
IKK-β (Xue et al., 
2010) 
Survival Non-hydroxylation Suppression 
IKK-γ (Fu and 
Taubman, 2013) 
Survival Non-hydroxylation Suppression 






Bcl2 (Liu et al., 
2010) 
Survival Non-hydroxylation Suppression 





















TRiC (Masson et al., 
2004) 
Chaperonin Unknown Unknown 
p53 (Rodriguez et al., 
2018) 
Apoptosis Hydroxylation Enhancement 






















Table 4.1.4-1: PHD3 binding partners. A list of binding partners that interact with 
PHD3, either through hydroxylation or non-hydroxylation Adapted and updated from 





4.1.5. PHD3 and metabolism 
PHD3 can regulate metabolism both directly and through the stabilisation of HIF-2α. 
HIF-2α can moderate glucose metabolism through the activity of PPAR-α (Aragonés 
et al., 2008), although studies in HIF-1α and HIF-2α over-expressing cells indicate 
PGK-1 and LDHA expression are not induced by overexpression of HIF-2α as they 
are by HIF-1α overexpression (Hu et al., 2003). HIF-2α can also positively regulate 
the transcription of the mitochondrial cytochrome c oxidase (COX) subunit COX4I2 
in hypoxia as part of the cell optimising aerobic metabolism machinery to hypoxic 
conditions (Fukuda et al., 2007). Fatty acid metabolism is controlled by HIF-2α 
expression; a study in hepatocytes showed HIF-2α controlled adipose differentiation-
related protein (Adfp) expression and β-oxidation, and that activation of HIF-2α was 
capable of suppressing fatty acid β-oxidation (Rankin et al., 2009). 
In addition to indirectly regulating glucose metabolism through HIF-2α, a number of 
studies have also confirmed the ability of PHD3 to regulate glycolysis directly.  Two 
contemporaneous studies describe the interaction of PHD3 with the glycolytic 
enzyme PKM2 and the ability of PHD3 to modulate glucose metabolism (Chen et 
al., 2011)(Luo et al., 2011). Subsequent studies have shown silencing of PHD3 
regulates the expression of a wide variety of metabolic genes involved in glucose 
metabolism, including glycolytic enzymes LDHA and GLUT1, the Krebs cycle 
enzyme MDH2, and G6PD, the critical rate-limiting enzyme of the pentose 
phosphate pathway (Miikkulainen et al., 2017). Given that neutrophils are reliant on 
glycolysis, and PHD3 has been shown to inhibit neutrophil hypoxia survival, it will 
be important to investigate whether PHD3 expression regulates neutrophil 
metabolism and whether this affects neutrophil lifespan in hypoxia. Acute deletion 
of PHD3 has been investigated as a potential target for metabolic diseases such as 
diabetes, as PHD3 deletion improves sensitivity and reduces the severity of a model 
of diabetes in mice through stabilisation of HIF-2α, which increases Irs2 
transcription and insulin-stimulated Akt activation (Taniguchi et al., 2013).  
4.1.6. PHD3 regulates neutrophil apoptosis 
Loss of PHD3 has no effect on apoptosis in neutrophils cultured at room oxygen 




a critical modulator of neutrophil apoptosis in hypoxic (1%) conditions (Walmsley et 
al., 2011). This correlated with enhanced expression of Siva-1, an apoptosis-
inducing gene, and abrogation of Bcl-XL upregulation in hypoxia. Similarly, PHD3 
knock out animals have fewer neutrophils at the site of inflammation after induction 
of a sterile lung inflammation with LPS, and neutrophils isolated from the airways 
were more apoptotic in hypoxia but not normoxia. In a model of hind-limb 
ischaemia, PHD3-/- animals have fewer Ly6G/CD11b-positive cells at the site of 
injury 3 days after surgery, indicating a dampened inflammatory response or more 
efficient clearance of neutrophils from the site of inflammation potentially through 
enhanced apoptosis (Beneke et al., 2017). Whether or not enhanced apoptosis 
influences resolution of inflammation in a model of infection is unclear. 
4.1.7. Neutrophil killing of Staphylococcus aureus  
Staphylococcus aureus is a Gram-positive, commonly commensal pathogenic 
bacteria which can cause a range of pathologies including skin infections, 
septicaemia, endocarditis and necrotising pneumonia (Klevens et al., 2007). 
Neutrophils are known to be essential for the control of S. aureus infection. Patients 
with conditions typified by compromised neutrophil numbers or function, such as 
severe congenital neutropenia, leukocyte adhesion deficiency, Chediak-Higashi 
syndrome and neutrophil-specific granule deficiency, present with frequent 
incidences of S. aureus infection (Lekstrom-Himes and Gallin, 2000). Moreover, in a 
model of S. aureus infection, repletion of neutrophils significantly compromises 
mouse survival (Gresham et al., 2000). Neutrophils clear S. aureus through 
phagocytosis and then digestion with toxic granule contents including ROS and 
antimicrobial peptides. The induction of neutrophil respiratory burst is known to be 
essential for S. aureus killing as patients with chronic granulatomous disease, a 
disease characterised by a defect in NADPH oxidase and associated defects in ROS 
production, suffer recurrent bacterial infections including infections of S. aureus 
(Lekstrom-Himes and Gallin, 2000).  
S. aureus have a number of mechanisms to evade killing, including inhibiting 
neutrophil recruitment, phagocytosis, and inducing neutrophil lysis following 




to exist in neutrophils, which can then act as a pool of infection and passage of 
bacteria into tissues. As such, neutrophil infiltration into the site of infection, 
although essential for control of S. aureus infection, can also negatively affect the 
resolution of infection. Limiting neutrophil migration into the site of infection 
through knockout of integrin-associated protein (CD47) expression can actually 
improve survival in response to an interperitoneal S. aureus infection (Gresham et 
al., 2000). This is in contrast with other pathogens where CD47 deficiency can result 
in increased bacterial burden and mortality (Lindberg et al., 1996). 
4.1.8. Neutrophil killing of Streptococcus pneumoniae  
Streptococcus pneumoniae is a pathogenic Gram-positive bacteria, the main cause of 
both pneumonia and meningitis in children and the elderly. S. pneumoniae is capable 
of inducing bacteraemia and sepsis (Christensen et al., 2012). Killing of S. 
pneumoniae differs slightly from that of S. aureus in that it is thought to be mediated 
through the activity of serine proteases as opposed to reactive oxygen species. 
Inhibition of NADPH oxidase activity does not modulate the efficiency of S. 
pneumonia killing by isolated neutrophils (Standish and Weiser, 2009). Moreover, 
mice with deficiency in the gp91phox subunit of NADPH oxidase have been found to 
fare better in a model of fulminant pneumonia, with enhanced bacterial clearance 
and survival compared to wildtype controls (Marriott et al., 2008). 
4.1.9. Hypoxia and bacterial killing 
Wound healing and bacterial clearance from the skin is impaired in hypoxia, and 
supplemental inspired oxygen has long been known to improve wound healing and 
control infection (Knighton, Halliday and Hunt, 1984). Studies by McGovern et al 
indicate that loss of respiratory burst function in hypoxia due to the absence of 
molecular oxygen reduces the capacity of neutrophils to kill S. aureus in vitro 
(McGovern et al., 2011). Likewise, inhibition of neutrophils with the NADPH-
oxidase inhibitor DPI significantly inhibitors killing of S. aureus (Standish and 
Weiser, 2009). Subsequent studies from our group show mice with either localised S. 
aureus or systemic S. pneumonia infection have enhanced sickness in hypoxia, 
which can be rescued by inhibition of HIF-1α (Thompson et al., 2017), implicating 




S. pneumoniae. That killing of both S. aureus and S. pneumoniae are compromised 
by hypoxia implicates a mechanism independent of reactive oxygen species 
production, although this has yet to be investigated. Modulation of other components 
of the hypoxic response pathway have been shown to alter the response of 
neutrophils to inflammation, but not to bacterial infection specifically; inhibition of 
either PHD3 and HIF-2α can inhibit neutrophilic inflammation (Walmsley et al., 
2011)(Thompson et al., 2014), but whether manipulation of these components is 
advantageous in infective inflammation models is unclear. There has been little work 
investigating how PHD3 can modulate neutrophil bacterial killing and function. 
4.1.10. Aims of this chapter 
Work so far has identified PHD3 as an essential modulator of immune function in 
inflammatory disease and hypoxia-driven inflammation such as ischaemia 
reperfusion injury and acute injury. Other components of the hypoxic response 
pathway have been investigated and HIF-1α has been shown to exacerbate infection 
in the context of hypoxia. 
My hypothesis is that: 
PHD3 expression is associated with prolonged neutrophil inflammation in the 
context of infection and that inhibiting PHD3 expression can improve bacterial 
clearance and resolution of infection. 
In this chapter I aim to: 
1. Examine the effects of knocking out myeloid PHD3 expression in a model of 
localized skin infection to assess whether loss of PHD3 is beneficial in a 
model of infective inflammation to complement previous studies from the 
group in sterile inflammation models. 
2. Investigate whether PHD3 influences the capacity of neutrophils to 
phagocytose and clear bacteria in vitro. 
3. Interrogate the mechanism of enhanced inflammation resolution in PHD3-
deficient animals. 
4. Measure metabolic flux in PHD3-deficient neutrophils in the context of 





4.2.1. PHD3 is upregulated in hypoxia and loss of PHD3 has no 
systemic health effects in normoxic or hypoxic animals 
Knockdown of PHD3 was confirmed through qPCR of neutrophils isolated from 
mouse BAL. BAL cells were cultured in both normoxia and hypoxia and PHD3 
expression analysed via qPCR. Neutrophils isolated from PHD3fl/fl  LysMCre+/- mice 
have significantly lower expression of PHD3 transcript in both normoxia (Mean 
(±SEM), WT = 0.0754 (0.0200), KO = 0.00283 (0.000535), n = 4, p**<0.01)(Figure 
4.2.1-1, A) and hypoxia (Mean (±SEM), WT = 2.45 (0.478), KO = 0.0378 
(0.00960), n = 4, p***<0.001)(Figure 4.2.1-1, B). Low-level PHD3 expression in 
neutrophils isolated from PHD3fl/fl  LysMCre+/- may be due to a small number of 
contaminating lung epithelial cells in the BAL.  
 Rested mice with myeloid-specific PHD3 deletion have no negative health 
consequences and equivalent weights (mean (±SEM), WT = 24.7 (0.651), KO = 24.0 



































































Figure 4.2.1-1. Successful knockout of PHD3 expression in murine BAL 
neutrophils. PHD3fl/fl  LysMCre+/- and littermate LysMCre-/- mice were nebulised 
with 1mg/ml LPS, housed for 24 hours and then neutrophils isolated via 
bronchoalveolar lavage. Isolated neutrophils were cultured in normoxia (21% 
O2)(A) or hypoxia (1% O2)(B) for 4 hours, RNA extracted and PHD3 transcript 
levels measured via quantitative PCR and normalised to β-actin transcript levels. 
Data expressed as mean±SEM and analysed with unpaired two-tailed Student’s T 
tests, p**<0.01, p***<0.001. WT = wildtype (PHD3fl/fl  LysMCre-/-) . KO =  








Figure 4.2.1-2. Unchallenged mice with myeloid-specific PHD3 knockout are 
phenotypically normal and display no signs of sickness. PHD3fl/fl  LysMCre+/- and 
littermate PHD3fl/fl  LysMCre-/- mice were weighed (A) and rectal temperatures taken 
(B) at baseline. Data expressed as mean±SEM and analysed with unpaired two-tailed 
Student’s T tests, ns. WT = wildtype (PHD3fl/fl  LysMCre-/-), KO = knockout 































4.2.2. Loss of PHD3 is beneficial for the resolution of a S. aureus 
skin abscess 
To examine how PHD3 deletion influences the response of neutrophils to an 
infection, mice were injected with 50μl of 1x109 CFU/ml SH1000 S. aureus into the 
right flank and rectal temperature, weight, abscess size and sickness scores taken 
every day to monitor the health of the animals and progression of infection. 
Mice show no signs of gross sickness at any point during the experiment (mean 
(±SEM), WT = 0 (0), KO = 0 (0), n = 6)(Figure 4.2.2-1, B, C). Even mice with large 
abscesses extending to an area greater than 1cm2 exhibit no systemic symptoms of 
infection (Figure 4.2.2-1, A). Knockout and wild-type mice have equivalent rectal 
temperatures over the course of the 7 days of infection (mean (±SEM), WT day 0 = 
38.2 (0.186), KO day 0 = 38.2 (0.317), WT day 1 = 38.0 (0.257), KO day 1 = 37.8 
(0.105), WT day 7 = 37.9 (0.251), KO day 7 = 37.9 (0.304), n = 6)(Figure 4.2.2-2, 
A). Some mice experience a change in temperature the day following initial 
infection; however, the degree of this change is equivalent between WT and KO 
mice (mean (±SEM), WT = -0.207 (0.235), KO = 0.0786 (0.208), n= 14, ns)(Figure 
4.2.2-2, B). Mice experience some weight loss in the first day of infection (mean 
(±SEM), WT day 0 = 23.85 (1.11), KO day 0 = 22.4 (1.07), WT day 1 = 22.4 (1.35), 
KO day 1 = 21.2 (1.05) grams, n = 6)(Figure 4.2.2-2, C), which then recovers 
completely by day 3 (mean (±SEM), WT day 3 = 23.0 (1.09), KO day 3 = 22.4 
(0.908) grams, n = 6)(Figure 4.2.2-2, C). There is no difference in weight loss 
between WT and KO mice in the first 24 hours of infection (mean (±SEM), WT = -
5.51 (0.687), KO = -4.32 (0.554) grams, n = 14)(Figure 4.2.2-2, D), indicating loss 
of PHD3 in the neutrophils has no significant impact on the systemic health of the 
mice in this model. 
The progression of the localised bacterial infection is profoundly affected by the loss 
of PHD3. Mice with a myeloid-specific PHD3 deletion have macroscopically 
smaller abscesses over the course of the infection (Figure 4.2.2-3, A).  Abscesses 
were significantly smaller at days 1 and 2 after inoculation (mean (±SEM), WT day 
1 = 33.2 (9.75), KO day 1 = 8.67 (2.82), WT day 2 = 74.5 (11.3), KO day 2 = 42.7 




significantly smaller at later timepoints because of the large standard deviation in 
abscess sizes of wildtype mice at this point in the experiment. However, the 
progression of infection was significant different between Cre- and Cre+ mice by 
ANCOVA analysis. 
Abscesses culled at 2, 4 and 7 days were homogenised and bacterial burden 
calculated as the number of viable CFUs per abscess. At 2 days after infection, when 
abscess size was significantly different, knockout mice have significantly less viable 
bacteria in the abscess compared to wildtype mice (mean (±SEM), WT day 2 = 4.49 
x106 (2.47x105), KO day 2 = 1.98x106 (4.98 x105) CFU, n = 4, p*<0.05)(Figure 
4.2.2-4, A). At later time-points, bacterial counts are not significantly lower in KO 
mice (mean (±SEM), WT day 4 = 1.35x107 (6.95x106), KO day 4 = 4.83x106 
(2.59x106), WT day 7 = 2.21x107 (1.10x107), KO day 7 = 1.15x107 (5.97x106) CFU, 
n = 4, p*<0.05)(Figure 4.2.2-4, A). This is because of a high variation in abscess 
CFUs in the wildtype mice. Some abscesses have begun to resolve at this point in the 
infection, whereas others are continuing to grow, leading to a wide degree of 
variation within the experiment group.  
The size of the abscesses is proportional to the concentration of bacteria in the tissue, 
indicating size of the abscess relates directly to the efficiency of bacterial control in 
the tissue (Slope mean (±SEM), WT = 4.61x106 (1.07x106), KO = 9.17x106 (1.71 
x106) (Figure 4.2.2-4, B). Larger abscesses in wildtype animals therefore reflect less 
efficient bacterial killing and clearance. 
Abscesses were lysed and MPO activity measured. At 2, 4 and 7 days, MPO activity 
of the tissue is equivalent between wildtype and knockout mice (mean (±SEM), Day 
2 Cre- = 0.241 (0.0941), Day 2 Cre+ = 0.395 (0.0471), Day 4 Cre- = 0.569 (0.183), 
Day 4 Cre+ = 0.474 (0.127), Day 7 Cre- = 0.206 (0.165), Day 7 Cre+ = 0.257 
(0.252), n = 4)(Figure 4.2.2-5, A).  
Abscess tissue from wildtype animals is heavily fibrotic, with a greater degree of 
destruction of the ultrastructure of the tissue than in knockout mice (Figure 4.2.2-6, 
A-B). Myeloperoxidase staining shows neutrophil infiltration into the adipose layer 




by neutrophils in the subcutaneous tissue, but little neutrophil activity in the skin 







Figure 4.2.2-1: Mice with myeloid specific knockout of PHD3 show no 
macroscopic signs of sickness following subcutaneous infection with 
Staphylococcus aureus. PHD3fl/fl  LysMCre+/- and littermate PHD3fl/fl  LysMCre-/-  
mice were inoculated with 5x107 S. aureus in 50μl of PBS subcutaneously into the 
right flank and sickness assessed through mouse appearance and behaviour (A, B, 
C). Data expressed as mean±SEM and analysed with linear regression analysis 
followed by ANCOVA, n = 12, ns. WT = wildtype (PHD3fl/fl  LysMCre-/-), KO = 
knockout (PHD3fl/fl  LysMCre+/-). 
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Figure 4.2.2-2: Mice with myeloid specific knockout of PHD3 have equivalent 
weight loss and temperature change to wildtype mice following subcutaneous 
infection with Staphylococcus aureus. Mice were inoculated with 5x107 S. aureus 
in 50μl PBS subcutaneously into the right flank and rectal temperature (A, B) taken 
and weight recorded (C,D) every day. Data expressed as mean±SEM and analysed 
with ANCOVA (A, C) or unpaired two-tailed Student’s T tests (B, D), n = 14, ns. 












































































Figure 4.2.2-3: Myeloid specific knockout of PHD3 reduces localized skin 
inflammation in response to Staphylococcus aureus infection. Mice were 
inoculated with 5x107 S. aureus in 50µl PBS subcutaneously into the right flank and 
abscesses developed over the course of 7 days, with noticeable abscesses by day 2 
(A, B). Abscess size was measured on a daily basis from photographs of the abscess 
(B). Data expressed as mean±SEM and slopes of WT and KO compared via 
ANCOVA, n = 12, p*<0.05. WT = wildtype (PHD3fl/fl  LysMCre-/-), KO = knockout 



































Figure 4.2.2-4: Myeloid specific knockout of PHD3 enhances bacterial control 
in a model of Staphylococcus aureus skin infection. Mice were inoculated with 
5x107 S. aureus in 50µl PBS subcutaneously into the right flank and abscesses 
developed over the course of 7 days. Mice were culled at day 2, 4 and 7 and 
abscesses homogenised and viable bacteria counted. Data expressed as mean±SEM 
and analysed with paired two-tailed Student’s T tests, p*<0.05, n = 4 (A), or 
Pearson’s rank coefficient and ANCOVA (B), n = 12. CFU/g and abscess area are 
significantly correlated, but WT and KO are not significant as determined by 






























WT r = 0.609, p<0.001






Figure 4.2.2-5: Myeloid specific knockout of PHD3 has no effect on MPO 
concentration at the site of infection. Mice were inoculated with 5x107 S. aureus in 
50μl PBS subcutaneously into the right flank and abscesses developed over the 
course of 7 days. Mice were culled at day 2, 4 and 7 and abscesses homogenised and 
MPO activity measured via fluorimetric assay. Data expressed as mean±SEM and 
analysed with paired two-tailed Student’s T tests, n = 4. WT = wildtype (PHD3fl/fl  
LysMCre-/-), KO = knockout (PHD3fl/fl  LysMCre+/-). 

































Figure 4.2.2-6: Tissue damage associated with a Staphyloccocus aureus abscess 
is diminished in mice with myeloid-specific PHD3 knockout. Mice were 
inoculated with 5x107 S. aureus in 50μl PBS subcutaneously into the right flank and 
abscesses developed over the course of 7 days. Mice were culled at day 7 and 
abscesses preserved in 4% formaldehyde before processing and staining with anti-







4.2.3. Loss of PHD3 enhances resolution of infection in a model of 
Streptococcal pneumonia  
To ascertain whether myeloid-specific knockout of PHD3 can adequately protect 
against bacterial infection in a more serious, fulminant model of infection, mice were 
inoculated with 50µl of 1x107 CFUml-1 mD39 S. pneumonia intratracheally and 
culled after 14 hours..  
Knockout mice have significantly lower bacterial burden in the airways at 24 hours 
post inoculation compared to wildtype mice (mean (±SEM), WT = 2.23x105 
(1.18x105), KO = 4.23x103 (2.38x103) CFU, n = 10, p*<0.05)(Figure 4.2.3-1, A). 
Mice with fulminant pneumonia have bacteria present in their blood. Knockout mice 
appear to have slightly reduced bacterial burden in the blood (mean (±SEM), WT = 
1.66x107 (1.07x107), KO = 2.41x105 (1.68x105) CFU, n = 10, p=0.095)(Figure 4.2.3-
1, B). Total numbers of infiltrating inflammatory cells in the airways are equivalent 
between wildtype and knockout mice (mean (±SEM), WT = 9.89x106 (1.18x106), 
KO = 10.5x106 (1.21x106), n = 10, ns)(Figure 4.2.3-1, C), as are neutrophil numbers 
(mean (±SEM), WT = 8.08x106 (9.22x105), KO = 8.80x106 (8.59x105), n = 10, 
ns(Figure 4.2.3-1, D). Airway IgM levels were also equivalent, indicating 
comparable vascular leak between genotypes (mean (±SEM), WT = 222 (28.2), KO 
= 204 (28.9) ng/ml, n = 10, ns)(Figure 4.2.3-1, E). 
ELISA of BAL inflammatory cytokines shows no evidence that knockdown of 
PHD3 modulates the expression of inflammatory cytokines or chemokines. All 
neutrophil-derived chemokines measured were equivalent between wildtype and 
knockout mice, including the neutrophil chemoattractants CXCL1/KC (mean 
(±SEM), WT = 22.2 (7.11), KO = 18.6 (5.04) pg/ml, n = 10, ns)(Figure 4.2.3-2, A) 
and CCL4/MIP-1β (mean (±SEM), WT = 165 (32.1), KO = 122 (20.1), n = 10, 
ns)(Figure 4.2.3-2, A). Expression of neutrophil pro-inflammatory cytokines is 
unchanged by loss of PHD3, including IL-1α (mean (±SEM), WT = 12.7 (1.40), KO 
= 10.9 (1.15) pg/ml, n = 10, ns)(Figure 4.2.3-2, B), IL-1β (mean (±SEM), WT = 13.8 
(1.69), KO = 12.5 (0.935) pg/ml, n = 10, ns)(Figure 4.2.3-2, B), IL-6 (mean (±SEM), 
WT = 277 (45.7), KO = 210 (42.3) pg/ml, n =10, ns), IL-12 (mean (±SEM), WT = 




167 (27.3), KO = 133 (21.5) pg/ml, n = 10, ns). Levels of the anti-inflammatory 
cytokine IL-10 were also unchanged (mean (±SEM), WT = 5.11 (1.03), KO = 5.70 















































































Figure 4.2.3-1: Mice with myeloid specific knockout of PHD3 are more 
efficient at bacterial clearance than wildtype controls in a model of fulminant 
Streptococcus pneumoniae lung infection. Mice were inoculated with 1x107 S. 
aureus in 50μl PBS intratracheally and culled after 14 hours. Bacteria were grown 
from BAL (A) and blood (B) samples, and BAL cell counts (C), neutrophil 
differentials (D) and IgM concentration (E) calculated. Data expressed as 
mean±SEM and analysed with unpaired two-tailed Student’s T tests, n = 11. WT = 
wildtype (PHD3fl/fl  LysMCre-/-), KO = knockout (PHD3fl/fl  LysMCre+/-). 
Experiments performed by Professor Sarah Walmsley.  
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Figure 4.2.3-2: BAL cytokine and chemokine levels are equivalent in wildtype 
and knockout mice exposed to a fulminant Streptococcus pneumoniae lung 
infection. Mice were inoculated with 1x107 S. aureus in 50μl PBS intertracheally 
and culled after 14 hours. BAL chemokines KC and MIP-1β	(A) and cytokines IL-
1α, IL-1β, IL-6, IL-12, TNF-α and IL-10 (B) concentrations were determined by 
ELISA. Data expressed as mean±SEM and analysed with paired two-tailed Student’s 
T tests, n = 11. WT = wildtype (PHD3fl/fl  LysMCre-/-), KO = knockout (PHD3fl/fl  

























































4.2.4. Loss of PHD3 does not influence systemic effects of infection 
in mice experiencing acute systemic hypoxia 
To ascertain whether PHD3 influences response to infection in the context of 
systemic hypoxia, mice were inoculated with S. aureus subcutaneously into the right 
flank and then housed in either room oxygen (21% O2) or hypoxia (10% O2). 
Previous studies by A.A.R. Thompson have shown that mice inoculated with S. 
aureus and house in hypoxia become extremely ill by 24 hours after inoculation. We 
chose 14 hours as a timepoint for this reason. 
Mice inoculated with S. aureus become ill after being housed in hypoxia for 14 
hours. Mice housed in hypoxia have significantly higher sickness scores (mean 
(±SEM), WT N = 0 (0), WT H = 1.13 (0.350), KO N = 0 (0), KO H = 1.25 (0.164), n 
= 8, p**<0.01, p****<0.0001)(Figure 4.2.3-1, A)(mean (±SEM), WT N = 0 (0), WT 
H = 3.25 (1.01), KO N = 0 (0), KO H = 2.75 (0.773), n = 8, p**<0.01)(Figure4.2.3-
1, B) and a significant degree of hypothermia (mean (±SEM), WT N = -0.225 
(0.149), WT H = -2.53 (0.390), KO N = -0.45 (0.290), KO H = -3.08 (0.275)°C, n = 
4, p**<0.01, p***<0.001)(Figure 4.2.3-1, C) and weight loss (mean (SEM), WT N = 
-0.475 (0.125), WT H = -1.85 (0.477), KO N = -0.8 (0.324), KO H = -2.08 (0.320) 
grams, n=4, p*<0.05)(Figure 4.2.3-1, D). There was no difference between wildtype 
and knockout animals in either normoxia or hypoxia in terms of systemic illness in 
the animals, indicating loss of PHD3, even in hypoxia in the context of infection, 
does not negatively influence the health of the mice. 
  












































































Figure 4.2.4-1: Myeloid specific knockout of PHD3 does not influence systemic 
effects of Staphylococcus aureus infection in mice experiencing systemic 
hypoxia. Mice infected with SH1000 S. aureus subcutaneously were assessed for 
signs of systemic illness via sickness scores (A, B), and change in rectal 
temperature (C) and weight (D) 14 hours following infection. Data expressed as 
mean±SEM and analysed with paired two-tailed Student’s T tests, p*<0.05, 
p**<0.01, p***<0.001, n = 4. WT = wildtype (PHD3fl/fl  LysMCre-/-), KO = 







4.2.5. Myeloid-specific loss of PHD3 enhances resolution of sterile 
inflammation 
Mice with whole-animal PHD3 knockout have been shown to possess a dampened 
immune response. To ascertain whether resolution of neutrophil inflammation is due 
to a loss of PHD3 in the myeloid cells specifically, we investigated this model of 
inflammation in the PHD3fl/fl LysMCre+/- animals. A model of sterile lung 
inflammation was induced through nebulisation of the mice with LPS and mice were 
housed for 24 hours in normoxia, and inflammatory neutrophils isolated via 
bronchoalveolar lavage. 
Mice with myeloid-specific PHD3 knockout have significantly less inflammatory 
cells in the airways following nebulised LPS challenge (mean (±SEM), WT = 
7.71x106 (9.65x105), KO = 4.99x106 (4.79x105), n = 8, p*<0.05)(Figure 4.2.4-1, A) 
and significantly less infiltrating neutrophils in the airway (mean (±SEM), WT = 
7.28x106 (9.31x105), KO = 4.60x106 (4.49x105), n = 8, p**<0.01)(Figure 4.2.4-1, 
B). The abundance of macrophages in the BAL is equivalent between wild-type and 
knockout mice (mean (±SEM), WT = 0.425 (0.0708), KO = 0.391 (0.0544), n = 8, 
p**<0.01)(Figure 4.2.4-1, C). Myeloid-specific PHD3 deletion does appear to 
increase apoptosis in the knockout mice consistent with previous studies, although 
the result is not significant (mean (±SEM), WT = 0.962 (0.222), KO = 1.64 
(0.328)%, n = 12, ns)(Figure 4.2.4-1, D). The levels of apoptosis are extremely low 
in the BAL, likely due to apoptotic neutrophils being cleared by alveolar 
macrophages. 
Loss of PHD3 in myeloid cells reduces the IgM concentration in the airway 24 hours 
after inflammatory insult regardless of oxygen tension, indicating knockout animals 
experience less airway damage in this model, likely due to lower numbers of 
inflammatory cells in the airways (mean (±SEM), WT = 1170 (144), KO = 828 
(149), n=9, p*<0.05)(Figure 4.2.4-3, A). When normalised to neutrophil number, 
IgM levels are equivalent between wildtype and knockout mice (mean (±SEM), WT 
= 153 (27.3), KO = 173 (29.9), n = 6, ns)(Figure 4.2.4-3, B). Loss of PHD3 in 
myeloid cells slightly reduces MPO concentration in the BAL, likely due to reduced 




(2.37), n = 12, ns)(Figure 4.2.4-3, C); however, when normalised to neutrophil 
number, MPO levels are slightly higher in the knockout mice, although this 
difference is not significant (mean (±SEM), WT = 2.00 (0.612(, KO = 2.83 (0.87), n 
= 9, ns)(Figure 4.2.4-3, D). Elastase concentration is also slightly lower in knockout 
mice, again likely due to less neutrophils in the airway (mean (±SEM), WT = 1.18 
(0.359), KO = 0.652 (0.0904), n = 3)(Figure 4.2.4-3, E), with lower neutrophil 
elastase concentrations after normalisation to neutrophil number (mean (±SEM), WT 
= 0.196 (0.0409), KO = 0.137 (0.0395), n = 3)(Figure 4.2.4-3, F). 
 





















Figure 4.2.5-1: Myeloid specific loss of PHD3 enhances resolution of a sterile 
lung inflammation induced by LPS. Mice nebulised with 1mg/ml LPS were housed 
in normoxia (21% O2) and culled after 24 hours and BAL taken. Cell counts were 
determined via haemocytometer (A) and differential counts and apoptosis calculated 
from cytospins (B, C, D). Data expressed as mean±SEM and analysed with unpaired 
two-tailed Student’s T tests, p*<0.05, n = 9. WT = wildtype (PHD3fl/fl  LysMCre-/-), 

































































































































































Figure 4.2.5-2: Mice with myeloid specific knockout of PHD3 have significantly 
less airway damage than wildtype littermate controls but equivalent levels of 
granule proteins. Mice nebulised with 1mg/ml LPS were housed in normoxia  
(N)(21% O2) or hypoxia (H)(10% O2) and culled after 24 hours and BAL taken. IgM 
(A, B), MPO (C, D) and Elastase (E, F) levels were analysed via ELISA. Data 
expressed as mean±SEM and analysed with unpaired two-tailed Student’s T test, 









4.2.6. Neutrophils have equivalent phagocytic capacity of 
Staphylococcus aureus and Streptococcus pneumoniae 
To examine the phenotype of enhanced bacterial control in the model of S. aureus 
skin infection, we examined whether PHD3-deficient neutrophils were more capable 
of phagocytosing bacteria than wildtype controls. To do this, neutrophils isolated 
from LPS-nebulised wildtype and PHD3 knockout mouse BAL were co-incubated 
with FITC-labelled S. aureus bioparticles and CFSE-labelled D39 S. pneumoniae in 
either normoxia (21% O2) or hypoxia (1% O2). 
By 1 hour of culture, neutrophils internalise fewer S. aureus bioparticles in hypoxia, 
but loss of PHD3 does not influence the phagocytic capacity of the neutrophils 
(mean (±SEM), WT N = 49.2 (3.46), KO N = 50.8 (5.81), WT H = 26.6 (0.609), KO 
H = 31.4 (5.95)%, n=3, p**<0.01)(Figure 4.2.5-1, A-B). 
Neutrophils also internalise CFSE-labelled S. pneumoniae more slowly in hypoxia, 
but again loss of PHD3 does not influence phagocytic capacity of the neutrophils 
(mean (±SEM), WT N = 28.5 (3.93), KO N = 29.9 (2.52), WT H = 14.8 (1.81), KO 







Figure 4.2.6-1: PHD3 knockout neutrophils have equivalent capacity for 
phagocytosis of Staphylococcus aureus bioparticles. Neutrophils were cultured for 
1 hour with FITC-labelled S. aureus particles with and without cytochalasin D and 
fluorescence measured via flow cytometry. Phagocytosis (%) = % FITC-positive 
neutrophils - % FITC-positive cytochalasin D-treated neutrophils. Data expressed as 
mean±SEM and analysed with two-way ANOVA with Tukey’s multiple 
comparisons, p**<0.01, n = 3. WT = wildtype (PHD3fl/fl  LysMCre-/-), KO = 






























Figure 4.2.6-2: PHD3 knockout neutrophils have equivalent capacity for 
phagocytosis of heat-killed, CFSE-labelled D39 Streptococcus pneumoniae. 
Neutrophils were cultured for 1 hour with CFSE-labelled heat-killed S. pneumonia 
with and without cytochalasin D and fluorescence measured via flow cytometry.  
Phagocytosis (%) = % CFSE-positive neutrophils – % CFSE-positive cytochalasin 
D-treated neutrophils. Data expressed as mean±SEM and analysed with two-way 
ANOVA with Tukey’s multiple comparisons, p**<0.01, n = 3. WT = wildtype 
(PHD3fl/fl  LysMCre-/-), KO = knockout (PHD3fl/fl  LysMCre+/-). 
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4.2.7. PHD3-deficient neutrophils have equivalent ROS production 
and respiratory burst activity 
To understand why bacterial clearance and killing are enhanced in PHD3-deficient 
mice, we studied the capacity of neutrophils to mount a respiratory burst.  
In parallel with our human studies (see Chapter 3), we measured the capacity of the 
neutrophils to regulate the pentose phosphate pathway. PHD3 deletion has been 
implicated in the upregulation of G6PD in clear cell Renal cell carcinoma cells 
(Miikkulainen et al., 2017). Therefore, we examined expression of pentose 
phosphate pathway enzyme transcripts and looked at metabolic flux through these 
pathways. 
Transcription of G6pdx, the rate-limiting enzyme of the pentose phosphate pathway 
involved in converting the glycolytic intermediate glucose 6-phosphate into ribulose 
5-phosphate, is significantly upregulated in PHD3-deficient neutrophils compared to 
wildtype controls (mean (±SEM), WT = 1.09 (0.0609), KO= 2.55 (0.434), n = 4, 
p*<0.05)(Figure 4.2.7-1, A). Other enzymes studied are not significantly increased, 
although transcription of RpiA and Rpe appear higher (Figure 4.2.7-1, B-D). Despite 
enhanced transcription of G6pdx, flux through the pentose phosphate pathway is not 
significantly altered by the loss of PHD3 (mean (±SEM), WT ribose 5-
phosphate/ribulose 5-phosphate = 3.20x104 (17.2x104), KO ribose 5-
phosphate/ribulose 5-phosphate = 2.45x104 (7.81x103), WT sedoheptulose 7-
phosphate = 1.01x105 (3.75x104), KO sedoheptulose 7-phosphate = 1.51x105 
(6.12x104), erythrose 4-phosphate = 0 (0), erythrose 4-phosphate = 0 (0), n = 
5)(Figure 4.2.7-2, B) with no change in NADP+/NADPH ratio (mean (±SEM), WT = 
1.13 (0.144), KO = 0.915 (0.0849), n = 5)(Figure 4.2.6-2, C) or GSH/GSSG ratio 
(mean (±SEM), WT = 234.9 (45.5), KO = 181 (15.9), n = 5)(Figure 4.2.7-2, D).  
Furthermore, generation of reactive oxygen species is unaffected by loss of PHD3. 
Unstimulated cells baseline ROS production was unchanged by loss of PHD3 in both 
normoxic (21% O2) and hypoxic (1% O2) culture (mean (±SEM), WT N = 3.65x103 
(926), KO N = 4.54x103 (1.92x103), WT H = 4.32x103 (1.19x103), KO H = 
5.57x103), n = 5)(Figure 4.2.6-3, A). There was no difference between cells 




(1.54x103), WT H = 5.31x103 (1.36x103), KO H = 6.71x103 (2.37x103), n = 
5)(Figure 4.2.7-3, B). The capacity for cells to undergo respiratory burst was also 
unchanged by loss of PHD3 (mean (±SEM), WT N = 1.57 (0.0897), KO N = 1.41 
(0.160), WT H = 1.28 (0.0635), KO H = 1.23 (0.0538), n = 5, p*<0.05)(Figure 4.2.7-
3, C). These data show that PHD3 expression does not alter pentose phosphate 
pathway activity or the ability of the cells to undergo a respiratory burst, and this 
does not account for the enhanced efficiency of bacterial clearance in PHD3fl/fl  







Figure 4.2.7-1: PHD3 deficient neutrophils have significantly greater expression 
of pentose phosphate pathway enzyme transcripts in normoxia. Mice nebulised 
with 1mg/ml LPS were housed in normoxia (21% O2) and culled after 24 hours and 
BAL taken. Neutrophils isolated from mouse BAL were lysed and transcript level 
analysed via Taqman (A, B, C, D). Data expressed as mean±SEM and analysed with 
unpaired Student’s two-tailed T test, p*<0.05, n = 4. WT = wildtype (PHD3fl/fl  




























































































































































Figure 4.2.7-2: PHD3 deficient neutrophils do not have significantly increased 
pentose phosphate flux or a more oxidised NADP+/NADPH pool. Mice nebulised 
with 1mg/ml LPS were housed in normoxia  (N)(21% O2) and culled after 24 hours 
and BAL taken. Neutrophils isolated from mouse BAL were further purified by 
percoll density centrifugation and metabolite abundance measured via LC-MS. (A, 
B, C, D). Data expressed as mean±SEM and analysed with 2-way ANOVA (B) or 
paired two-tailed Student’s T tests (C,D), n = 5. WT = wildtype (PHD3fl/fl  LysMCre-





















































































Figure 4.2.7-3: PHD3 deficient neutrophils have equivalent ROS production 
and capacity to undergo respiratory burst compared to wildtype controls.  Mice 
nebulised with 1mg/ml LPS were housed in normoxia and culled after 24 hours and 
BAL taken. BAL neutrophils were cultured in normoxia (21%) or hypoxia (1%) 
either unstimulated (A) or cultured with 100nM fMLP (B) and ROS production 
measured through DCF staining and flow cytometry (A, B, C). Respiratory burst 
capacity was calculated as fold change in DCF fluorescence of fMLP stimulated 
cells from untreated control (C). Data expressed as mean±SEM and analysed with 2-
way ANOVA, p*<0.05, n = 5. WT = wildtype (PHD3fl/fl  LysMCre-/-), KO = 





























4.2.8. Loss of PHD3 does not influence glucose metabolism in 
normoxic conditions 
	
To understand whether loss of PHD3 alone may affect metabolism as hypoxia does 
in human cells, we measured metabolic flux in neutrophils cultured in normoxia. 
Loss of PHD3 does not affect energy production in the cell in normoxia as measured 
by ATP (mean (±SEM), WT = 3.33x105 (1.71x105), KO = 3.35x105 (1.16x105), n = 
5, ns)(Figure 4.2.8-1, A), ADP (mean (±SEM), WT = 1.94x105 (1.15x105), KO = 
1.72x105 (6.03x104), n = 5, ns)(Figure 4.2.8-1, B), AMP (mean (±SEM), WT = 
1.21x105 (4.00x104), KO = 1.26x105 (4.62x104), n = 5, ns)(Figure 4.2.7-1, C) and 
energy status (mean (±SEM), WT = 1.77 (0.0738), KO = 2.00 (0.247), n = 5, 
ns)(Figure 4.2.8-1, D) and energy charge (mean (±SEM), WT = 0.630 (0.0466), KO 
= 0.655 (0.0792), n = 5, ns)(Figure 4.2.8-1, E). 
Neutrophils from mice with myeloid-specific PHD3 deficiency also have equivalent 
levels of glycolytic intermediates compared to wildtype mice in normoxia (mean 
(±SEM), WT G-6P/F-6P = 3.39x105 (1.41x105), KO G-6P/F-6P = 6.00x105 
(2.93x105), WT F-1,6 = 1.79x104 (1.09x104), KO F-1, = 2.87x104 (1.37x104), WT 
GAP = 2.00x104 (8.13x103), KO GAP = 3.22x104 (1.56x104), WT 2,3-PG = 
1.62x104 (1.04x104), KO 2,3-PG = 1.69x104 (6.64x103), WT PEP = 1.47x104 
(6.36x103), KO PEP = 2.05x104 (8.24x103), WT Lactate = 4.99x105 (1.39x105), KO 
Lactate = 6.50x105 (2.141x105), n = 5, ns)(Figure 4.2.8-2), indicating loss of PHD3 
does not significantly influence glycolytic flux or energy production in inflammatory 
neutrophils. 
Neutrophils isolated from mice with myeloid-specific PHD3 deletion have 
equivalent Krebs cycle flux compared to wildtype mice (mean (±SEM), WT citrate = 
4.43x106 (1.47x106), KO citrate = 4.74x106 (1.93x106), WT α-KG = 9.10x104 
(2.48x104), KO α-KG = 9.87x104 (3.22x104), WT succinate = 7.48x104 (2.92x104), 
KO succinate = 9.12x104 (3.25x104), WT malate = 9.68x105 (3.65x105), KO malate 
= 1.31x106 (5.44x105), WT fumarate = 1.84x105 (7.33x104), KO fumarate = 
2.29x105 (9.07x104), n = 5, ns)(Figure 4.2.8-3). Likewise, neutrophils from myeloid-




wildtype mice (mean (±SEM), WT glutamine = 4.29x104 (5.86x103), KO glutamine 
= 1.05x105 (5.49x104), WT glutamic acid = 1.42x106 (3.84x105), KO glutamic acid 
= 1.91x106 (7.50x105), WT serine = 8.46x104 (1.63x104), KO serine = 1.42x105 
(6.13x104), WT aspartic acid= 6.16x105 (1.52x105), KO aspartic acid = 7.52x105 
(3.00x105), WT asparagine = 9.86x104 (2.33x104), KO asparagine = 1.56x105 
(6.74x104), WT glycine = 4.09x104 (1.29x104), KO glycine = 6.29x104 (2.76x104), 
WT alanine = 2.15x105 (6.58x104), KO alanine = 2.77x105 (1.10x105), WT valine = 
2.87x104 (1.18x104), KO valine = 3.07x104 (1.20x104), WT leucine = 1.20x105 
(5.03x104), KO leucine = 1.30x105 (4.92x104), WT arginine = 9.64x104 (4.31x104), 
KO arginine = 1.00x105 (3.97x104), WT proline = 6.12x104 (1.98x104), KO proline 





    
Figure 4.2.8-1: Loss of PHD3 does not affect neutrophil energy metabolism in 
normoxia.  Mice nebulised with 1mg/ml LPS were housed in normoxia  (21% O2) 
and culled after 24 hours and BAL taken. Neutrophils isolated from mouse BAL 
were further purified by percoll density centrifugation and metabolite abundance 
measured via LC-MS. (A, B, C). D: Energy status was calculated as ATP/ADP. E: 
Energy charge was calculated as (ATP+0.5ADP)(AMP+ADP+ATP). Data 
expressed as mean±SEM and analysed with unpaired two-tailed Student’s T tests, 























































































Figure 4.2.8-2: PHD3-deficient neutrophils have equivalent glycolytic flux 
compared to wildtype controls. Mice nebulised with 1mg/ml LPS were housed in 
normoxia and culled after 24 hours and BAL taken. Neutrophils isolated from mouse 
BAL were further purified by percoll density centrifugation and metabolite 
abundance measured via LC-MS. Data expressed as mean±SEM and analysed with 
2-way ANOVA, n = 5, ns. WT = wildtype (PHD3fl/fl  LysMCre-/-), KO = knockout 
(PHD3fl/fl  LysMCre+/-). 
 





























Figure 4.2.8-3: PHD3-deficient neutrophils have equivalent Krebs cycle flux 
compared to wildtype controls. Mice nebulised with 1mg/ml LPS were housed in 
normoxia and culled after 24 hours and BAL taken. Neutrophils isolated from mouse 
BAL were further purified by percoll density centrifugation and metabolite 
abundance measured via LC-MS. Data expressed as mean±SEM and analysed with 2-
way ANOVA, n = 5, ns. WT = wildtype (PHD3fl/fl  LysMCre-/-), KO = knockout 






















































Figure 4.2.8-4: PHD3-deficient neutrophils have equivalent free amino acids 
compared to wildtype controls. Mice nebulised with 1mg/ml LPS were housed in 
normoxia and culled after 24 hours and BAL taken. Neutrophils isolated from 
mouse BAL were further purified by percoll density centrifugation and metabolite 
abundance measured via LC-MS. Data expressed as mean±SEM and analysed with 
2-way ANOVA, n = 5, ns. WT = wildtype (PHD3fl/fl  LysMCre-/-), KO = knockout 















































































4.2.9. Loss of PHD3 in hypoxia significantly reduces glycolytic flux 
Although PHD3 requires oxygen to hydroxylase target proteins, PHD3 transcription 
is profoundly upregulated in hypoxia (mean (±SEM), N = 0.0754 (0.0200), H = 2.45 
(0.478), n = 4, p**<0.01)(Figure 4.2.9-1). Therefore, examining the metabolic 
effects of PHD3 deletion is important in determining how PHD3 regulates metabolic 
regulation in inflammation  
Neutrophils isolated from myeloid-specific PHD3 knockouts have significantly 
lower levels of glycolytic metabolites after culture in hypoxia (mean (±SEM), WT 
G-6P/F-6P = 2.82x105 (7.44x104), KO G-6P/F-6P = 2.36x105 (7.00x104), WT F-1,6 
= 1.87x104 (5.74x103), KO F-1,6 = 7.08x103 (2.44x103), WT GAP = 1.55x104 
(4.57x103), KO GAP = 1.25x104 (3.29x103), WT 2,3-PG = 1.21x104 (3.08x103), KO 
2,3-PG = 4.67x103 (2.25x103), WT PEP = 1.62x104 (3.72x103), KO PEP = 1.12x104 
(3.05x103), WT Lactate = 7.33x105 (1.93x105), KO Lactate = 3.89x105 (7.31x104), n 
= 5, p*<0.05)(Figure 4.2.9-2). This reduced flux in glycolysis is paralleled by a 
reduction in flux through the Krebs cycle. Neutrophils isolated from myeloid-
specific PHD3 knockouts have significantly lower flux through the Krebs cycle 
following hypoxic culture (mean (±SEM), WT citrate = 5.64x106 (1.01x106), KO 
citrate = 2.95x106, (9.97x105), WT α-KG = 8.69x104 (1.87x104), KO α-KG = 
6.65x104 (1.14x104), WT succinate = 6.78x104 (1.47x104), KO succinate = 3.84x104 
(1.38x104), WT malate = 1.25x106 (2.58x105), KO = 7.43x105 (1.77x105), WT 
oxaloacetate = 0 (0), KO oxaloacetate = 0 (0), n = 5, p*<0.05)(Figure 4.2.9-3). 
 Although PHD3-deficient neutrophils have a significant and profound drop 
in glycolytic and Krebs cycle flux, levels of ATP and energy charge are unchanged 
(mean (±SEM), WT = 2.80x105 (5.49x104), KO = 1.69x105 (5.28x104), n = 5, 
ns)(Figure 4.2.9-4, A), ADP (mean (±SEM), WT = 1.88x105 (3.04x104), KO = 
1.02x105 (3.77x104), n = 5, ns)(Figure 4.2.9-4, B), AMP (mean (±SEM), WT = 
1.58x105 (5.94x104), KO = 1.26x105 (6.54x104), n = 5, ns)(Figure 4.2.9-4, C), and 
energy status (mean (±SEM), WT = 1.50 (0.129), KO = 1.70 (0.140), n = 5, 
ns)(Figure 4.2.9-4, D) and energy charge (mean (±SEM), WT = 0.596 (0.0338), KO 




PHD3-deficient neutrophils from mice housed in hypoxia also have significantly less 
free amino acids than wildtype mice (mean (±SEM), WT glutamine = 6.13x104 
(2.38x104), KO glutamine = 2.37x104 (4.28x103), WT glutamic acid = 1.46x106 
(3.81x105), KO glutamic acid = 8.71x105 (1.77x105), WT serine = 1.17x105 
(3.44x104), KO serine = 5.51x104 (1.17x104), WT aspartic acid = 6.18x105 
(1.43x105), KO aspartic acid = 3.86x105 (7.77x104), WT asparagine = 1.24x105 
(3.18x104), KO asparagine = 6.63x104 (1.77x104), WT glycine = 4.68x104 
(1.16x104), KO glycine = 2.21x104 (6.13x103), WT alanine = 2.32x105 (4.16x104), 
KO alanine = 1.39x105 (3.89x104), WT valine = 2.60x104 (5.84x103), KO valine = 
1.54x104 (4.25x103), WT leucine = 1.09x105 (2.67x104), KO leucine = 6.38x104 
(2.00x104), WT arginine = 8.24x104 (1.56x104), KO arginine = 4.51x104 (1.25x104), 
WT proline = 6.50x104 (1.48x104), KO proline = 2.89x104 (7.17x103), n = 5, 
p*0.05)(Figure 4.2.9-5). These data indicate PHD3-deficient neutrophils are 




































Figure 4.2.9-1. Neutrophil PHD3 expression is significantly upregulated in 
hypoxia. Wild-type PHD3fl/fl  LysMCre+/- mice were nebulised with 1mg/ml LPS, 
housed for 24 hours and then neutrophils isolated via bronchoalveolar lavage. 
Isolated neutrophils were cultured in normoxia (N) and hypoxia (H) for 4 hours, 
RNA extracted and PHD3 transcript levels measured via quantitative PCR and 
normalised to β-actin transcript levels. Data expressed as mean±SEM and analysed 






Figure 4.2.9-2: Neutrophils isolated from mice with myeloid-specific PHD3 
knockout cultured in hypoxia have diminished glycolytic flux. Mice nebulised 
with 1mg/ml LPS were housed in hypoxia (10% O2) and culled after 24 hours and 
BAL taken. Neutrophils isolated from mouse BAL were further purified by percoll 
density centrifugation and metabolite abundance measured via LC-MS. Data 
expressed as mean±SEM and analysed with 2-way ANOVA, p*<0.05, n =5 . WT = 
wildtype (PHD3fl/fl  LysMCre-/-), KO = knockout (PHD3fl/fl  LysMCre+/-). 





























Figure 4.2.9-3: Neutrophils isolated from mice with myeloid-specific PHD3 
knockout cultured in hypoxia have diminished krebs cycle activity. Mice 
nebulised with 1mg/ml LPS were housed in hypoxia (10% O2) and culled after 24 
hours and BAL taken. Neutrophils isolated from mouse BAL were further purified 
by percoll density centrifugation and metabolite abundance measured via LC-MS. 
(A, B). Data expressed as mean±SEM and analysed with 2-way ANOVA, p*<0.05, 



































































































































Figure 4.2.9-4: Loss of PHD3 does not influence energy status or availability of 
ATP in neutrophils from hypoxic mice. Mice nebulised with 1mg/ml LPS were 
housed in hypoxia (10% O2) and culled after 24 hours and BAL taken. Neutrophils 
isolated from mouse BAL were further purified by percoll density centrifugation 
and metabolite abundance measured via LC-MS. (A-C).  Energy status and charge 
were calculated from metabolite abundance (D, E). Data expressed as mean±SEM 
and analysed with paired two-tailed Student’s T tests, n=5. WT = wildtype 
(PHD3fl/fl  LysMCre-/-), KO = knockout (PHD3fl/fl  LysMCre+/-). 






Figure 4.2.9-5: Neutrophils isolated from mice with myeloid specific PHD3 
knockout cultured in hypoxia have diminished levels of free amino acids. Mice 
nebulised with 1mg/ml LPS were housed in hypoxia (10% O2) and culled after 24 
hours and BAL taken. Neutrophils isolated from mouse BAL were further purified 
by percoll density centrifugation and metabolite abundance measured via LC-MS. 
Data expressed as mean±SEM and analysed with 2-way ANOVA, p*<0.05, n=5. 










































































4.3.1. Deletion of PHD3 activity in myeloid cells is associated with 
reduced inflammation and enhanced bacterial clearance 
Deletion of PHD3 has been shown to be beneficial for inflammation resolution in 
models of ischaemic injury (Rishi et al., 2015)(Beneke et al., 2017), acute lung 
injury and colitis (Walmsley et al., 2011)., implicating PHD3 as a potential 
therapeutic target for combatting injury caused by chronic or acute inflammatory 
conditions. These studies use models of sterile inflammation induced by hypoxic 
ischaemic injury and immunomodulatory complexes, respectively. The role of PHD3 
in mediating the immune response to invading pathogens, therefore, is unknown. 
Our study is the first to show that PHD3 deletion in myeloid cells is beneficial for 
the resolution of a pathogen-mediated inflammatory response. PHD3fl/fl  LysMCre+/- 
mice are more capable of bacterial control and resolution of infection in models of 
both S. aureus skin infection and a fulminant model of streptococcal pneumonia. In a 
S. aureus infection, knockout mice have significantly less localised inflammation 
and tissue damage over the course of 7 days of infection, as typified by smaller 
lesions (Figure 4.2.2-3, A-B) and less compromised tissue ultrastructure in the skin 
(Figure 4.2.2-6, A-B). Knockout mice have significantly diminished bacterial burden 
as measured 1 or 2 days after the induction of infection compared to wildtype 
littermate controls (Figure 4.2.2-4, A). Smaller abscesses correlate with lower 
bacterial burden in the tissue (Figure 4.2.2-4, B), suggesting smaller abscesses in 
PHD3fl/fl LysMCre+/- animals are therefore due to more effective control of bacterial 
infection. Moreover, from 4 to 7 days following infection, all abscesses from 
PHD3fl/fl LysMCre+/- animals begin to resolve, whereas abscesses in wildtype 
animals either resolve or are still developing by the end of the experiment, indicating 
animals with PHD3 deletion, from controlling the infection early on, are able to 
prevent bacteria proliferating in the skin and resolve the infection more efficiently. 
In a model of S. pneumonia infection, after 14 hours PHD3fl/fl  LysMCre+/- mice have 
lower bacterial burden (Figure 4.2.3-1, A-B). In this model of infection, there is no 
change to total cell counts, neutrophil counts or signs of damage in the lung (Figure 




themselves account for enhanced bacterial clearance, rather than differences in cell 
number or recruitment efficiency, or efficiency of apoptosis as described in other 
studies (Walmsley et al., 2011).  
Myeloid-specific loss of PHD3 has no affect on animal health in a non-inflammatory 
context. As PHD3 is highly induced in inflammation and hypoxia (Walmsley et al., 
2011), it is not surprising that loss of PHD3 itself is not detrimental to the mice. 
Mice with myeloid-specific knockout of PHD3 are phenotypically normal and have 
equivalent weight and temperatures to littermate wild-type PHD3fl/fl LysMCre-/- mice 
(Figure 4.2.1-2, A, B). Interestingly, in the inflammatory context, throughout the 
development of a S. aureus abscess, neither PHD3fl/fl  LysMCre+/- nor wildtype 
littermate control mice experienced any visible signs of sickness (Figure 4.2.2-1, A-
C)(Figure 4.2.2-2, A-D). Even in subtle measurements of systemic illness such as 
rectal temperature change and weight loss, myeloid-specific PHD3 deficiency was 
not shown to exacerbate systemic symptoms of inflammation. To examine whether 
loss of PHD3 influenced the capability of hypoxic animals to respond to infection, 
we repeated the S. aureus skin infection model in mice housed in hypoxia (10% O2). 
Consistent with previous studies in this model, we found hypoxia significantly 
induced sickness in the mice (Thompson et al., 2017)(Figure 4.2.4-1). The degree of 
systemic sickness is equivalent between wildtype and knockout mice, with 
equivalent levels of hypoxia-induced hypothermia (Figure 4.2.4-1, C) and weight 
loss (Figure 4.2.4-1, D) following infection, as well as comparable signs of visible 
sickness (Figure 4.2.4-1, A, B), indicating that even in an inflammatory and hypoxic 
environment where PHD3 expression is the highest, myeloid-specific PHD3 
expression is not essential in protecting the host from systemic symptoms of 
infection, although due to the degree of sickness experienced by the hypoxic mice, 
the experiment could not be extended to later time-points. Previous studies in this 
model by Thompson et al show that suppression of HIF-1α through preconditioning 
mice to hypoxia can prevent illness in hypoxic mice in this S. aureus abscess model 
through suppression of neutrophil glucose metabolism (Thompson et al., 2017). That 
PHD3 deletion does not exacerbate symptoms in hypoxic mice therefore indicates 
that in this model, HIF-1α stability in neutrophils may not be controlled by PHD3 




inflammation, whereas our model shows a profound pro-resolving effect of PHD3 
inhibition (Elks et al., 2011). PHD3 overexpression in adipose tissue is capable of 
suppressing HIF-1α activity (Kim et al., 2014), although regulation of HIF-1α by 
PHD3 may be cell-type specific and dependent on the oxygen tension of the tissue 
and inflammatory context. Moreover, in hypoxia we see a reduction in glycolytic 
flux that is at odds with a HIF-1α activation phenotype. This could suggest that the 
benefit in our model occurs through a HIF-1α-independent mechanism, although 
further work is needed to confirm this.  
4.3.2. Enhanced control of bacteria is not due to enhanced 
phagocytosis, respiratory burst or capacity for degranulation 
To try and understand how knockout mice manage bacterial infection more 
efficiently, we looked at the capacity for these neutrophils to internalise bacteria 
through phagocytosis. PHD3-deficient neutrophils isolated from mouse BAL were 
not more efficient at phagocytosing S. aureus bioparticles (Figure 4.2.6-1, A, B), or 
S. pneumonia bacteria (Figure 4.2.6-2, A, B) in either normoxia or hypoxia. 
Interestingly, hypoxic cells are less effective at taking up both S. aureus and S. 
pneumonia (Figure 4.2.6-1, A, B)(Figure 4.2.6-2, A, B).  In contrast, previous work 
has indicated that hypoxia does not influence the capacity for unstimulated human 
neutrophils to phagocytose S. pneumonia (McGovern et al., 2011). Our experimental 
conditions differ as the neutrophils are derived from an inflammatory environment 
and exposed to hypoxia in vivo. The cells are isolated following 24 hours of 
inflammation; therefore, it is possible this level of acute hypoxia compromises the 
ability of the neutrophils to phagocytose bacteria. These airway neutrophils will also 
have translocated to the airway that will affect exposure to cytokines, expression of 
surface markers etc.  
As wildtype and knockout neutrophils have equivalent phagocytic capacity (Figure 
4.2.6-1, A, B)(Figure 4.2.6-2, A, B), we looked at whether at the capacity for 
neutrophils to undergo respiratory burst activity was altered by PHD3 knockout and 
whether this accounted for enhanced resolution of infection in knockout animals. 
Studies in clear cell renal cell carcinoma cells (ccRRCs), cells with an extensive 




a regulator of glucose metabolism, with loss of PHD3 suppressing the transcription 
of a number of carbohydrate metabolism genes in hypoxia including GLUT1, PFKP 
and LDHA, but enhancing the expression of G6PD, the rate limiting enzyme of the 
pentose phosphate pathway (Miikkulainen et al., 2017). Moreover, killing of S. 
aureus is known to be mediated by the production of reactive oxygen species 
following activation of NADPH oxidase (Lekstrom-Himes and Gallin, 2000). From 
our data, it is clear that loss of PHD3 does not change the capacity for neutrophils to 
undergo a respiratory burst in normoxia or hypoxia. Baseline oxidant production was 
unchanged by loss of PHD3 (Figure 4.2.7-3, A). Neutrophils stimulated with fMLP 
upregulate ROS production, and the maximum threshold of ROS production in 
fMLP-treated cells was equivalent between wildtype and knockout mice (Figure 
4.2.7-3, B). Moreover, this capacity to undergo respiratory burst is unchanged 
between wildtype and knockout mice as measured by fold change in DCF 
fluorescence between unstimulated and stimulated cells (Figure 4.2.7-3, C). We 
examined the capacity for neutrophils to regulate the OxPPP pathway as we did with 
human peripheral neutrophils in the previous chapter. Mass spectrometry analysis 
also showed no change in OxPPP flux (Figure 4.2.7-2, A, B) or NADP+/NADPH 
ratio (Figure 4.2.7-2, C). There is no difference in GSH/GSSG ratio (Figure 4.2.7-3, 
D) and no change in ATP, ADP or AMP abundance or energy status (ATP/ADP) or 
energy charge (ATP/ADP/AMP)(Figure 4.2.8-1, C). Interestingly, despite no clear 
signs that the cells are regulating their ROS production, transcription of G6pdx, the 
rate-limiting enzyme for the pentose phosphate pathway, is significantly upregulated 
in neutrophils lacking PHD3 (Figure 4.2.7-1, A, B) consistent with studies in ccRCC 
cells, indicating in these cells that PHD3 may regulate G6pdx expression, but in cells 
from the inflammatory environment these processes are not regulated in a 
biologically relevant way that contributes to bacterial killing. That PHD3 knockout 
is also advantageous for killing of S. pneumoniae, which is known to be dependent 
on serine proteases rather than NADPH oxidase activity, it is clear regulation of 
oxidants by PHD3 does not account for the phenotype of enhanced bacterial 
clearance in these models (Standish and Weiser, 2009).  
As it does not seem that oxidant production is being regulated by PHD3 knockout, 




capacity for PHD3 knockout neutrophils to produce neutrophil elastase and MPO in 
an inflammatory environment. Other components of the hypoxic response pathway 
are closely linked to granule protease production; HIF-1α expression correlates with 
neutrophil elastase activity in murine neutrophils (Peyssonnaux et al., 2005). 
Hypoxia can also regulate the expression of Cathepsin G in macrophages (Fang et 
al., 2009). In inflammatory BAL, elastase and MPO levels are slightly lower in 
PHD3 knockout animals, although this is likely due to a lower number of bacteria in 
the airways (Figure 4.2.5, B, D). When normalized to neutrophil number, MPO 
levels do appear slightly elevated (Figure 4.2.5, C). In a S. aureus infection, MPO 
levels in the abscess at 2 days after infection also appear higher in the knockout 
mice, although this is not significant (Figure 4.2.2-5, A). Measurement of MPO 
levels earlier in the course of infection may shed more light on the early regulation 
of degranulation in this model. Therefore, we cannot discount regulation of 
degranulation or granule protein production in mediating the enhanced bacterial 
clearance we see in PHD3fl/fl LysMCre+/- animals. 
4.3.3. PHD3 differentially modulates neutrophil metabolism in 
normoxic and hypoxic conditions 
PHD3 knockdown is known to regulate glucose metabolism in cancer cells 
(Miikkulainen et al., 2017). Therefore, we investigated whether neutrophil 
metabolism was regulated by loss of PHD3. Carbohydrate metabolism is closely 
linked to neutrophil function and lifespan; high energy products such as ATP 
(Vaughan et al., 2007) and Krebs cycle metabolites (Jones et al., 2016) play key 
roles in modulating apoptosis. Of BAL neutrophils isolated from mice housed in 
normoxia, PHD3fl/fl  LysMCre+/- neutrophils show no significant difference in energy 
and ATP availability (Figure 4.2.8-1, A) or levels of glycolytic metabolites (Figure 
4.2.8-2, A), Krebs cycle metabolites (Figure 4.2.8-3, A) and free amino acids (Figure 
4.2.8-4, A) compared to wildtype littermate controls. Although not significant, levels 
of all amino acids and glycolytic and Krebs cycle metabolites measured do appear 
subtly elevated in knockout neutrophils. It is possible this is because PHD3 is 
expressed in extremely low levels in normoxic cells. By contrast, in hypoxia, where 
PHD3 is usually highly expressed and hydroxylation activity is inhibited, PHD3fl/fl  




metabolites (Figure 4.2.9-2, A), Krebs cycle metabolites (Figure 4.2.9-3, A) and free 
amino acids (Figure 4.2.9-5, A). ATP levels in knockout neutrophils also appear 
diminished, but not significantly (Figure 4.2.9-4, A). It is possible that in normoxic 
conditions, PHD3 expression is low but activity is high, and PHD3 may hydroxylate 
HIF-1α and HIF-2α, targeting them for degradation and suppressing glycolytic flux. 
Conversely, in hypoxia, PHD3 is highly upregulated in hypoxia (Figure 4.2.9-1), and 
upregulates glycolysis through non-hydroxylase enzymatic activity. This would 
account for why knockout of PHD3 slightly enhances glycolytic flux in normoxia, 
and strongly suppresses glycolytic flux in hypoxia (Figure 4.2.8-1, Figure 4.2.9-1). 
This phenotype is supported by studies in cancer cells which show in hypoxia, loss 
of PHD3 downregulates the transcription of a number of glycolytic genes and the 
glucose transporter GLUT1 (Chen et al., 2011)(Miikkulainen et al., 2017). 
Interestingly, knockout of PHD3 has been shown to have no effect on lactate or ATP 
levels in BMDMs (Guentsch et al., 2017). 
The consequences of this metabolic modulation is unclear. Diminished glycolytic 
flux has been associated with advanced apoptosis (Pradelli et al., 2014), which is 
mirrored in apoptosis data from knockout BAL neutrophils (Figure 4.2.5-1, D), and 
correlates with enhanced apoptosis in PHD3-deficient neutrophils in previous studies 
(Walmsley et al., 2011). It is possible this reduction in glycolytic metabolite 
abundance precedes apoptosis, or that cells isolated from knockout BAL do not show 
more outward signs of apoptosis in their morphology, but are more advanced in the 
process of apoptosis than wildtype cells. Metabolic effects of PHD3 knockdown and 
inhibition are likely to be context and cell-specific due to the degree of interaction of 
PHD3 with HIF-1α and HIF-2α, balanced against non-hydroxylase activities of 
PHD3 on metabolic enzymes such as pyruvate kinase (Chen et al., 2011).  
4.3.4. Future of PHD3 inhibition 
A major limitation of studying PHD3 is the absence of specific inhibitors for PHD3 
activity. There are a number of available pan-hydroxylase inhibitors (Kim and Yang, 
2015). The most often used is DMOG, an analogue of α-KG (Cunliffe et al., 1992) . 
The overriding phenotype of pan-hydroxylase inhibition is of PHD2 inhibition and 




hydroxylases such as JHDM histone demethylases JMJD2A, 2C and 2D(Hamada et 
al., 2009). Since then, a number of new compounds have been synthesised which 
have variable specificity for 2OG-dependent oxygenases, but higher specificity and 
less capable of inhibiting JDHM histone demethylases such as JARID1A-D and 
JMJD3 (Yeh et al., 2017).  
Most PHD inhibitors are pan-PHD inhibitors, and the phenotype of inhibition is 
predominantly due to PHD2 inhibition. Few efficient PHD3 inhibitors have been 
described in the literature. The Na group describe Pyrithione Zn (PZ) as an inhibitor 
which favours the inhibition of PHD3 over PHD2; however, they do not explore the 
activity of the molecule on other 2-OG dependent oxygenases (Na et al., 2016). 
Zhang et al describe salidroside, an active ingredient of the Chinese herb Rhodiola, 
as a PHD3, but not PHD1 and 2, specific inhibitor which could enhance endothelial 
and smooth muscle cell migration (Zhang et al., 2017). 
Our data show that inhibition of PHD3 can have profound beneficial effects on 
bacterial clearance and inflammation resolution. However, inhibition of PHD2 can 
cause aberrant neutrophil inflammation. Molidustat, a 2OG-dependent high 
oxygenase inhibitor with a specificity to PHD2, exacerbated the inflammatory 
response to nebulised LPS (Sadiku et al., 2017). Moreover, a range of PHD 
inhibitors including DMOG, L-mimosine, FG0041 and Roxadustat have been shown 
to have off target effects and are capable of suppressing C1q secretion by human 
macrophages, which could have deleterious effects in the context of inflammation 
resolution as C1q limits inflammasome activity following ingestion of apoptotic 
cells (Benoit et al., 2012)(Kiriakidis et al., 2017). 
4.3.5. Summary 
Myeloid specific PHD3 deletion is beneficial for bacterial control in models of both 
S. pneumoniae lung infection and S. aureus skin infection. Phenotyping of PHD3 
deficient neutrophils shows no differences in capacity for phagocytosis, respiratory 
burst, degranulation or cytokine production. However, metabolism is globally 
regulated by PHD3 knockout in a way dependent on oxygen concentration, although 





5.1. Summary of findings 
My work on examining the role of neutrophil mitochondrial function leads on from 
two distinct branches of recent literature. The first describes the involvement of 
mitochondrial metabolism in regulating macrophage polarisation (Tannahill et al., 
2013) (Kelly and O’Neill, 2015). Although there have recently been numerous 
studies investigating M1, M2 and T cell metabolism, there have been very few 
studies investigating how neutrophil metabolism can modulate the inflammatory 
functions of this very abundant and metabolically active cell, largely due to the idea 
that neutrophils are predominantly glycolytic cells and therefore have limited 
capacity for metabolic regulation. The second was describing roles for the neutrophil 
mitochondria in a number of processes such as phagocytosis, apoptosis, chemotaxis, 
respiratory burst activation and autocrine purinergic signalling (Fossati et al., 
2003)(Bao et al., 2014). These studies predominantly investigated metabolism in the 
context of ATP production, and not modulation of mROS or active 
immunomodulatory metabolites themselves.  
I investigated the metabolic profile of the neutrophils in both hypoxia and in PHD3 
knockouts. I found in unstimulated neutrophils, hypoxia enhances mROS release, 
which augments HIF-1α stability and neutrophil survival. Mitochondria-targeted 
antioxidants can induce neutrophil apoptosis, showing mROS are a pro-survival 
stimulus in the neutrophil. Acute hypoxia also increases flux through glycolysis and 
the pentose phosphate pathway. This metabolic switch is essential for maintaining 
hypoxic survival of the neutrophils, as treatment with the glycolytic inhibitor 2-DG 
or 6AN, or removal of glucose from the culture media, blocks neutrophil hypoxic 
survival (Figure 3.2.7-3, Figure 3.2.8-3). Increase in pentose phosphate pathway flux 
was shown to be important for maintaining hypoxic survival, potentially through the 
production of antioxidants including glutathione. In neutrophils cultured in hypoxia 
completely lacking glucose where neutrophil apoptosis is markedly accelerated, 
addition of antioxidants can completely prevent glucose-starvation-induced 




aside from ATP production in maintaining neutrophil survival through the pentose 
phosphate pathway. 
In contrast to studies in macrophages, pro-inflammatory stimuli, in this case 
hypoxia, do not change Krebs cycle activity and flux. Unpublished data from our 
group has also indicated LPS does not regulate neutrophil Krebs cycle flux or cause 
accumulation of succinate and citrate as it does in macrophages. This indicates 
neutrophils do not use their cycle to modulate their function. However, our data does 
show regulation of glycolytic capacity and pentose phosphate pathway flux are key 
determinants of neutrophil survival and function. Therefore, a parallel between 
mitochondrial metabolism and pro-inflammatory activity, as has been described in 
macrophages, is not present in neutrophils. It is clear non-mitochondrial metabolism 
is key in regulating neutrophil function and lifespan, with little regulation of 
mitochondrial metabolism. 
In my data, I have shown that the regulation of metabolism by PHD3 has opposing 
effects depending on oxygen tension. Hypoxia appears to globally inhibit neutrophil 
metabolism in PHD3-deficient neutrophils, whereas in normoxic conditions, 
metabolism is increased globally. This may account for the divergent effects of 
PHD3 knockout in varying conditions. In highly oxidative environments, for 
example in the vasculature in models of sepsis, PHD3 deletion may be detrimental to 
resolving inflammation (Kiss et al., 2012). However, in potentially hypoxic 
environments such as an ischaemic limb or S. aureus abscess, PHD3 deletion could 
be advantageous. Inflammation and hypoxia are extremely closely related, with 
inflamed sites often experiencing profound hypoxia, and hypoxia exacerbating 
inflammation (Bartels, Grenz and Eltzschig, 2013). 
The metabolic signature of PHD3 knockout is totally distinct from PHD2 or HIF-1α 
knockout. HIF-1α regulation is known to switch cellular metabolism from 
mitochondrial metabolism to glycolysis through induction of glycolytic enzymes and 
PDK1, which suppresses pyruvate dehydrogenase and blocks entry of metabolites 
into the Krebs cycle (Semenza, 2007). In neutrophils, knockout of PHD2 profoundly 
induces glycolysis in both normoxic and hypoxic conditions due to enhanced 




response in a model of inflammation (Sadiku et al., 2017). Knockout of PHD3 in 
this case is beneficial for the resolution of infection and has suppressive effects on 
glycolysis and glucose metabolism. Regulation and inhibition of PHD3 therefore 
may be a novel therapeutic target in the treatment of chronic inflammatory diseases. 
5.2. Therapeutic implications of this work  
HIF-1α has been identified as a potent regulator of inflammation and has been linked 
to both acute and chronic inflammation. It is therefore a candidate as a therapeutic 
target. Directly modulating HIF-1α activity is a risky therapeutic strategy. HIF-1α 
inhibitors have been administered in the context of hypoxic tumours, and some 
compounds have shown success in suppressing tumour growth and metastasis in in 
vivo murine models (Dikmen et al., 2008)(Jacoby et al., 2010). In the context of 
infection, loss of HIF-1α can be disastrous, with suppression of HIF-1α limiting 
bactericidal activity and exacerbating systemic and localised measures of infection 
(Peyssonnaux et al., 2005), and enhanced stabilization of HIF-1α through knockout 
of PHD2 can cause an exaggerated immune response (Sadiku et al., 2017). One 
aspect of the therapeutic challenge in these pathways, therefore, is suppressing 
inappropriate HIF-1α expression in inflammation without compromising the normal 
function of the immune system. Our data show mROS can stabilise HIF-1α in 
hypoxia and are capable of subtly positively modulating neutrophil survival in 
hypoxia, specifically. Although this work is at an early stage, our data support the 
idea that mROS can modulate neutrophil survival, which could in turn modulate 
inflammation and may be a potential route for therapeutic intervention against 
chronic inflammation. Targeting neutrophil mROS has already shown some success 
in murine inflammatory models, as administration of complex III inhibitors can aid 
the resolution of an acute lung injury (Zmijewski et al., 2008). Understanding the 
mechanism of how this occurs in neutrophils may therefore lead to a novel, 
targetable pathway which could be inhibited to limit, but not abrogate, HIF-1α 
stabilisation and neutrophil function in chronically inflamed sites where neutrophil 
activity is detrimental.  
Our work also links neutrophil PHD3 expression with delayed  bacterial clearance 




have shown inhibition of PHD3 is beneficial for the resolution of a sterile 
inflammation in hind limb ischaemia and LPS-induced lung injury (Walmsley et al., 
2011)(Swain et al., 2014). This is the first study to show that in a bacterial infection, 
PHD3 knockout is beneficial. Often in chronic inflammatory diseases, patients 
present with frequent bacterial infections; therefore, the therapeutic challenge is to 
suppress the overactive immune response in these patients without compromising 
bactericidal activities of these immune cells. PHD3 could therefore offer an 
attractive target in these diseases.  
5.3. Limitations  
It is an important point that the work so far has used murine models of infection; the 
relevance of using mice to model the human immune system is controversial. The 
primary mechanism for S. aureus sensing neutrophils is through alpha defensin 1 
(HNP-1) released by neutrophils triggering the activation of the saeR/S machinery; 
however, murine neutrophils do not produce HNP-1, indicating there may be 
differences in the S. aureus response against murine neutrophils (Guerra et al., 
2017). Moreover, the murine cytokine profile is markedly different to human 
neutrophils (Tecchio, Micheletti and Cassatella, 2014). The activity of S. aureus 
toxins such as HlgA, HlgC and LukF-PVL is limited against murine cells compared 
to human cells.  One method for circumventing this could be to use a humanised 
murine model where profoundly immunodeficient NOD/SCID/IL2rynull mice are 
seeded with human CD34+ umbilical cord blood, replacing components of the 
murine immune system with human immune cells (Shultz, Ishikawa and Greiner, 
2007). These mice are more susceptible to S. aureus infection and may be a better 
model of human S. aureus infection that mouse models (Tseng et al., 2015). Whether 
the progression of a S. aureus infection in a human would be modulated by PHD3 
inhibition has yet to be elucidated. 
A further limitation is associated with this work is use of the LysMCre mouse 
knockout model. LysM is expressed in all granulocytes subtypes and in mature 
macrophages (Clausen et al., 1999). This is important as knockout of PHD3 is 
known to modulate macrophage function and apoptosis (Swain et al., 2014), 




inflammation (Figure 4.2.5-1, C). To confirm our phenotype is caused by neutrophils 
specifically, another model of knockout may need to be used. To address this 
limitation, we have derived a PHD3fl/fl Mrp8Cre+/- mouse line. Mrp8Cre restricts Cre 
expression to neutrophils and a small fraction of granulocyte/macrophage progenitor 
cells in the bone marrow (Passegué, Wagner and Weissman, 2004). 
A limitation of the in vitro model we use is that we use a binary model of hypoxia 
where “hypoxia” is defined at 1% oxygen and “normoxia” is 21% oxygen. This 
model is used in wide range of in vitro cell culture models in both immune and non-
immune cells (Hannah et al., 1995)(Hoenderdos et al., 2016)(Sadiku et al., 2017). 
This model allows us to clearly differentiate phenotypic differences between hypoxic 
and normoxic cells. More involved models of oxygen regulation, for example the use 
of multiple oxygen tensions or cycling of arterial/venous/tissue oxygen tensions, 
may give a more accurate representation of the oxygen tensions experienced by a 
neutrophil in the body, although this is outside the scope of this study. 
5.4. Future work 
The mechanism for enhanced mitochondrial ROS production in hypoxia is currently 
unknown. The glycerol 3-phosphate is a possible candidate for this regulation. 
Unpublished data from our group suggests neutrophil modulate expression of 
cytoplasmic GPD1 protein expression, and addition of the mitochondrial glycerol 3-
phosphate dehydrogenase inhibitor iGP-1 can inhibitor mitochondrial membrane 
hyperpolarization in hypoxia in a dose dependent way, although further studies are 
needed to ascertain whether this pathway accounts for the increase in mitochondrial 
ROS production we see in hypoxia. 
Although inhibiting electron transport chain activity would likely modulate 
neutrophil reactive oxygen species production, these inhibitors tend to be profoundly 
toxic. Therefore, identification of a novel mitochondrial ROS-mediating pathway in 
neutrophils could offer a potential therapeutic target for limiting neutrophil 
inflammation in disease without side effects associated with inhibition of oxidative 
phosphorylation itself. The advent of novel GPD2 inhibitors will allow us to 




GPD2 is non-lethal in mice, suggesting this pathway may be targetable in vivo 
without lethal consequences (Mracek, Drahota and Hou, 2013). 
The mechanism behind improved bacterial clearance in PHD3fl/fl LysMCre+/- mice 
has not fully been elucidated either. There are some indications in the data that 
myeloperoxidase activity in inflamed tissue in both infective and sterile models of 
inflammation may be slightly elevated (Figure 4.2.2-5, Figure 4.2.2-6, Figure 4.2.5-
2, D); whether or not this accounts for enhanced bacterial control in the absence of 
changes to phagocytic capacity or ROS generation is unclear. It is surprising that 
metabolism is highly regulated in the PHD3 knockouts, yet serine protease and MPO 
expression seems unaffected at the timepoints we have measured in these models. 
Future work will investigate whether MPO capacity is affected at earlier timepoints 
in this model. We do not know conclusively whether global regulation of 
metabolism in PHD3-deficient neutrophils contributes to the phenotype of enhanced 
bacterial control or apoptosis. Moreover, it is unclear whether the divergent effects 
of PHD3 knockout attribute to the enhancement of inflammation resolution. It 
follows that a reduction of global metabolism in hypoxic conditions may be due to 
either enhanced apoptosis in hypoxia as demonstrated in previous papers (Walmsley 
et al., 2011). Indeed, we have shown inhibition of glycolysis through addition of 
inhibitors or withdrawal of glucose from the culture medium can induce apoptosis 
(Figure 3.2.7-3). It is possible that PHD3 knockout therefore prevents neutrophils 
from upregulated glucose metabolism in hypoxia and prevents them generating 
antioxidants and ATP that causes them to apoptose more rapidly. This may account 
for the enhanced resolution of inflammation but does not account for more effective 
bacterial clearance in infection models. Therefore, further work is needed to 
ascertain how regulation of metabolism by PHD3 modulates neutrophil function and 
apoptosis, and also how neutrophils clear bacteria more effective from the site of 
infection. Regulation of HIF-1α or HIF-2α may account for modulation of 
metabolism by PHD3, although as PHD3 is a negative regulator of HIF-1α, knockout 
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7.1. 8% SDS gel composition 
The following solutions were prepared in separate 50ml Falcon tubes. Volumes are 
per gel. 
 Stacking Gel Resolving Gel 
dH2O. 3ml 8ml 
40% Acrylamide 620µl 3ml 
1.5M Tris-HCl pH 8 
(BioRad®) 
- 3.8ml 
0.5M Tris-HCl pH 6.8 
(BioRad®) 
1260µl - 
20% SDS 25µl 75µl 









7.2. Western blotting solutions 
10x Running Buffer stock 
190g Glycine, 30.3g Tris Base, 50ml 20% SDS (BioRad®), made up to 1L with 
dH2O. 
1x Running Buffer 
100ml 10x Running Buffer, 900ml dH2O 
10x Transfer Buffer stock 
145g Glycine, 29g Tris Base, made up to 800ml with dH2O. 
1x Transfer Buffer. 
Make immediately before use. 150ml 10x Transfer Buffer, 300ml Methanol, 1050ml 
dH2O. 
10x TBS stock 
100ml Tris-HCl 1M pH8.0 (BioRad®), 97.3g NaCl, made up to 1000ml with dH2O. 
1x TBS  
100ml 10x TBS, 900ml dH2O. 
10x TBS-Tween stock 
100ml Tris-HCl 1M pH8.0 (BioRad®), 97.3g NaCl, 5ml Tween-20, made up to 
1000ml with dH2O 
1x TBS-Tween 
100ml 10x TBS-Tween, 900ml d dH2O. 
Blocking buffer 





7.3. Primers used to genotype transgenic murine colonies 











7.4. Mouse sickness Score 
7.4.1. Sickness score 1 
 A single score was applied to each animal as follows: 
A normal and unremarkable condition =0 
Slight illness, defined as lethargy and ruffled fur =1 
Mild illness, defined as severe lethargy, ruffled fur and hunched 
back 
=2 
Moderate illness, with the above signs plus exudative 
accumulation around partially closed eyes 
=3 
Severe illness =4 
Death =5 
 
7.4.2. Sickness score 2 
Mice were assessed by 5 criteria: Coat, activity, breathing, dehydration and 
movement. A total score was calculated from individual scores for these criteria. 
  
 0 1 2 3 





Loss of fur 







Breathing Normal Rapid, shallow Rapid, abdominal Laboured, 
blue 
Dehydration Nil Skin less elastic Skin tents Skin tents, 
eyes sunken 












7.5. Murine BAL MPO assay buffers 
HTAB buffer 
5mg/ml hexadecyltrimethylammonium bromide in 50mM potassium phosphate 
buffer pH 6.0 
O-dianisidine  
0.167mg/ml O-dianisidine hydrochloride (Cayman Chemicals, UK). 
0.0005% H2O2 in 50mM potassium phosphate buffer pH 6.0 
50mM potassium phosphate buffer pH 6.0 
6.392g potassium phosphate monobasic (KH2PO4) 
0.522g potassium phosphate dibasic (K2HPO4) 





7.6. Murine qPCR 
7.6.1. Real time polymerase chain reaction 
1ul of cDNA was added to 19ul of the following RT qPCR mastermix:  
2x mastermix     10ul 
Water       8ul 
Primer/probe mix     1ul 
 
 
7.6.2. Murine primers for real time polymerase chain reactions 
Commercially available primer-probe pairs all from Thermofisher Scientific, UK. 
 




Phosphogluconate dehydrogenase (Pgd)  Mm00503037_m1 
Ribose 5-phosphate isomerase A (RpiA)  Mm00485790_m1 

























7.8. Western blot antibodies 
Antibody Supplier Dilution 
HIF-1a Cell Signalling 1:500 
P38 MAP kinase Cell Signalling 1:2000 
Goat anti-rabbit HRP Mako 1:2000 
 
